id	sid	tid	token	lemma	pos
dpc-2201	1	1	dermatology	dermatology	NOUN
dpc-2201	1	2	:	:	PUNCT
dpc-2201	1	3	practical	practical	ADJ
dpc-2201	1	4	and	and	CCONJ
dpc-2201	1	5	conceptual	conceptual	ADJ
dpc-2201	1	6	review	review	NOUN
dpc-2201	1	7	|	|	ADV
dpc-2201	1	8	dermatol	dermatol	ADJ
dpc-2201	1	9	pract	pract	NOUN
dpc-2201	1	10	concept	concept	NOUN
dpc-2201	1	11	.	.	PUNCT
dpc-2201	2	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	2	2	1	1	NUM
dpc-2201	2	3	various	various	ADJ
dpc-2201	2	4	application	application	NOUN
dpc-2201	2	5	of	of	ADP
dpc-2201	2	6	tofacitinib	tofacitinib	NOUN
dpc-2201	2	7	and	and	CCONJ
dpc-2201	2	8	ruxolitinib	ruxolitinib	NOUN
dpc-2201	2	9	(	(	PUNCT
dpc-2201	2	10	janus	janus	PROPN
dpc-2201	2	11	kinase	kinase	PROPN
dpc-2201	2	12	inhibitors	inhibitor	NOUN
dpc-2201	2	13	)	)	PUNCT
dpc-2201	2	14	in	in	ADP
dpc-2201	2	15	dermatology	dermatology	NOUN
dpc-2201	2	16	and	and	CCONJ
dpc-2201	2	17	rheumatology	rheumatology	NOUN
dpc-2201	2	18	:	:	PUNCT
dpc-2201	2	19	a	a	DET
dpc-2201	2	20	review	review	NOUN
dpc-2201	2	21	of	of	ADP
dpc-2201	2	22	current	current	ADJ
dpc-2201	2	23	evidence	evidence	NOUN
dpc-2201	2	24	and	and	CCONJ
dpc-2201	2	25	future	future	ADJ
dpc-2201	2	26	perspective	perspective	PROPN
dpc-2201	2	27	sara	sara	NOUN
dpc-2201	2	28	sadeghi1	sadeghi1	PROPN
dpc-2201	2	29	,	,	PUNCT
dpc-2201	2	30	azadeh	azadeh	VERB
dpc-2201	2	31	goodarzi1,2	goodarzi1,2	PROPN
dpc-2201	2	32	1	1	NUM
dpc-2201	2	33	rasool	rasool	PROPN
dpc-2201	2	34	akram	akram	PROPN
dpc-2201	2	35	medical	medical	ADJ
dpc-2201	2	36	complex	complex	ADJ
dpc-2201	2	37	clinical	clinical	ADJ
dpc-2201	2	38	research	research	NOUN
dpc-2201	2	39	development	development	NOUN
dpc-2201	2	40	center	center	NOUN
dpc-2201	2	41	(	(	PUNCT
dpc-2201	2	42	rcrdc	rcrdc	ADJ
dpc-2201	2	43	)	)	PUNCT
dpc-2201	2	44	,	,	PUNCT
dpc-2201	2	45	iran	iran	PROPN
dpc-2201	2	46	university	university	PROPN
dpc-2201	2	47	of	of	ADP
dpc-2201	2	48	medical	medical	ADJ
dpc-2201	2	49	sciences	sciences	PROPN
dpc-2201	2	50	,	,	PUNCT
dpc-2201	2	51	tehran	tehran	PROPN
dpc-2201	2	52	,	,	PUNCT
dpc-2201	2	53	iran	iran	PROPN
dpc-2201	2	54	2	2	NUM
dpc-2201	2	55	department	department	NOUN
dpc-2201	2	56	of	of	ADP
dpc-2201	2	57	dermatology	dermatology	NOUN
dpc-2201	2	58	,	,	PUNCT
dpc-2201	2	59	faculty	faculty	NOUN
dpc-2201	2	60	of	of	ADP
dpc-2201	2	61	dermatology	dermatology	NOUN
dpc-2201	2	62	,	,	PUNCT
dpc-2201	2	63	rasool	rasool	PROPN
dpc-2201	2	64	akram	akram	PROPN
dpc-2201	2	65	medical	medical	PROPN
dpc-2201	2	66	complex	complex	ADJ
dpc-2201	2	67	clinical	clinical	ADJ
dpc-2201	2	68	research	research	NOUN
dpc-2201	2	69	development	development	NOUN
dpc-2201	2	70	center	center	NOUN
dpc-2201	2	71	(	(	PUNCT
dpc-2201	2	72	rcrdc	rcrdc	ADJ
dpc-2201	2	73	)	)	PUNCT
dpc-2201	2	74	,	,	PUNCT
dpc-2201	2	75	school	school	NOUN
dpc-2201	2	76	of	of	ADP
dpc-2201	2	77	medicine	medicine	NOUN
dpc-2201	2	78	,	,	PUNCT
dpc-2201	2	79	iran	iran	PROPN
dpc-2201	2	80	university	university	PROPN
dpc-2201	2	81	of	of	ADP
dpc-2201	2	82	medical	medical	ADJ
dpc-2201	2	83	sciences	sciences	PROPN
dpc-2201	2	84	,	,	PUNCT
dpc-2201	2	85	tehran	tehran	PROPN
dpc-2201	2	86	,	,	PUNCT
dpc-2201	2	87	iran	iran	PROPN
dpc-2201	2	88	key	key	ADJ
dpc-2201	2	89	words	word	NOUN
dpc-2201	2	90	:	:	PUNCT
dpc-2201	2	91	tofacitinib	tofacitinib	PROPN
dpc-2201	2	92	,	,	PUNCT
dpc-2201	2	93	ruxolitinib	ruxolitinib	NOUN
dpc-2201	2	94	,	,	PUNCT
dpc-2201	2	95	janus	janus	PROPN
dpc-2201	2	96	kinase	kinase	PROPN
dpc-2201	2	97	inhibitors	inhibitor	NOUN
dpc-2201	2	98	,	,	PUNCT
dpc-2201	2	99	skin	skin	NOUN
dpc-2201	2	100	,	,	PUNCT
dpc-2201	2	101	mucosa	mucosa	NOUN
dpc-2201	2	102	citation	citation	NOUN
dpc-2201	2	103	:	:	PUNCT
dpc-2201	2	104	sadeghi	sadeghi	PROPN
dpc-2201	2	105	s	s	PART
dpc-2201	2	106	,	,	PUNCT
dpc-2201	2	107	goodarzi	goodarzi	VERB
dpc-2201	2	108	a.	a.	NOUN
dpc-2201	2	109	various	various	ADJ
dpc-2201	2	110	application	application	NOUN
dpc-2201	2	111	of	of	ADP
dpc-2201	2	112	tofacitinib	tofacitinib	NOUN
dpc-2201	2	113	and	and	CCONJ
dpc-2201	2	114	ruxolitinib	ruxolitinib	NOUN
dpc-2201	2	115	(	(	PUNCT
dpc-2201	2	116	janus	janus	PROPN
dpc-2201	2	117	kinase	kinase	PROPN
dpc-2201	2	118	inhibitors	inhibitor	NOUN
dpc-2201	2	119	)	)	PUNCT
dpc-2201	2	120	in	in	ADP
dpc-2201	2	121	dermatology	dermatology	NOUN
dpc-2201	2	122	and	and	CCONJ
dpc-2201	2	123	rheumatology	rheumatology	NOUN
dpc-2201	2	124	:	:	PUNCT
dpc-2201	2	125	a	a	DET
dpc-2201	2	126	review	review	NOUN
dpc-2201	2	127	of	of	ADP
dpc-2201	2	128	current	current	ADJ
dpc-2201	2	129	evidence	evidence	NOUN
dpc-2201	2	130	and	and	CCONJ
dpc-2201	2	131	future	future	ADJ
dpc-2201	2	132	perspective	perspective	NOUN
dpc-2201	2	133	.	.	PUNCT
dpc-2201	3	1	dermatol	dermatol	NOUN
dpc-2201	3	2	pract	pract	PROPN
dpc-2201	3	3	concept	concept	NOUN
dpc-2201	3	4	.	.	PUNCT
dpc-2201	4	1	2022;12(4):e2022178	2022;12(4):e2022178	X
dpc-2201	4	2	.	.	PUNCT
dpc-2201	5	1	doi	doi	NOUN
dpc-2201	5	2	:	:	PUNCT
dpc-2201	5	3	https://doi.org/10.5826/dpc.1204a178	https://doi.org/10.5826/dpc.1204a178	ADJ
dpc-2201	5	4	accepted	accept	VERB
dpc-2201	5	5	:	:	PUNCT
dpc-2201	5	6	february	february	PROPN
dpc-2201	5	7	1	1	NUM
dpc-2201	5	8	,	,	PUNCT
dpc-2201	5	9	2022	2022	NUM
dpc-2201	5	10	;	;	PUNCT
dpc-2201	5	11	published	publish	VERB
dpc-2201	5	12	:	:	PUNCT
dpc-2201	5	13	october	october	PROPN
dpc-2201	5	14	2022	2022	NUM
dpc-2201	6	1	copyright	copyright	NOUN
dpc-2201	6	2	:	:	PUNCT
dpc-2201	6	3	©	©	PROPN
dpc-2201	6	4	2022	2022	NUM
dpc-2201	6	5	sadeghi	sadeghi	PROPN
dpc-2201	6	6	et	et	PROPN
dpc-2201	6	7	al	al	PROPN
dpc-2201	6	8	.	.	PUNCT
dpc-2201	7	1	this	this	PRON
dpc-2201	7	2	is	be	AUX
dpc-2201	7	3	an	an	DET
dpc-2201	7	4	open	open	ADJ
dpc-2201	7	5	-	-	PUNCT
dpc-2201	7	6	access	access	NOUN
dpc-2201	7	7	article	article	NOUN
dpc-2201	7	8	distributed	distribute	VERB
dpc-2201	7	9	under	under	ADP
dpc-2201	7	10	the	the	DET
dpc-2201	7	11	terms	term	NOUN
dpc-2201	7	12	of	of	ADP
dpc-2201	7	13	the	the	DET
dpc-2201	7	14	creative	creative	ADJ
dpc-2201	7	15	commons	common	NOUN
dpc-2201	7	16	attribution	attribution	NOUN
dpc-2201	7	17	-	-	PUNCT
dpc-2201	7	18	noncommercial	noncommercial	ADJ
dpc-2201	7	19	license	license	NOUN
dpc-2201	7	20	(	(	PUNCT
dpc-2201	7	21	by	by	ADP
dpc-2201	7	22	-	-	PUNCT
dpc-2201	7	23	nc-4.0	nc-4.0	NOUN
dpc-2201	7	24	)	)	PUNCT
dpc-2201	7	25	,	,	PUNCT
dpc-2201	7	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2201	7	27	,	,	PUNCT
dpc-2201	7	28	which	which	PRON
dpc-2201	7	29	permits	permit	VERB
dpc-2201	7	30	unrestricted	unrestricted	ADJ
dpc-2201	7	31	noncommercial	noncommercial	ADJ
dpc-2201	7	32	use	use	NOUN
dpc-2201	7	33	,	,	PUNCT
dpc-2201	7	34	distribution	distribution	NOUN
dpc-2201	7	35	,	,	PUNCT
dpc-2201	7	36	and	and	CCONJ
dpc-2201	7	37	reproduction	reproduction	NOUN
dpc-2201	7	38	in	in	ADP
dpc-2201	7	39	any	any	DET
dpc-2201	7	40	medium	medium	NOUN
dpc-2201	7	41	,	,	PUNCT
dpc-2201	7	42	provided	provide	VERB
dpc-2201	7	43	the	the	DET
dpc-2201	7	44	original	original	ADJ
dpc-2201	7	45	authors	author	NOUN
dpc-2201	7	46	and	and	CCONJ
dpc-2201	7	47	source	source	NOUN
dpc-2201	7	48	are	be	AUX
dpc-2201	7	49	credited	credit	VERB
dpc-2201	7	50	.	.	PUNCT
dpc-2201	8	1	funding	funding	NOUN
dpc-2201	8	2	:	:	PUNCT
dpc-2201	8	3	none	none	NOUN
dpc-2201	8	4	.	.	PUNCT
dpc-2201	9	1	competing	compete	VERB
dpc-2201	9	2	interests	interest	NOUN
dpc-2201	9	3	:	:	PUNCT
dpc-2201	9	4	none	none	NOUN
dpc-2201	9	5	.	.	PUNCT
dpc-2201	10	1	authorship	authorship	NOUN
dpc-2201	10	2	:	:	PUNCT
dpc-2201	10	3	all	all	DET
dpc-2201	10	4	authors	author	NOUN
dpc-2201	10	5	have	have	AUX
dpc-2201	10	6	contributed	contribute	VERB
dpc-2201	10	7	significantly	significantly	ADV
dpc-2201	10	8	to	to	ADP
dpc-2201	10	9	this	this	DET
dpc-2201	10	10	publication	publication	NOUN
dpc-2201	10	11	.	.	PUNCT
dpc-2201	11	1	corresponding	correspond	VERB
dpc-2201	11	2	author	author	NOUN
dpc-2201	11	3	:	:	PUNCT
dpc-2201	11	4	azadeh	azadeh	PROPN
dpc-2201	11	5	goodarzi	goodarzi	PROPN
dpc-2201	11	6	,	,	PUNCT
dpc-2201	11	7	md	md	PROPN
dpc-2201	11	8	,	,	PUNCT
dpc-2201	11	9	department	department	PROPN
dpc-2201	11	10	of	of	ADP
dpc-2201	11	11	dermatology	dermatology	NOUN
dpc-2201	11	12	,	,	PUNCT
dpc-2201	11	13	associate	associate	ADJ
dpc-2201	11	14	professor	professor	NOUN
dpc-2201	11	15	of	of	ADP
dpc-2201	11	16	dermatology	dermatology	NOUN
dpc-2201	11	17	,	,	PUNCT
dpc-2201	11	18	rasool	rasool	PROPN
dpc-2201	11	19	akram	akram	PROPN
dpc-2201	11	20	medical	medical	PROPN
dpc-2201	11	21	complex	complex	ADJ
dpc-2201	11	22	clinical	clinical	ADJ
dpc-2201	11	23	research	research	NOUN
dpc-2201	11	24	development	development	NOUN
dpc-2201	11	25	center	center	NOUN
dpc-2201	11	26	(	(	PUNCT
dpc-2201	11	27	rcrdc	rcrdc	ADJ
dpc-2201	11	28	)	)	PUNCT
dpc-2201	11	29	,	,	PUNCT
dpc-2201	11	30	school	school	NOUN
dpc-2201	11	31	of	of	ADP
dpc-2201	11	32	medicine	medicine	NOUN
dpc-2201	11	33	,	,	PUNCT
dpc-2201	11	34	iran	iran	PROPN
dpc-2201	11	35	university	university	PROPN
dpc-2201	11	36	of	of	ADP
dpc-2201	11	37	medical	medical	ADJ
dpc-2201	11	38	sciences	sciences	PROPN
dpc-2201	11	39	,	,	PUNCT
dpc-2201	11	40	tehran	tehran	PROPN
dpc-2201	11	41	,	,	PUNCT
dpc-2201	11	42	iran	iran	PROPN
dpc-2201	11	43	.	.	PUNCT
dpc-2201	12	1	e	e	X
dpc-2201	12	2	-	-	NOUN
dpc-2201	12	3	mail	mail	NOUN
dpc-2201	12	4	:	:	PUNCT
dpc-2201	12	5	azadeh_goodarzi1984@yahoo.com	azadeh_goodarzi1984@yahoo.com	X
dpc-2201	12	6	,	,	PUNCT
dpc-2201	12	7	goodarzi.a@iums.ac.ir	goodarzi.a@iums.ac.ir	PROPN
dpc-2201	12	8	introduction	introduction	NOUN
dpc-2201	12	9	:	:	PUNCT
dpc-2201	12	10	janus	janus	PROPN
dpc-2201	12	11	kinase	kinase	PROPN
dpc-2201	12	12	inhibitors	inhibitor	NOUN
dpc-2201	12	13	(	(	PUNCT
dpc-2201	12	14	jaki	jaki	PROPN
dpc-2201	12	15	)	)	PUNCT
dpc-2201	12	16	are	be	AUX
dpc-2201	12	17	anti	anti	ADJ
dpc-2201	12	18	-	-	ADJ
dpc-2201	12	19	inflammatory	inflammatory	ADJ
dpc-2201	12	20	medications	medication	NOUN
dpc-2201	12	21	suppressing	suppress	VERB
dpc-2201	12	22	janus	janus	PROPN
dpc-2201	12	23	kinase	kinase	PROPN
dpc-2201	12	24	-	-	PUNCT
dpc-2201	12	25	signal	signal	NOUN
dpc-2201	12	26	transducer	transducer	NOUN
dpc-2201	12	27	and	and	CCONJ
dpc-2201	12	28	activator	activator	NOUN
dpc-2201	12	29	of	of	ADP
dpc-2201	12	30	transcription	transcription	NOUN
dpc-2201	12	31	(	(	PUNCT
dpc-2201	12	32	jak	jak	NOUN
dpc-2201	12	33	-	-	PUNCT
dpc-2201	12	34	stat	stat	NOUN
dpc-2201	12	35	)	)	PUNCT
dpc-2201	12	36	pathway	pathway	NOUN
dpc-2201	12	37	by	by	ADP
dpc-2201	12	38	inhibiting	inhibit	VERB
dpc-2201	12	39	various	various	ADJ
dpc-2201	12	40	cytokines	cytokine	NOUN
dpc-2201	12	41	receptors	receptor	NOUN
dpc-2201	12	42	on	on	ADP
dpc-2201	12	43	the	the	DET
dpc-2201	12	44	membrane	membrane	NOUN
dpc-2201	12	45	of	of	ADP
dpc-2201	12	46	cells	cell	NOUN
dpc-2201	12	47	.	.	PUNCT
dpc-2201	13	1	mutations	mutation	NOUN
dpc-2201	13	2	and	and	CCONJ
dpc-2201	13	3	polymorphisms	polymorphism	NOUN
dpc-2201	13	4	on	on	ADP
dpc-2201	13	5	jak	jak	PROPN
dpc-2201	13	6	and	and	CCONJ
dpc-2201	13	7	stat	stat	PROPN
dpc-2201	13	8	proteins	protein	NOUN
dpc-2201	13	9	can	can	AUX
dpc-2201	13	10	cause	cause	VERB
dpc-2201	13	11	dysregulation	dysregulation	NOUN
dpc-2201	13	12	in	in	ADP
dpc-2201	13	13	the	the	DET
dpc-2201	13	14	balance	balance	NOUN
dpc-2201	13	15	of	of	ADP
dpc-2201	13	16	immune	immune	ADJ
dpc-2201	13	17	system	system	NOUN
dpc-2201	13	18	,	,	PUNCT
dpc-2201	13	19	and	and	CCONJ
dpc-2201	13	20	ultimately	ultimately	ADV
dpc-2201	13	21	result	result	VERB
dpc-2201	13	22	in	in	ADP
dpc-2201	13	23	autoimmune	autoimmune	ADJ
dpc-2201	13	24	disorders	disorder	NOUN
dpc-2201	13	25	.	.	PUNCT
dpc-2201	14	1	objectives	objective	NOUN
dpc-2201	14	2	:	:	PUNCT
dpc-2201	14	3	to	to	PART
dpc-2201	14	4	record	record	VERB
dpc-2201	14	5	and	and	CCONJ
dpc-2201	14	6	summarize	summarize	VERB
dpc-2201	14	7	the	the	DET
dpc-2201	14	8	overall	overall	ADJ
dpc-2201	14	9	efficacy	efficacy	NOUN
dpc-2201	14	10	and	and	CCONJ
dpc-2201	14	11	safety	safety	NOUN
dpc-2201	14	12	of	of	ADP
dpc-2201	14	13	jaki	jaki	PROPN
dpc-2201	14	14	in	in	ADP
dpc-2201	14	15	various	various	ADJ
dpc-2201	14	16	autoimmune	autoimmune	ADJ
dpc-2201	14	17	conditions	condition	NOUN
dpc-2201	14	18	such	such	ADJ
dpc-2201	14	19	as	as	ADP
dpc-2201	14	20	alopecia	alopecia	NOUN
dpc-2201	14	21	areata	areata	ADJ
dpc-2201	14	22	(	(	PUNCT
dpc-2201	14	23	aa	aa	NOUN
dpc-2201	14	24	)	)	PUNCT
dpc-2201	14	25	,	,	PUNCT
dpc-2201	14	26	psoriasis	psoriasis	NOUN
dpc-2201	14	27	vulgaris	vulgaris	NOUN
dpc-2201	14	28	(	(	PUNCT
dpc-2201	14	29	pv	pv	NOUN
dpc-2201	14	30	)	)	PUNCT
dpc-2201	14	31	,	,	PUNCT
dpc-2201	14	32	psoriatic	psoriatic	ADJ
dpc-2201	14	33	arthritis	arthritis	NOUN
dpc-2201	14	34	(	(	PUNCT
dpc-2201	14	35	psa	psa	NOUN
dpc-2201	14	36	)	)	PUNCT
dpc-2201	14	37	,	,	PUNCT
dpc-2201	14	38	atopic	atopic	NOUN
dpc-2201	14	39	dermatitis	dermatitis	NOUN
dpc-2201	14	40	(	(	PUNCT
dpc-2201	14	41	ad	ad	NOUN
dpc-2201	14	42	)	)	PUNCT
dpc-2201	14	43	,	,	PUNCT
dpc-2201	14	44	vitiligo	vitiligo	VERB
dpc-2201	14	45	,	,	PUNCT
dpc-2201	14	46	hidradenitis	hidradenitis	NOUN
dpc-2201	14	47	suppurative	suppurative	ADJ
dpc-2201	14	48	(	(	PUNCT
dpc-2201	14	49	hs	hs	X
dpc-2201	14	50	)	)	PUNCT
dpc-2201	14	51	,	,	PUNCT
dpc-2201	14	52	lichen	lichen	NOUN
dpc-2201	14	53	planus	planus	NOUN
dpc-2201	14	54	(	(	PUNCT
dpc-2201	14	55	lp	lp	NOUN
dpc-2201	14	56	)	)	PUNCT
dpc-2201	14	57	,	,	PUNCT
dpc-2201	14	58	and	and	CCONJ
dpc-2201	14	59	pyoderma	pyoderma	NOUN
dpc-2201	14	60	gangrenosum	gangrenosum	NOUN
dpc-2201	14	61	(	(	PUNCT
dpc-2201	14	62	pg	pg	NOUN
dpc-2201	14	63	)	)	PUNCT
dpc-2201	14	64	.	.	PUNCT
dpc-2201	15	1	methods	method	NOUN
dpc-2201	15	2	:	:	PUNCT
dpc-2201	15	3	a	a	DET
dpc-2201	15	4	thorough	thorough	ADJ
dpc-2201	15	5	review	review	NOUN
dpc-2201	15	6	of	of	ADP
dpc-2201	15	7	articles	article	NOUN
dpc-2201	15	8	was	be	AUX
dpc-2201	15	9	performed	perform	VERB
dpc-2201	15	10	across	across	ADP
dpc-2201	15	11	pubmed	pubmed	PROPN
dpc-2201	15	12	and	and	CCONJ
dpc-2201	15	13	google	google	PROPN
dpc-2201	15	14	scholar	scholar	NOUN
dpc-2201	15	15	on	on	ADP
dpc-2201	15	16	meta	meta	NOUN
dpc-2201	15	17	-	-	PUNCT
dpc-2201	15	18	analyses	analysis	NOUN
dpc-2201	15	19	,	,	PUNCT
dpc-2201	15	20	systematic	systematic	ADJ
dpc-2201	15	21	reviews	review	NOUN
dpc-2201	15	22	,	,	PUNCT
dpc-2201	15	23	clinical	clinical	ADJ
dpc-2201	15	24	trials	trial	NOUN
dpc-2201	15	25	and	and	CCONJ
dpc-2201	15	26	case	case	NOUN
dpc-2201	15	27	studies	study	NOUN
dpc-2201	15	28	evaluating	evaluate	VERB
dpc-2201	15	29	the	the	DET
dpc-2201	15	30	treatment	treatment	NOUN
dpc-2201	15	31	of	of	ADP
dpc-2201	15	32	autoimmune	autoimmune	ADJ
dpc-2201	15	33	disorders	disorder	NOUN
dpc-2201	15	34	such	such	ADJ
dpc-2201	15	35	as	as	ADP
dpc-2201	15	36	aa	aa	NOUN
dpc-2201	15	37	,	,	PUNCT
dpc-2201	15	38	pv	pv	INTJ
dpc-2201	15	39	,	,	PUNCT
dpc-2201	15	40	psa	psa	NOUN
dpc-2201	15	41	,	,	PUNCT
dpc-2201	15	42	ad	ad	NOUN
dpc-2201	15	43	,	,	PUNCT
dpc-2201	15	44	vitiligo	vitiligo	NOUN
dpc-2201	15	45	,	,	PUNCT
dpc-2201	15	46	lp	lp	PROPN
dpc-2201	15	47	,	,	PUNCT
dpc-2201	15	48	hs	hs	PROPN
dpc-2201	15	49	,	,	PUNCT
dpc-2201	15	50	and	and	CCONJ
dpc-2201	15	51	pg	pg	VERB
dpc-2201	15	52	with	with	ADP
dpc-2201	15	53	jaki	jaki	PROPN
dpc-2201	15	54	.	.	PUNCT
dpc-2201	16	1	duplicated	duplicate	VERB
dpc-2201	16	2	data	datum	NOUN
dpc-2201	16	3	and	and	CCONJ
dpc-2201	16	4	animal	animal	NOUN
dpc-2201	16	5	experiments	experiment	NOUN
dpc-2201	16	6	or	or	CCONJ
dpc-2201	16	7	in	in	ADP
dpc-2201	16	8	vitro	vitro	X
dpc-2201	16	9	/	/	SYM
dpc-2201	16	10	ex	ex	X
dpc-2201	16	11	vivo	vivo	NOUN
dpc-2201	16	12	studies	study	NOUN
dpc-2201	16	13	were	be	AUX
dpc-2201	16	14	excluded	exclude	VERB
dpc-2201	16	15	.	.	PUNCT
dpc-2201	17	1	results	result	NOUN
dpc-2201	17	2	:	:	PUNCT
dpc-2201	17	3	all	all	DET
dpc-2201	17	4	the	the	DET
dpc-2201	17	5	reviewed	review	VERB
dpc-2201	17	6	articles	article	NOUN
dpc-2201	17	7	reported	report	VERB
dpc-2201	17	8	beneficial	beneficial	ADJ
dpc-2201	17	9	effects	effect	NOUN
dpc-2201	17	10	of	of	ADP
dpc-2201	17	11	tofacitinib	tofacitinib	NOUN
dpc-2201	17	12	and	and	CCONJ
dpc-2201	17	13	ruxolitinib	ruxolitinib	NOUN
dpc-2201	17	14	application	application	NOUN
dpc-2201	17	15	in	in	ADP
dpc-2201	17	16	the	the	DET
dpc-2201	17	17	treatment	treatment	NOUN
dpc-2201	17	18	of	of	ADP
dpc-2201	17	19	disorders	disorder	NOUN
dpc-2201	17	20	mentioned	mention	VERB
dpc-2201	17	21	above	above	ADV
dpc-2201	17	22	with	with	ADP
dpc-2201	17	23	the	the	DET
dpc-2201	17	24	autoimmune	autoimmune	ADJ
dpc-2201	17	25	predisposition	predisposition	NOUN
dpc-2201	17	26	.	.	PUNCT
dpc-2201	18	1	abstract	abstract	ADJ
dpc-2201	18	2	2	2	NUM
dpc-2201	18	3	review	review	NOUN
dpc-2201	18	4	|	|	ADV
dpc-2201	18	5	dermatol	dermatol	ADJ
dpc-2201	18	6	pract	pract	NOUN
dpc-2201	18	7	concept	concept	NOUN
dpc-2201	18	8	.	.	PUNCT
dpc-2201	19	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	19	2	introduction	introduction	NOUN
dpc-2201	19	3	the	the	DET
dpc-2201	19	4	janus	janus	PROPN
dpc-2201	19	5	kinase	kinase	PROPN
dpc-2201	19	6	inhibitors	inhibitor	NOUN
dpc-2201	19	7	are	be	AUX
dpc-2201	19	8	a	a	DET
dpc-2201	19	9	category	category	NOUN
dpc-2201	19	10	of	of	ADP
dpc-2201	19	11	anti	anti	ADJ
dpc-2201	19	12	inflammatory	inflammatory	ADJ
dpc-2201	19	13	medications	medication	NOUN
dpc-2201	19	14	,	,	PUNCT
dpc-2201	19	15	targeting	target	VERB
dpc-2201	19	16	jak	jak	PROPN
dpc-2201	19	17	-	-	PUNCT
dpc-2201	19	18	stat	stat	NOUN
dpc-2201	19	19	pathways	pathway	NOUN
dpc-2201	19	20	.	.	PUNCT
dpc-2201	20	1	many	many	ADJ
dpc-2201	20	2	inflammatory	inflammatory	ADJ
dpc-2201	20	3	cytokines	cytokine	NOUN
dpc-2201	20	4	function	function	VERB
dpc-2201	20	5	through	through	ADP
dpc-2201	20	6	the	the	DET
dpc-2201	20	7	jakstat	jakstat	NOUN
dpc-2201	20	8	pathways	pathway	NOUN
dpc-2201	20	9	in	in	ADP
dpc-2201	20	10	the	the	DET
dpc-2201	20	11	human	human	ADJ
dpc-2201	20	12	body	body	NOUN
dpc-2201	20	13	[	[	X
dpc-2201	20	14	1,2	1,2	NUM
dpc-2201	20	15	]	]	PUNCT
dpc-2201	20	16	.	.	PUNCT
dpc-2201	21	1	cytokines	cytokine	NOUN
dpc-2201	21	2	are	be	AUX
dpc-2201	21	3	crucial	crucial	ADJ
dpc-2201	21	4	molecules	molecule	NOUN
dpc-2201	21	5	working	work	VERB
dpc-2201	21	6	on	on	ADP
dpc-2201	21	7	the	the	DET
dpc-2201	21	8	immune	immune	ADJ
dpc-2201	21	9	system	system	NOUN
dpc-2201	21	10	regulation	regulation	NOUN
dpc-2201	21	11	,	,	PUNCT
dpc-2201	21	12	and	and	CCONJ
dpc-2201	21	13	their	their	PRON
dpc-2201	21	14	dysregulation	dysregulation	NOUN
dpc-2201	21	15	might	might	AUX
dpc-2201	21	16	be	be	AUX
dpc-2201	21	17	important	important	ADJ
dpc-2201	21	18	in	in	ADP
dpc-2201	21	19	the	the	DET
dpc-2201	21	20	pathogenesis	pathogenesis	NOUN
dpc-2201	21	21	of	of	ADP
dpc-2201	21	22	autoimmune	autoimmune	ADJ
dpc-2201	21	23	disorders	disorder	NOUN
dpc-2201	22	1	[	[	X
dpc-2201	22	2	3	3	NUM
dpc-2201	22	3	]	]	PUNCT
dpc-2201	22	4	.	.	PUNCT
dpc-2201	23	1	genetic	genetic	ADJ
dpc-2201	23	2	polymorphisms	polymorphism	NOUN
dpc-2201	23	3	and	and	CCONJ
dpc-2201	23	4	different	different	ADJ
dpc-2201	23	5	mutations	mutation	NOUN
dpc-2201	23	6	can	can	AUX
dpc-2201	23	7	occur	occur	VERB
dpc-2201	23	8	within	within	ADP
dpc-2201	23	9	jak	jak	PROPN
dpc-2201	23	10	-	-	PUNCT
dpc-2201	23	11	stat	stat	NOUN
dpc-2201	23	12	pathways	pathway	NOUN
dpc-2201	23	13	,	,	PUNCT
dpc-2201	23	14	resulting	result	VERB
dpc-2201	23	15	in	in	ADP
dpc-2201	23	16	several	several	ADJ
dpc-2201	23	17	forms	form	NOUN
dpc-2201	23	18	of	of	ADP
dpc-2201	23	19	malignancies	malignancy	NOUN
dpc-2201	23	20	and	and	CCONJ
dpc-2201	23	21	autoimmune	autoimmune	ADJ
dpc-2201	23	22	disorders	disorder	NOUN
dpc-2201	23	23	,	,	PUNCT
dpc-2201	23	24	ie	ie	X
dpc-2201	23	25	polymorphisms	polymorphism	NOUN
dpc-2201	23	26	of	of	ADP
dpc-2201	23	27	jak2	jak2	NOUN
dpc-2201	23	28	and	and	CCONJ
dpc-2201	23	29	stat3	stat3	NOUN
dpc-2201	23	30	are	be	AUX
dpc-2201	23	31	involved	involve	VERB
dpc-2201	23	32	in	in	ADP
dpc-2201	23	33	psoriasis	psoriasis	NOUN
dpc-2201	23	34	[	[	X
dpc-2201	23	35	4	4	NUM
dpc-2201	23	36	]	]	PUNCT
dpc-2201	23	37	.	.	PUNCT
dpc-2201	24	1	jaki	jaki	PROPN
dpc-2201	24	2	medications	medications	PROPN
dpc-2201	24	3	provide	provide	VERB
dpc-2201	24	4	us	we	PRON
dpc-2201	24	5	with	with	ADP
dpc-2201	24	6	the	the	DET
dpc-2201	24	7	possibility	possibility	NOUN
dpc-2201	24	8	of	of	ADP
dpc-2201	24	9	shutting	shut	VERB
dpc-2201	24	10	down	down	ADP
dpc-2201	24	11	the	the	DET
dpc-2201	24	12	impaired	impaired	ADJ
dpc-2201	24	13	jak	jak	PROPN
dpc-2201	24	14	-	-	PUNCT
dpc-2201	24	15	stat	stat	NOUN
dpc-2201	24	16	pairs	pair	NOUN
dpc-2201	24	17	.	.	PUNCT
dpc-2201	25	1	ruxolitinib	ruxolitinib	NOUN
dpc-2201	25	2	and	and	CCONJ
dpc-2201	25	3	tofacitinib	tofacitinib	NOUN
dpc-2201	25	4	are	be	AUX
dpc-2201	25	5	the	the	DET
dpc-2201	25	6	prototypes	prototype	NOUN
dpc-2201	25	7	of	of	ADP
dpc-2201	25	8	jaki	jaki	PROPN
dpc-2201	25	9	.	.	PUNCT
dpc-2201	26	1	ruxolitinib	ruxolitinib	PROPN
dpc-2201	26	2	is	be	AUX
dpc-2201	26	3	a	a	DET
dpc-2201	26	4	jak1/2	jak1/2	PROPN
dpc-2201	26	5	selective	selective	ADJ
dpc-2201	26	6	inhibitor	inhibitor	NOUN
dpc-2201	26	7	;	;	PUNCT
dpc-2201	26	8	it	it	PRON
dpc-2201	26	9	affects	affect	VERB
dpc-2201	26	10	several	several	ADJ
dpc-2201	26	11	parts	part	NOUN
dpc-2201	26	12	of	of	ADP
dpc-2201	26	13	the	the	DET
dpc-2201	26	14	innate	innate	ADJ
dpc-2201	26	15	and	and	CCONJ
dpc-2201	26	16	adaptive	adaptive	ADJ
dpc-2201	26	17	immune	immune	ADJ
dpc-2201	26	18	system	system	NOUN
dpc-2201	26	19	,	,	PUNCT
dpc-2201	26	20	including	include	VERB
dpc-2201	26	21	natural	natural	ADJ
dpc-2201	26	22	killer	killer	NOUN
dpc-2201	26	23	cells	cell	NOUN
dpc-2201	26	24	(	(	PUNCT
dpc-2201	26	25	nkc	nkc	PROPN
dpc-2201	26	26	)	)	PUNCT
dpc-2201	26	27	,	,	PUNCT
dpc-2201	26	28	dendritic	dendritic	ADJ
dpc-2201	26	29	cells	cell	NOUN
dpc-2201	26	30	,	,	PUNCT
dpc-2201	26	31	t	t	NOUN
dpc-2201	26	32	-	-	PUNCT
dpc-2201	26	33	helpers	helper	NOUN
dpc-2201	26	34	,	,	PUNCT
dpc-2201	26	35	and	and	CCONJ
dpc-2201	26	36	regulatory	regulatory	ADJ
dpc-2201	26	37	t	t	PROPN
dpc-2201	26	38	-	-	PUNCT
dpc-2201	26	39	cells	cell	NOUN
dpc-2201	26	40	[	[	X
dpc-2201	26	41	5	5	NUM
dpc-2201	26	42	]	]	PUNCT
dpc-2201	26	43	.	.	PUNCT
dpc-2201	27	1	tofacitinib	tofacitinib	PROPN
dpc-2201	27	2	preferentially	preferentially	ADV
dpc-2201	27	3	blocks	block	VERB
dpc-2201	27	4	jak1/3	jak1/3	PRON
dpc-2201	27	5	and	and	CCONJ
dpc-2201	27	6	,	,	PUNCT
dpc-2201	27	7	to	to	ADP
dpc-2201	27	8	some	some	DET
dpc-2201	27	9	degree	degree	NOUN
dpc-2201	27	10	,	,	PUNCT
dpc-2201	27	11	jak2	jak2	NOUN
dpc-2201	27	12	and	and	CCONJ
dpc-2201	27	13	tyk2	tyk2	VERB
dpc-2201	27	14	[	[	PUNCT
dpc-2201	27	15	6	6	NUM
dpc-2201	27	16	]	]	PUNCT
dpc-2201	27	17	.	.	PUNCT
dpc-2201	28	1	jaki	jaki	PROPN
dpc-2201	28	2	,	,	PUNCT
dpc-2201	28	3	like	like	ADP
dpc-2201	28	4	other	other	ADJ
dpc-2201	28	5	medications	medication	NOUN
dpc-2201	28	6	,	,	PUNCT
dpc-2201	28	7	have	have	VERB
dpc-2201	28	8	adverse	adverse	ADJ
dpc-2201	28	9	effects	effect	NOUN
dpc-2201	28	10	(	(	PUNCT
dpc-2201	28	11	aes	aes	NOUN
dpc-2201	28	12	)	)	PUNCT
dpc-2201	28	13	on	on	ADP
dpc-2201	28	14	the	the	DET
dpc-2201	28	15	human	human	ADJ
dpc-2201	28	16	body	body	NOUN
dpc-2201	28	17	.	.	PUNCT
dpc-2201	29	1	jaki	jaki	PROPN
dpc-2201	29	2	suppress	suppress	VERB
dpc-2201	29	3	the	the	DET
dpc-2201	29	4	immune	immune	ADJ
dpc-2201	29	5	system	system	NOUN
dpc-2201	29	6	at	at	ADP
dpc-2201	29	7	some	some	DET
dpc-2201	29	8	levels	level	NOUN
dpc-2201	29	9	,	,	PUNCT
dpc-2201	29	10	and	and	CCONJ
dpc-2201	29	11	their	their	PRON
dpc-2201	29	12	consumption	consumption	NOUN
dpc-2201	29	13	increases	increase	VERB
dpc-2201	29	14	the	the	DET
dpc-2201	29	15	risk	risk	NOUN
dpc-2201	29	16	of	of	ADP
dpc-2201	29	17	some	some	DET
dpc-2201	29	18	infections	infection	NOUN
dpc-2201	29	19	such	such	ADJ
dpc-2201	29	20	as	as	ADP
dpc-2201	29	21	herpes	herpe	NOUN
dpc-2201	29	22	zoster	zoster	NOUN
dpc-2201	29	23	(	(	PUNCT
dpc-2201	29	24	hz	hz	PROPN
dpc-2201	29	25	)	)	PUNCT
dpc-2201	29	26	.	.	PUNCT
dpc-2201	30	1	vaccination	vaccination	NOUN
dpc-2201	30	2	against	against	ADP
dpc-2201	30	3	hz	hz	NOUN
dpc-2201	30	4	prior	prior	ADV
dpc-2201	30	5	to	to	ADP
dpc-2201	30	6	the	the	DET
dpc-2201	30	7	treatment	treatment	NOUN
dpc-2201	30	8	with	with	ADP
dpc-2201	30	9	tofacitinib	tofacitinib	NOUN
dpc-2201	30	10	is	be	AUX
dpc-2201	30	11	recommended	recommend	VERB
dpc-2201	30	12	.	.	PUNCT
dpc-2201	31	1	non	non	ADJ
dpc-2201	31	2	-	-	ADJ
dpc-2201	31	3	hz	hz	ADJ
dpc-2201	31	4	opportunistic	opportunistic	ADJ
dpc-2201	31	5	infections	infection	NOUN
dpc-2201	31	6	,	,	PUNCT
dpc-2201	31	7	including	include	VERB
dpc-2201	31	8	cytomegalovirus	cytomegalovirus	NOUN
dpc-2201	31	9	,	,	PUNCT
dpc-2201	31	10	cryptococcus	cryptococcus	NOUN
dpc-2201	31	11	,	,	PUNCT
dpc-2201	31	12	histoplasmosis	histoplasmosis	NOUN
dpc-2201	31	13	and	and	CCONJ
dpc-2201	31	14	clostridium	clostridium	NOUN
dpc-2201	31	15	difficile	difficile	NOUN
dpc-2201	31	16	are	be	AUX
dpc-2201	31	17	also	also	ADV
dpc-2201	31	18	reported	report	VERB
dpc-2201	31	19	in	in	ADP
dpc-2201	31	20	jaki	jaki	PROPN
dpc-2201	31	21	recipients	recipient	NOUN
dpc-2201	31	22	[	[	X
dpc-2201	31	23	5,7	5,7	NUM
dpc-2201	31	24	]	]	PUNCT
dpc-2201	31	25	.	.	PUNCT
dpc-2201	32	1	there	there	PRON
dpc-2201	32	2	is	be	VERB
dpc-2201	32	3	a	a	DET
dpc-2201	32	4	potential	potential	ADJ
dpc-2201	32	5	risk	risk	NOUN
dpc-2201	32	6	of	of	ADP
dpc-2201	32	7	increasing	increase	VERB
dpc-2201	32	8	venous	venous	ADJ
dpc-2201	32	9	thromboembolism	thromboembolism	NOUN
dpc-2201	32	10	(	(	PUNCT
dpc-2201	32	11	vte	vte	NOUN
dpc-2201	32	12	)	)	PUNCT
dpc-2201	32	13	events	event	NOUN
dpc-2201	32	14	following	follow	VERB
dpc-2201	32	15	the	the	DET
dpc-2201	32	16	treatment	treatment	NOUN
dpc-2201	32	17	with	with	ADP
dpc-2201	32	18	jaki	jaki	PROPN
dpc-2201	32	19	so	so	SCONJ
dpc-2201	32	20	it	it	PRON
dpc-2201	32	21	is	be	AUX
dpc-2201	32	22	recommended	recommend	VERB
dpc-2201	32	23	to	to	PART
dpc-2201	32	24	avoid	avoid	VERB
dpc-2201	32	25	prescribing	prescribe	VERB
dpc-2201	32	26	jaki	jaki	NOUN
dpc-2201	32	27	in	in	ADP
dpc-2201	32	28	patients	patient	NOUN
dpc-2201	32	29	with	with	ADP
dpc-2201	32	30	age	age	NOUN
dpc-2201	32	31	>	>	X
dpc-2201	32	32	50	50	NUM
dpc-2201	32	33	,	,	PUNCT
dpc-2201	32	34	previous	previous	ADJ
dpc-2201	32	35	vte	vte	NOUN
dpc-2201	32	36	,	,	PUNCT
dpc-2201	32	37	hypercoagulability	hypercoagulability	NOUN
dpc-2201	32	38	,	,	PUNCT
dpc-2201	32	39	smoking	smoking	NOUN
dpc-2201	32	40	,	,	PUNCT
dpc-2201	32	41	cardiovascular	cardiovascular	ADJ
dpc-2201	32	42	disease	disease	NOUN
dpc-2201	32	43	(	(	PUNCT
dpc-2201	32	44	cvd	cvd	PROPN
dpc-2201	32	45	)	)	PUNCT
dpc-2201	32	46	,	,	PUNCT
dpc-2201	32	47	long	long	ADJ
dpc-2201	32	48	-	-	PUNCT
dpc-2201	32	49	term	term	NOUN
dpc-2201	32	50	immobilization	immobilization	NOUN
dpc-2201	32	51	,	,	PUNCT
dpc-2201	32	52	recent	recent	ADJ
dpc-2201	32	53	trauma	trauma	NOUN
dpc-2201	32	54	or	or	CCONJ
dpc-2201	32	55	surgery	surgery	NOUN
dpc-2201	32	56	,	,	PUNCT
dpc-2201	32	57	paralysis	paralysis	NOUN
dpc-2201	32	58	,	,	PUNCT
dpc-2201	32	59	malignancy	malignancy	NOUN
dpc-2201	32	60	,	,	PUNCT
dpc-2201	32	61	obesity	obesity	NOUN
dpc-2201	32	62	,	,	PUNCT
dpc-2201	32	63	frequent	frequent	ADJ
dpc-2201	32	64	long	long	ADJ
dpc-2201	32	65	flights	flight	NOUN
dpc-2201	32	66	,	,	PUNCT
dpc-2201	32	67	and	and	CCONJ
dpc-2201	32	68	hormonal	hormonal	ADJ
dpc-2201	32	69	therapy	therapy	NOUN
dpc-2201	32	70	.	.	PUNCT
dpc-2201	33	1	a	a	DET
dpc-2201	33	2	further	further	ADJ
dpc-2201	33	3	consideration	consideration	NOUN
dpc-2201	33	4	is	be	AUX
dpc-2201	33	5	required	require	VERB
dpc-2201	33	6	to	to	ADP
dpc-2201	33	7	either	either	CCONJ
dpc-2201	33	8	avoid	avoid	VERB
dpc-2201	33	9	or	or	CCONJ
dpc-2201	33	10	prescribe	prescribe	VERB
dpc-2201	33	11	jaki	jaki	PROPN
dpc-2201	33	12	with	with	ADP
dpc-2201	33	13	extra	extra	ADJ
dpc-2201	33	14	caution	caution	NOUN
dpc-2201	33	15	in	in	ADP
dpc-2201	33	16	patients	patient	NOUN
dpc-2201	33	17	with	with	ADP
dpc-2201	33	18	a	a	DET
dpc-2201	33	19	history	history	NOUN
dpc-2201	33	20	of	of	ADP
dpc-2201	33	21	cancer	cancer	NOUN
dpc-2201	33	22	;	;	PUNCT
dpc-2201	33	23	however	however	ADV
dpc-2201	33	24	,	,	PUNCT
dpc-2201	33	25	there	there	PRON
dpc-2201	33	26	is	be	VERB
dpc-2201	33	27	not	not	PART
dpc-2201	33	28	enough	enough	ADJ
dpc-2201	33	29	evidence	evidence	NOUN
dpc-2201	33	30	and	and	CCONJ
dpc-2201	33	31	data	datum	NOUN
dpc-2201	33	32	about	about	ADP
dpc-2201	33	33	the	the	DET
dpc-2201	33	34	carcinogenicity	carcinogenicity	NOUN
dpc-2201	33	35	of	of	ADP
dpc-2201	33	36	jaki	jaki	PROPN
dpc-2201	33	37	.	.	PUNCT
dpc-2201	34	1	other	other	ADJ
dpc-2201	34	2	aes	aes	PROPN
dpc-2201	34	3	include	include	VERB
dpc-2201	34	4	anemia	anemia	NOUN
dpc-2201	34	5	,	,	PUNCT
dpc-2201	34	6	reversible	reversible	ADJ
dpc-2201	34	7	hyperlipidemia	hyperlipidemia	NOUN
dpc-2201	34	8	and	and	CCONJ
dpc-2201	34	9	minimal	minimal	ADJ
dpc-2201	34	10	elevation	elevation	NOUN
dpc-2201	34	11	in	in	ADP
dpc-2201	34	12	liver	liver	NOUN
dpc-2201	34	13	transaminases	transaminase	NOUN
dpc-2201	34	14	and	and	CCONJ
dpc-2201	34	15	creatine	creatine	NOUN
dpc-2201	34	16	phosphokinase	phosphokinase	NOUN
dpc-2201	34	17	(	(	PUNCT
dpc-2201	34	18	cpk	cpk	PROPN
dpc-2201	34	19	)	)	PUNCT
dpc-2201	35	1	[	[	X
dpc-2201	35	2	7,8	7,8	NUM
dpc-2201	35	3	]	]	PUNCT
dpc-2201	35	4	.	.	PUNCT
dpc-2201	36	1	objectives	objective	VERB
dpc-2201	36	2	the	the	DET
dpc-2201	36	3	development	development	NOUN
dpc-2201	36	4	of	of	ADP
dpc-2201	36	5	jaki	jaki	PROPN
dpc-2201	36	6	in	in	ADP
dpc-2201	36	7	dermatology	dermatology	NOUN
dpc-2201	36	8	and	and	CCONJ
dpc-2201	36	9	rheumatology	rheumatology	NOUN
dpc-2201	36	10	is	be	AUX
dpc-2201	36	11	still	still	ADV
dpc-2201	36	12	in	in	ADP
dpc-2201	36	13	the	the	DET
dpc-2201	36	14	early	early	ADJ
dpc-2201	36	15	stage	stage	NOUN
dpc-2201	36	16	;	;	PUNCT
dpc-2201	36	17	however	however	ADV
dpc-2201	36	18	,	,	PUNCT
dpc-2201	36	19	there	there	PRON
dpc-2201	36	20	is	be	VERB
dpc-2201	36	21	favorable	favorable	ADJ
dpc-2201	36	22	evidence	evidence	NOUN
dpc-2201	36	23	about	about	ADP
dpc-2201	36	24	the	the	DET
dpc-2201	36	25	utility	utility	NOUN
dpc-2201	36	26	of	of	ADP
dpc-2201	36	27	jaki	jaki	PROPN
dpc-2201	36	28	in	in	ADP
dpc-2201	36	29	treating	treat	VERB
dpc-2201	36	30	some	some	PRON
dpc-2201	36	31	of	of	ADP
dpc-2201	36	32	the	the	DET
dpc-2201	36	33	autoimmune	autoimmune	ADJ
dpc-2201	36	34	disorders	disorder	NOUN
dpc-2201	36	35	.	.	PUNCT
dpc-2201	37	1	to	to	PART
dpc-2201	37	2	prevent	prevent	VERB
dpc-2201	37	3	extensive	extensive	ADJ
dpc-2201	37	4	efforts	effort	NOUN
dpc-2201	37	5	collecting	collect	VERB
dpc-2201	37	6	data	datum	NOUN
dpc-2201	37	7	from	from	ADP
dpc-2201	37	8	different	different	ADJ
dpc-2201	37	9	studies	study	NOUN
dpc-2201	37	10	to	to	PART
dpc-2201	37	11	answer	answer	VERB
dpc-2201	37	12	specific	specific	ADJ
dpc-2201	37	13	inquiries	inquiry	NOUN
dpc-2201	37	14	about	about	ADP
dpc-2201	37	15	such	such	ADJ
dpc-2201	37	16	disorders	disorder	NOUN
dpc-2201	37	17	and	and	CCONJ
dpc-2201	37	18	medications	medication	NOUN
dpc-2201	37	19	,	,	PUNCT
dpc-2201	37	20	we	we	PRON
dpc-2201	37	21	performed	perform	VERB
dpc-2201	37	22	a	a	DET
dpc-2201	37	23	narrative	narrative	NOUN
dpc-2201	37	24	review	review	NOUN
dpc-2201	37	25	to	to	PART
dpc-2201	37	26	summarize	summarize	VERB
dpc-2201	37	27	all	all	DET
dpc-2201	37	28	the	the	DET
dpc-2201	37	29	available	available	ADJ
dpc-2201	37	30	evidence	evidence	NOUN
dpc-2201	37	31	on	on	ADP
dpc-2201	37	32	the	the	DET
dpc-2201	37	33	utility	utility	NOUN
dpc-2201	37	34	of	of	ADP
dpc-2201	37	35	jaki	jaki	PROPN
dpc-2201	37	36	in	in	ADP
dpc-2201	37	37	treating	treat	VERB
dpc-2201	37	38	aa	aa	NOUN
dpc-2201	37	39	,	,	PUNCT
dpc-2201	37	40	pv	pv	ADV
dpc-2201	37	41	and	and	CCONJ
dpc-2201	37	42	psa	psa	VERB
dpc-2201	37	43	,	,	PUNCT
dpc-2201	37	44	ad	ad	NOUN
dpc-2201	37	45	,	,	PUNCT
dpc-2201	37	46	vitiligo	vitiligo	NOUN
dpc-2201	37	47	,	,	PUNCT
dpc-2201	37	48	lp	lp	PROPN
dpc-2201	37	49	,	,	PUNCT
dpc-2201	37	50	hs	hs	PROPN
dpc-2201	37	51	,	,	PUNCT
dpc-2201	37	52	and	and	CCONJ
dpc-2201	37	53	pg	pg	INTJ
dpc-2201	37	54	.	.	PUNCT
dpc-2201	38	1	methods	method	NOUN
dpc-2201	38	2	a	a	DET
dpc-2201	38	3	thorough	thorough	ADJ
dpc-2201	38	4	search	search	NOUN
dpc-2201	38	5	was	be	AUX
dpc-2201	38	6	performed	perform	VERB
dpc-2201	38	7	on	on	ADP
dpc-2201	38	8	pubmed	pubmed	PROPN
dpc-2201	38	9	,	,	PUNCT
dpc-2201	38	10	and	and	CCONJ
dpc-2201	38	11	google	google	PROPN
dpc-2201	38	12	scholar	scholar	NOUN
dpc-2201	38	13	using	use	VERB
dpc-2201	38	14	combinations	combination	NOUN
dpc-2201	38	15	of	of	ADP
dpc-2201	38	16	the	the	DET
dpc-2201	38	17	following	follow	VERB
dpc-2201	38	18	mesh	mesh	NOUN
dpc-2201	38	19	terms	term	NOUN
dpc-2201	38	20	:	:	PUNCT
dpc-2201	38	21	“	"	PUNCT
dpc-2201	38	22	tofacitinib	tofacitinib	PROPN
dpc-2201	38	23	,	,	PUNCT
dpc-2201	38	24	”	"	PUNCT
dpc-2201	38	25	“	"	PUNCT
dpc-2201	38	26	ruxolitinib	ruxolitinib	NOUN
dpc-2201	38	27	,	,	PUNCT
dpc-2201	38	28	”	"	PUNCT
dpc-2201	38	29	“	"	PUNCT
dpc-2201	38	30	jak	jak	PROPN
dpc-2201	38	31	inhibitors	inhibitor	NOUN
dpc-2201	38	32	,	,	PUNCT
dpc-2201	38	33	”	"	PUNCT
dpc-2201	38	34	“	"	PUNCT
dpc-2201	38	35	janus	janus	PROPN
dpc-2201	38	36	kinase	kinase	PROPN
dpc-2201	38	37	inhibitors	inhibitor	NOUN
dpc-2201	38	38	,	,	PUNCT
dpc-2201	38	39	”	"	PUNCT
dpc-2201	38	40	“	"	PUNCT
dpc-2201	38	41	alopecia	alopecia	NOUN
dpc-2201	38	42	areata	areata	NOUN
dpc-2201	38	43	,	,	PUNCT
dpc-2201	38	44	”	"	PUNCT
dpc-2201	38	45	“	"	PUNCT
dpc-2201	38	46	psoriasis	psoriasis	NOUN
dpc-2201	38	47	vulgaris	vulgaris	NOUN
dpc-2201	38	48	,	,	PUNCT
dpc-2201	38	49	”	"	PUNCT
dpc-2201	38	50	“	"	PUNCT
dpc-2201	38	51	psoriasis	psoriasis	NOUN
dpc-2201	38	52	arthritis	arthritis	NOUN
dpc-2201	38	53	,	,	PUNCT
dpc-2201	38	54	”	"	PUNCT
dpc-2201	38	55	“	"	PUNCT
dpc-2201	38	56	atopic	atopic	NOUN
dpc-2201	38	57	dermatitis	dermatitis	NOUN
dpc-2201	38	58	,	,	PUNCT
dpc-2201	38	59	”	"	PUNCT
dpc-2201	38	60	“	"	PUNCT
dpc-2201	38	61	vitiligo	vitiligo	VERB
dpc-2201	38	62	,	,	PUNCT
dpc-2201	38	63	”	"	PUNCT
dpc-2201	38	64	“	"	PUNCT
dpc-2201	38	65	hidradenitis	hidradenitis	NOUN
dpc-2201	38	66	suppurative	suppurative	NOUN
dpc-2201	38	67	,	,	PUNCT
dpc-2201	38	68	”	"	PUNCT
dpc-2201	38	69	“	"	PUNCT
dpc-2201	38	70	pyoderma	pyoderma	NOUN
dpc-2201	38	71	gangrenosum	gangrenosum	NOUN
dpc-2201	38	72	,	,	PUNCT
dpc-2201	38	73	”	"	PUNCT
dpc-2201	38	74	“	"	PUNCT
dpc-2201	38	75	lichen	lichen	NOUN
dpc-2201	38	76	planus	planus	NOUN
dpc-2201	38	77	,	,	PUNCT
dpc-2201	38	78	”	"	PUNCT
dpc-2201	38	79	“	"	PUNCT
dpc-2201	38	80	lichen	lichen	NOUN
dpc-2201	38	81	planopilaris	planopilaris	NOUN
dpc-2201	38	82	.	.	PUNCT
dpc-2201	38	83	”	"	PUNCT
dpc-2201	39	1	a	a	DET
dpc-2201	39	2	total	total	NOUN
dpc-2201	39	3	of	of	ADP
dpc-2201	39	4	672	672	NUM
dpc-2201	39	5	publications	publication	NOUN
dpc-2201	39	6	were	be	AUX
dpc-2201	39	7	found	find	VERB
dpc-2201	39	8	.	.	PUNCT
dpc-2201	40	1	after	after	ADP
dpc-2201	40	2	removing	remove	VERB
dpc-2201	40	3	duplicates	duplicate	NOUN
dpc-2201	40	4	and	and	CCONJ
dpc-2201	40	5	non	non	ADJ
dpc-2201	40	6	-	-	ADJ
dpc-2201	40	7	suitable	suitable	ADJ
dpc-2201	40	8	publications	publication	NOUN
dpc-2201	40	9	,	,	PUNCT
dpc-2201	40	10	we	we	PRON
dpc-2201	40	11	focused	focus	VERB
dpc-2201	40	12	on	on	ADP
dpc-2201	40	13	the	the	DET
dpc-2201	40	14	most	most	ADV
dpc-2201	40	15	recent	recent	ADJ
dpc-2201	40	16	and	and	CCONJ
dpc-2201	40	17	available	available	ADJ
dpc-2201	40	18	pooled	pool	VERB
dpc-2201	40	19	studies	study	NOUN
dpc-2201	40	20	such	such	ADJ
dpc-2201	40	21	as	as	ADP
dpc-2201	40	22	systematic	systematic	ADJ
dpc-2201	40	23	reviews	review	NOUN
dpc-2201	40	24	and	and	CCONJ
dpc-2201	40	25	meta	meta	NOUN
dpc-2201	40	26	-	-	PUNCT
dpc-2201	40	27	analyses	analysis	NOUN
dpc-2201	40	28	and	and	CCONJ
dpc-2201	40	29	then	then	ADV
dpc-2201	40	30	available	available	VERB
dpc-2201	40	31	clinical	clinical	ADJ
dpc-2201	40	32	trials	trial	NOUN
dpc-2201	40	33	,	,	PUNCT
dpc-2201	40	34	observational	observational	ADJ
dpc-2201	40	35	and	and	CCONJ
dpc-2201	40	36	case	case	NOUN
dpc-2201	40	37	studies	study	NOUN
dpc-2201	40	38	.	.	PUNCT
dpc-2201	41	1	results	result	VERB
dpc-2201	41	2	alopecia	alopecia	NOUN
dpc-2201	41	3	areata	areata	ADJ
dpc-2201	41	4	alopecia	alopecia	NOUN
dpc-2201	41	5	areata	areata	ADJ
dpc-2201	41	6	is	be	AUX
dpc-2201	41	7	a	a	DET
dpc-2201	41	8	non	non	ADJ
dpc-2201	41	9	-	-	ADJ
dpc-2201	41	10	cicatricial	cicatricial	ADJ
dpc-2201	41	11	alopecia	alopecia	NOUN
dpc-2201	41	12	with	with	ADP
dpc-2201	41	13	an	an	DET
dpc-2201	41	14	autoimmune	autoimmune	ADJ
dpc-2201	41	15	etiology	etiology	NOUN
dpc-2201	41	16	,	,	PUNCT
dpc-2201	41	17	affecting	affect	VERB
dpc-2201	41	18	approximately	approximately	ADV
dpc-2201	41	19	2	2	NUM
dpc-2201	41	20	%	%	NOUN
dpc-2201	41	21	of	of	ADP
dpc-2201	41	22	the	the	DET
dpc-2201	41	23	general	general	ADJ
dpc-2201	41	24	population	population	NOUN
dpc-2201	41	25	.	.	PUNCT
dpc-2201	42	1	histopathology	histopathology	NOUN
dpc-2201	42	2	assessment	assessment	NOUN
dpc-2201	42	3	on	on	ADP
dpc-2201	42	4	the	the	DET
dpc-2201	42	5	involved	involved	ADJ
dpc-2201	42	6	skin	skin	NOUN
dpc-2201	42	7	showed	show	VERB
dpc-2201	42	8	lymphocytic	lymphocytic	ADJ
dpc-2201	42	9	infiltration	infiltration	NOUN
dpc-2201	42	10	around	around	ADP
dpc-2201	42	11	the	the	DET
dpc-2201	42	12	hair	hair	NOUN
dpc-2201	42	13	follicles	follicle	VERB
dpc-2201	42	14	at	at	ADP
dpc-2201	42	15	the	the	DET
dpc-2201	42	16	level	level	NOUN
dpc-2201	42	17	of	of	ADP
dpc-2201	42	18	bulb	bulb	NOUN
dpc-2201	42	19	or	or	CCONJ
dpc-2201	42	20	lower	low	ADJ
dpc-2201	42	21	[	[	X
dpc-2201	42	22	9	9	NUM
dpc-2201	42	23	]	]	SYM
dpc-2201	42	24	.	.	PUNCT
dpc-2201	43	1	immune	immune	ADJ
dpc-2201	43	2	system	system	NOUN
dpc-2201	43	3	dysregulation	dysregulation	NOUN
dpc-2201	43	4	results	result	NOUN
dpc-2201	43	5	in	in	ADP
dpc-2201	43	6	hair	hair	NOUN
dpc-2201	43	7	follicles	follicle	VERB
dpc-2201	43	8	damage	damage	NOUN
dpc-2201	43	9	by	by	ADP
dpc-2201	43	10	t	t	PROPN
dpc-2201	43	11	-	-	PUNCT
dpc-2201	43	12	cells	cell	NOUN
dpc-2201	43	13	and	and	CCONJ
dpc-2201	43	14	nkc	nkc	PROPN
dpc-2201	43	15	.	.	PUNCT
dpc-2201	44	1	moreover	moreover	ADV
dpc-2201	44	2	,	,	PUNCT
dpc-2201	44	3	auto	auto	NOUN
dpc-2201	44	4	-	-	PUNCT
dpc-2201	44	5	reactivation	reactivation	NOUN
dpc-2201	44	6	of	of	ADP
dpc-2201	44	7	immune	immune	ADJ
dpc-2201	44	8	cells	cell	NOUN
dpc-2201	44	9	upregulates	upregulate	VERB
dpc-2201	44	10	ifn	ifn	PROPN
dpc-2201	44	11	-	-	PUNCT
dpc-2201	44	12	γ	γ	NOUN
dpc-2201	44	13	and	and	CCONJ
dpc-2201	44	14	cytokines	cytokine	NOUN
dpc-2201	44	15	and	and	CCONJ
dpc-2201	44	16	cause	cause	VERB
dpc-2201	44	17	further	further	ADJ
dpc-2201	44	18	cellular	cellular	ADJ
dpc-2201	44	19	damage	damage	NOUN
dpc-2201	44	20	and	and	CCONJ
dpc-2201	44	21	inflammation	inflammation	NOUN
dpc-2201	44	22	[	[	X
dpc-2201	44	23	10	10	NUM
dpc-2201	44	24	]	]	PUNCT
dpc-2201	44	25	.	.	PUNCT
dpc-2201	45	1	excessive	excessive	ADJ
dpc-2201	45	2	activation	activation	NOUN
dpc-2201	45	3	of	of	ADP
dpc-2201	45	4	jak	jak	PROPN
dpc-2201	45	5	-	-	PUNCT
dpc-2201	45	6	stat	stat	PROPN
dpc-2201	45	7	has	have	VERB
dpc-2201	45	8	a	a	DET
dpc-2201	45	9	major	major	ADJ
dpc-2201	45	10	effect	effect	NOUN
dpc-2201	45	11	on	on	ADP
dpc-2201	45	12	maintaining	maintain	VERB
dpc-2201	45	13	the	the	DET
dpc-2201	45	14	activation	activation	NOUN
dpc-2201	45	15	of	of	ADP
dpc-2201	45	16	cd8	cd8	PROPN
dpc-2201	45	17	+	+	PROPN
dpc-2201	45	18	t	t	PROPN
dpc-2201	45	19	-	-	PUNCT
dpc-2201	45	20	cells	cell	NOUN
dpc-2201	45	21	and	and	CCONJ
dpc-2201	45	22	nkc	nkc	PROPN
dpc-2201	45	23	.	.	PUNCT
dpc-2201	46	1	additionally	additionally	ADV
dpc-2201	46	2	,	,	PUNCT
dpc-2201	46	3	a	a	DET
dpc-2201	46	4	low	low	ADJ
dpc-2201	46	5	level	level	NOUN
dpc-2201	46	6	of	of	ADP
dpc-2201	46	7	t	t	PROPN
dpc-2201	46	8	-	-	PUNCT
dpc-2201	46	9	regulatory	regulatory	ADJ
dpc-2201	46	10	cells	cell	NOUN
dpc-2201	46	11	identified	identify	VERB
dpc-2201	46	12	in	in	ADP
dpc-2201	46	13	aa	aa	PROPN
dpc-2201	46	14	patients	patient	NOUN
dpc-2201	46	15	,	,	PUNCT
dpc-2201	46	16	makes	make	VERB
dpc-2201	46	17	it	it	PRON
dpc-2201	46	18	impossible	impossible	ADJ
dpc-2201	46	19	to	to	PART
dpc-2201	46	20	suppress	suppress	VERB
dpc-2201	46	21	excessive	excessive	ADJ
dpc-2201	46	22	amounts	amount	NOUN
dpc-2201	46	23	of	of	ADP
dpc-2201	46	24	cytokines	cytokine	NOUN
dpc-2201	46	25	.	.	PUNCT
dpc-2201	47	1	these	these	DET
dpc-2201	47	2	complexes	complex	NOUN
dpc-2201	47	3	of	of	ADP
dpc-2201	47	4	immune	immune	ADJ
dpc-2201	47	5	dysregulations	dysregulation	NOUN
dpc-2201	47	6	contribute	contribute	VERB
dpc-2201	47	7	to	to	ADP
dpc-2201	47	8	hair	hair	NOUN
dpc-2201	47	9	follicles	follicle	VERB
dpc-2201	47	10	damage	damage	NOUN
dpc-2201	47	11	[	[	X
dpc-2201	47	12	10,11	10,11	NOUN
dpc-2201	47	13	]	]	PUNCT
dpc-2201	47	14	.	.	PUNCT
dpc-2201	48	1	conclusions	conclusion	NOUN
dpc-2201	48	2	:	:	PUNCT
dpc-2201	48	3	tofacitinib	tofacitinib	PROPN
dpc-2201	48	4	and	and	CCONJ
dpc-2201	48	5	ruxolitinib	ruxolitinib	NOUN
dpc-2201	48	6	showed	show	VERB
dpc-2201	48	7	potential	potential	ADJ
dpc-2201	48	8	efficacy	efficacy	NOUN
dpc-2201	48	9	in	in	ADP
dpc-2201	48	10	treating	treat	VERB
dpc-2201	48	11	several	several	ADJ
dpc-2201	48	12	autoimmune	autoimmune	ADJ
dpc-2201	48	13	disorders	disorder	NOUN
dpc-2201	48	14	.	.	PUNCT
dpc-2201	49	1	based	base	VERB
dpc-2201	49	2	on	on	ADP
dpc-2201	49	3	records	record	NOUN
dpc-2201	49	4	in	in	ADP
dpc-2201	49	5	the	the	DET
dpc-2201	49	6	reviewed	review	VERB
dpc-2201	49	7	studies	study	NOUN
dpc-2201	49	8	,	,	PUNCT
dpc-2201	49	9	both	both	DET
dpc-2201	49	10	medications	medication	NOUN
dpc-2201	49	11	had	have	VERB
dpc-2201	49	12	acceptable	acceptable	ADJ
dpc-2201	49	13	safety	safety	NOUN
dpc-2201	49	14	profiles	profile	NOUN
dpc-2201	49	15	;	;	PUNCT
dpc-2201	49	16	however	however	ADV
dpc-2201	49	17	,	,	PUNCT
dpc-2201	49	18	physicians	physician	NOUN
dpc-2201	49	19	are	be	AUX
dpc-2201	49	20	recommended	recommend	VERB
dpc-2201	49	21	to	to	PART
dpc-2201	49	22	outweigh	outweigh	VERB
dpc-2201	49	23	the	the	DET
dpc-2201	49	24	risks	risk	NOUN
dpc-2201	49	25	and	and	CCONJ
dpc-2201	49	26	benefits	benefit	NOUN
dpc-2201	49	27	of	of	ADP
dpc-2201	49	28	such	such	ADJ
dpc-2201	49	29	treatments	treatment	NOUN
dpc-2201	49	30	for	for	ADP
dpc-2201	49	31	each	each	DET
dpc-2201	49	32	specific	specific	ADJ
dpc-2201	49	33	condition	condition	NOUN
dpc-2201	49	34	.	.	PUNCT
dpc-2201	50	1	review	review	NOUN
dpc-2201	50	2	|	|	ADV
dpc-2201	50	3	dermatol	dermatol	ADJ
dpc-2201	50	4	pract	pract	NOUN
dpc-2201	50	5	concept	concept	NOUN
dpc-2201	50	6	.	.	PUNCT
dpc-2201	51	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	51	2	3	3	NUM
dpc-2201	51	3	yu	yu	PROPN
dpc-2201	51	4	et	et	PROPN
dpc-2201	51	5	al	al	PROPN
dpc-2201	51	6	reviewed	review	VERB
dpc-2201	51	7	12	12	NUM
dpc-2201	51	8	studies	study	NOUN
dpc-2201	51	9	with	with	ADP
dpc-2201	51	10	346	346	NUM
dpc-2201	51	11	patients	patient	NOUN
dpc-2201	51	12	.	.	PUNCT
dpc-2201	52	1	in	in	ADP
dpc-2201	52	2	this	this	DET
dpc-2201	52	3	review	review	NOUN
dpc-2201	52	4	288	288	NUM
dpc-2201	52	5	participants	participant	NOUN
dpc-2201	52	6	received	receive	VERB
dpc-2201	52	7	oral	oral	ADJ
dpc-2201	52	8	tofacitinib	tofacitinib	NOUN
dpc-2201	52	9	and	and	CCONJ
dpc-2201	52	10	58	58	NUM
dpc-2201	52	11	received	receive	VERB
dpc-2201	52	12	oral	oral	ADJ
dpc-2201	52	13	ruxolitinib	ruxolitinib	NOUN
dpc-2201	52	14	.	.	PUNCT
dpc-2201	53	1	the	the	DET
dpc-2201	53	2	outcome	outcome	NOUN
dpc-2201	53	3	measurement	measurement	NOUN
dpc-2201	53	4	was	be	AUX
dpc-2201	53	5	reported	report	VERB
dpc-2201	53	6	with	with	ADP
dpc-2201	53	7	the	the	DET
dpc-2201	53	8	severity	severity	NOUN
dpc-2201	53	9	of	of	ADP
dpc-2201	53	10	alopecia	alopecia	NOUN
dpc-2201	53	11	tool50	tool50	NOUN
dpc-2201	53	12	(	(	PUNCT
dpc-2201	53	13	salt50	salt50	NOUN
dpc-2201	53	14	)	)	PUNCT
dpc-2201	53	15	,	,	PUNCT
dpc-2201	53	16	showing	show	VERB
dpc-2201	53	17	66	66	NUM
dpc-2201	53	18	%	%	NOUN
dpc-2201	53	19	overall	overall	ADJ
dpc-2201	53	20	improvement	improvement	NOUN
dpc-2201	53	21	in	in	ADP
dpc-2201	53	22	all	all	DET
dpc-2201	53	23	patients	patient	NOUN
dpc-2201	53	24	.	.	PUNCT
dpc-2201	54	1	there	there	PRON
dpc-2201	54	2	was	be	VERB
dpc-2201	54	3	no	no	DET
dpc-2201	54	4	statistically	statistically	ADJ
dpc-2201	54	5	difference	difference	NOUN
dpc-2201	54	6	when	when	SCONJ
dpc-2201	54	7	studies	study	NOUN
dpc-2201	54	8	categorized	categorize	VERB
dpc-2201	54	9	by	by	ADP
dpc-2201	54	10	sex	sex	NOUN
dpc-2201	54	11	,	,	PUNCT
dpc-2201	54	12	age	age	NOUN
dpc-2201	54	13	and	and	CCONJ
dpc-2201	54	14	subtypes	subtype	NOUN
dpc-2201	54	15	of	of	ADP
dpc-2201	54	16	aa	aa	NOUN
dpc-2201	54	17	(	(	PUNCT
dpc-2201	54	18	p	p	X
dpc-2201	54	19	=	=	NOUN
dpc-2201	54	20	0.81	0.81	NUM
dpc-2201	54	21	,	,	PUNCT
dpc-2201	54	22	p	p	X
dpc-2201	54	23	=	=	NOUN
dpc-2201	54	24	0.37	0.37	NUM
dpc-2201	54	25	and	and	CCONJ
dpc-2201	54	26	p	p	X
dpc-2201	54	27	=	=	NOUN
dpc-2201	54	28	 	 	SPACE
dpc-2201	54	29	0.91	0.91	NUM
dpc-2201	54	30	,	,	PUNCT
dpc-2201	54	31	respectively	respectively	ADV
dpc-2201	54	32	)	)	PUNCT
dpc-2201	54	33	.	.	PUNCT
dpc-2201	55	1	the	the	DET
dpc-2201	55	2	salt50	salt50	NOUN
dpc-2201	55	3	rates	rate	NOUN
dpc-2201	55	4	were	be	AUX
dpc-2201	55	5	lower	low	ADJ
dpc-2201	55	6	in	in	ADP
dpc-2201	55	7	patients	patient	NOUN
dpc-2201	55	8	who	who	PRON
dpc-2201	55	9	received	receive	VERB
dpc-2201	55	10	a	a	DET
dpc-2201	55	11	shorter	short	ADJ
dpc-2201	55	12	length	length	NOUN
dpc-2201	55	13	of	of	ADP
dpc-2201	55	14	treatment	treatment	NOUN
dpc-2201	55	15	but	but	CCONJ
dpc-2201	55	16	was	be	AUX
dpc-2201	55	17	not	not	PART
dpc-2201	55	18	statistically	statistically	ADV
dpc-2201	55	19	significant	significant	ADJ
dpc-2201	55	20	(	(	PUNCT
dpc-2201	55	21	p	p	X
dpc-2201	55	22	=	=	NOUN
dpc-2201	55	23	0.25	0.25	NUM
dpc-2201	55	24	)	)	PUNCT
dpc-2201	55	25	.	.	PUNCT
dpc-2201	56	1	the	the	DET
dpc-2201	56	2	reported	reported	ADJ
dpc-2201	56	3	aes	aes	PROPN
dpc-2201	56	4	were	be	AUX
dpc-2201	56	5	upper	upper	ADJ
dpc-2201	56	6	respiratory	respiratory	ADJ
dpc-2201	56	7	tract	tract	NOUN
dpc-2201	56	8	infections	infection	NOUN
dpc-2201	56	9	(	(	PUNCT
dpc-2201	56	10	urti	urti	ADJ
dpc-2201	56	11	)	)	PUNCT
dpc-2201	56	12	,	,	PUNCT
dpc-2201	56	13	urinary	urinary	ADJ
dpc-2201	56	14	tract	tract	NOUN
dpc-2201	56	15	infections	infection	NOUN
dpc-2201	56	16	(	(	PUNCT
dpc-2201	56	17	uti	uti	PROPN
dpc-2201	56	18	)	)	PUNCT
dpc-2201	56	19	,	,	PUNCT
dpc-2201	56	20	herpes	herpe	NOUN
dpc-2201	56	21	simplex	simplex	NOUN
dpc-2201	56	22	and	and	CCONJ
dpc-2201	56	23	herpes	herpe	NOUN
dpc-2201	56	24	zoster	zoster	NOUN
dpc-2201	56	25	infections	infection	NOUN
dpc-2201	56	26	,	,	PUNCT
dpc-2201	56	27	alteration	alteration	NOUN
dpc-2201	56	28	of	of	ADP
dpc-2201	56	29	blood	blood	NOUN
dpc-2201	56	30	cells	cell	NOUN
dpc-2201	56	31	count	count	VERB
dpc-2201	56	32	,	,	PUNCT
dpc-2201	56	33	the	the	DET
dpc-2201	56	34	elevation	elevation	NOUN
dpc-2201	56	35	of	of	ADP
dpc-2201	56	36	liver	liver	NOUN
dpc-2201	56	37	aminotransaminase	aminotransaminase	NOUN
dpc-2201	56	38	and	and	CCONJ
dpc-2201	56	39	lipids	lipid	NOUN
dpc-2201	56	40	;	;	PUNCT
dpc-2201	56	41	moreover	moreover	ADV
dpc-2201	56	42	,	,	PUNCT
dpc-2201	56	43	there	there	PRON
dpc-2201	56	44	were	be	VERB
dpc-2201	56	45	no	no	DET
dpc-2201	56	46	fatal	fatal	ADJ
dpc-2201	56	47	aes	aes	NOUN
dpc-2201	56	48	[	[	X
dpc-2201	56	49	12	12	NUM
dpc-2201	56	50	]	]	PUNCT
dpc-2201	56	51	.	.	PUNCT
dpc-2201	57	1	in	in	ADP
dpc-2201	57	2	another	another	DET
dpc-2201	57	3	meta	meta	ADJ
dpc-2201	57	4	-	-	PUNCT
dpc-2201	57	5	analysis	analysis	NOUN
dpc-2201	57	6	,	,	PUNCT
dpc-2201	57	7	hamilton	hamilton	PROPN
dpc-2201	57	8	et	et	PROPN
dpc-2201	57	9	al	al	PROPN
dpc-2201	57	10	reviewed	review	VERB
dpc-2201	57	11	ten	ten	NUM
dpc-2201	57	12	different	different	ADJ
dpc-2201	57	13	studies	study	NOUN
dpc-2201	57	14	on	on	ADP
dpc-2201	57	15	the	the	DET
dpc-2201	57	16	systemic	systemic	ADJ
dpc-2201	57	17	and	and	CCONJ
dpc-2201	57	18	topical	topical	ADJ
dpc-2201	57	19	tofacitinib	tofacitinib	NOUN
dpc-2201	57	20	and	and	CCONJ
dpc-2201	57	21	ruxolitinib	ruxolitinib	NOUN
dpc-2201	57	22	in	in	ADP
dpc-2201	57	23	children	child	NOUN
dpc-2201	57	24	and	and	CCONJ
dpc-2201	57	25	teenage	teenage	ADJ
dpc-2201	57	26	populations	population	NOUN
dpc-2201	57	27	(	(	PUNCT
dpc-2201	57	28	age	age	NOUN
dpc-2201	57	29	1	1	NUM
dpc-2201	57	30	–	–	PUNCT
dpc-2201	57	31	17	17	NUM
dpc-2201	57	32	years	year	NOUN
dpc-2201	57	33	)	)	PUNCT
dpc-2201	57	34	.	.	PUNCT
dpc-2201	58	1	the	the	DET
dpc-2201	58	2	review	review	NOUN
dpc-2201	58	3	affirmed	affirm	VERB
dpc-2201	58	4	success	success	NOUN
dpc-2201	58	5	for	for	ADP
dpc-2201	58	6	jaki	jaki	PROPN
dpc-2201	58	7	in	in	ADP
dpc-2201	58	8	children	child	NOUN
dpc-2201	58	9	and	and	CCONJ
dpc-2201	58	10	teens	teen	NOUN
dpc-2201	58	11	with	with	ADP
dpc-2201	58	12	higher	high	ADJ
dpc-2201	58	13	numbers	number	NOUN
dpc-2201	58	14	of	of	ADP
dpc-2201	58	15	complete	complete	ADJ
dpc-2201	58	16	responders	responder	NOUN
dpc-2201	58	17	and	and	CCONJ
dpc-2201	58	18	smaller	small	ADJ
dpc-2201	58	19	numbers	number	NOUN
dpc-2201	58	20	of	of	ADP
dpc-2201	58	21	poor	poor	ADJ
dpc-2201	58	22	responders	responder	NOUN
dpc-2201	58	23	compared	compare	VERB
dpc-2201	58	24	to	to	ADP
dpc-2201	58	25	adults	adult	NOUN
dpc-2201	58	26	.	.	PUNCT
dpc-2201	59	1	aes	aes	PROPN
dpc-2201	59	2	were	be	AUX
dpc-2201	59	3	small	small	ADJ
dpc-2201	59	4	and	and	CCONJ
dpc-2201	59	5	limited	limit	VERB
dpc-2201	59	6	to	to	ADP
dpc-2201	59	7	mild	mild	ADJ
dpc-2201	59	8	infections	infection	NOUN
dpc-2201	59	9	,	,	PUNCT
dpc-2201	59	10	diarrhea	diarrhea	NOUN
dpc-2201	59	11	and	and	CCONJ
dpc-2201	59	12	reversible	reversible	ADJ
dpc-2201	59	13	lab	lab	NOUN
dpc-2201	59	14	abnormalities	abnormality	NOUN
dpc-2201	59	15	[	[	X
dpc-2201	59	16	13	13	NUM
dpc-2201	59	17	]	]	PUNCT
dpc-2201	59	18	.	.	PUNCT
dpc-2201	60	1	in	in	ADP
dpc-2201	60	2	addition	addition	NOUN
dpc-2201	60	3	,	,	PUNCT
dpc-2201	60	4	guo	guo	PROPN
dpc-2201	60	5	et	et	PROPN
dpc-2201	60	6	al	al	PROPN
dpc-2201	60	7	conducted	conduct	VERB
dpc-2201	60	8	a	a	DET
dpc-2201	60	9	meta	meta	ADJ
dpc-2201	60	10	-	-	PUNCT
dpc-2201	60	11	analysis	analysis	NOUN
dpc-2201	60	12	on	on	ADP
dpc-2201	60	13	14	14	NUM
dpc-2201	60	14	studies	study	NOUN
dpc-2201	60	15	with	with	ADP
dpc-2201	60	16	275	275	NUM
dpc-2201	60	17	patients	patient	NOUN
dpc-2201	60	18	treating	treat	VERB
dpc-2201	60	19	with	with	ADP
dpc-2201	60	20	oral	oral	ADJ
dpc-2201	60	21	and	and	CCONJ
dpc-2201	60	22	topical	topical	ADJ
dpc-2201	60	23	tofacitinib	tofacitinib	NOUN
dpc-2201	60	24	.	.	PUNCT
dpc-2201	61	1	a	a	DET
dpc-2201	61	2	complete	complete	ADJ
dpc-2201	61	3	response	response	NOUN
dpc-2201	61	4	in	in	ADP
dpc-2201	61	5	54.0	54.0	NUM
dpc-2201	61	6	%	%	NOUN
dpc-2201	61	7	and	and	CCONJ
dpc-2201	61	8	partial	partial	ADJ
dpc-2201	61	9	response	response	NOUN
dpc-2201	61	10	in	in	ADP
dpc-2201	61	11	26.1	26.1	NUM
dpc-2201	61	12	%	%	NOUN
dpc-2201	61	13	of	of	ADP
dpc-2201	61	14	patients	patient	NOUN
dpc-2201	61	15	were	be	AUX
dpc-2201	61	16	reported	report	VERB
dpc-2201	61	17	.	.	PUNCT
dpc-2201	62	1	the	the	DET
dpc-2201	62	2	aa	aa	PROPN
dpc-2201	62	3	relapse	relapse	NOUN
dpc-2201	62	4	rates	rate	NOUN
dpc-2201	62	5	were	be	AUX
dpc-2201	62	6	24.0	24.0	NUM
dpc-2201	62	7	%	%	NOUN
dpc-2201	62	8	in	in	ADP
dpc-2201	62	9	the	the	DET
dpc-2201	62	10	pooled	pool	VERB
dpc-2201	62	11	results	result	NOUN
dpc-2201	62	12	,	,	PUNCT
dpc-2201	62	13	and	and	CCONJ
dpc-2201	62	14	the	the	DET
dpc-2201	62	15	main	main	ADJ
dpc-2201	62	16	reason	reason	NOUN
dpc-2201	62	17	was	be	AUX
dpc-2201	62	18	medication	medication	NOUN
dpc-2201	62	19	discontinuation	discontinuation	NOUN
dpc-2201	62	20	.	.	PUNCT
dpc-2201	63	1	a	a	DET
dpc-2201	63	2	7.2	7.2	NUM
dpc-2201	63	3	%	%	NOUN
dpc-2201	63	4	of	of	ADP
dpc-2201	63	5	patients	patient	NOUN
dpc-2201	63	6	presented	present	VERB
dpc-2201	63	7	aes	aes	PROPN
dpc-2201	63	8	,	,	PUNCT
dpc-2201	63	9	and	and	CCONJ
dpc-2201	63	10	the	the	DET
dpc-2201	63	11	most	most	ADV
dpc-2201	63	12	common	common	ADJ
dpc-2201	63	13	ae	ae	PROPN
dpc-2201	63	14	was	be	AUX
dpc-2201	63	15	urti	urti	ADJ
dpc-2201	64	1	[	[	X
dpc-2201	64	2	14	14	NUM
dpc-2201	64	3	]	]	PUNCT
dpc-2201	64	4	.	.	PUNCT
dpc-2201	65	1	psoriasis	psoriasis	NOUN
dpc-2201	65	2	vulgaris	vulgaris	NOUN
dpc-2201	65	3	psoriasis	psoriasis	NOUN
dpc-2201	65	4	is	be	AUX
dpc-2201	65	5	a	a	DET
dpc-2201	65	6	chronic	chronic	ADJ
dpc-2201	65	7	autoimmune	autoimmune	ADJ
dpc-2201	65	8	inflammatory	inflammatory	ADJ
dpc-2201	65	9	disease	disease	NOUN
dpc-2201	65	10	with	with	ADP
dpc-2201	65	11	the	the	DET
dpc-2201	65	12	prevalence	prevalence	NOUN
dpc-2201	65	13	of	of	ADP
dpc-2201	65	14	2	2	NUM
dpc-2201	65	15	%	%	NOUN
dpc-2201	65	16	worldwide	worldwide	ADV
dpc-2201	65	17	.	.	PUNCT
dpc-2201	66	1	psoriasis	psoriasis	NOUN
dpc-2201	66	2	has	have	VERB
dpc-2201	66	3	several	several	ADJ
dpc-2201	66	4	subtypes	subtype	NOUN
dpc-2201	66	5	,	,	PUNCT
dpc-2201	66	6	including	include	VERB
dpc-2201	66	7	plaque	plaque	NOUN
dpc-2201	66	8	,	,	PUNCT
dpc-2201	66	9	guttate	guttate	ADJ
dpc-2201	66	10	,	,	PUNCT
dpc-2201	66	11	inverse	inverse	NOUN
dpc-2201	66	12	,	,	PUNCT
dpc-2201	66	13	and	and	CCONJ
dpc-2201	66	14	pustular	pustular	ADJ
dpc-2201	66	15	.	.	PUNCT
dpc-2201	67	1	overactivation	overactivation	NOUN
dpc-2201	67	2	of	of	ADP
dpc-2201	67	3	dendritic	dendritic	ADJ
dpc-2201	67	4	cells	cell	NOUN
dpc-2201	67	5	is	be	AUX
dpc-2201	67	6	responsible	responsible	ADJ
dpc-2201	67	7	for	for	ADP
dpc-2201	67	8	the	the	DET
dpc-2201	67	9	initial	initial	ADJ
dpc-2201	67	10	phase	phase	NOUN
dpc-2201	67	11	of	of	ADP
dpc-2201	67	12	psoriasis	psoriasis	NOUN
dpc-2201	67	13	and	and	CCONJ
dpc-2201	67	14	unbalanced	unbalanced	ADJ
dpc-2201	67	15	elevated	elevated	ADJ
dpc-2201	67	16	levels	level	NOUN
dpc-2201	67	17	of	of	ADP
dpc-2201	67	18	cytokines	cytokine	NOUN
dpc-2201	67	19	such	such	ADJ
dpc-2201	67	20	as	as	ADP
dpc-2201	67	21	il-17	il-17	NOUN
dpc-2201	67	22	,	,	PUNCT
dpc-2201	67	23	il-21	il-21	NUM
dpc-2201	67	24	and	and	CCONJ
dpc-2201	67	25	il-22	il-22	PRON
dpc-2201	67	26	(	(	PUNCT
dpc-2201	67	27	mostly	mostly	ADV
dpc-2201	67	28	th17	th17	PROPN
dpc-2201	67	29	and	and	CCONJ
dpc-2201	67	30	il-23	il-23	NOUN
dpc-2201	67	31	driven	drive	VERB
dpc-2201	67	32	[	[	X
dpc-2201	67	33	15	15	NUM
dpc-2201	67	34	]	]	PUNCT
dpc-2201	67	35	)	)	PUNCT
dpc-2201	67	36	for	for	ADP
dpc-2201	67	37	the	the	DET
dpc-2201	67	38	maintenance	maintenance	NOUN
dpc-2201	67	39	phase	phase	NOUN
dpc-2201	67	40	of	of	ADP
dpc-2201	67	41	inflammation	inflammation	NOUN
dpc-2201	67	42	.	.	PUNCT
dpc-2201	68	1	medications	medication	NOUN
dpc-2201	68	2	such	such	ADJ
dpc-2201	68	3	as	as	ADP
dpc-2201	68	4	tofacitinib	tofacitinib	NOUN
dpc-2201	68	5	and	and	CCONJ
dpc-2201	68	6	ruxolitinib	ruxolitinib	NOUN
dpc-2201	68	7	targeting	target	VERB
dpc-2201	68	8	tnf	tnf	PROPN
dpc-2201	68	9	-	-	PUNCT
dpc-2201	68	10	α	α	NOUN
dpc-2201	68	11	,	,	PUNCT
dpc-2201	68	12	il-23	il-23	NOUN
dpc-2201	68	13	and	and	CCONJ
dpc-2201	68	14	il-17	il-17	ADV
dpc-2201	68	15	and	and	CCONJ
dpc-2201	68	16	jak	jak	PROPN
dpc-2201	68	17	/	/	SYM
dpc-2201	68	18	stat	stat	PROPN
dpc-2201	68	19	pathways	pathway	NOUN
dpc-2201	68	20	can	can	AUX
dpc-2201	68	21	be	be	AUX
dpc-2201	68	22	effective	effective	ADJ
dpc-2201	68	23	in	in	ADP
dpc-2201	68	24	treating	treat	VERB
dpc-2201	68	25	pv	pv	NOUN
dpc-2201	69	1	[	[	X
dpc-2201	69	2	16	16	NUM
dpc-2201	69	3	]	]	PUNCT
dpc-2201	69	4	.	.	PUNCT
dpc-2201	70	1	kvist	kvist	PROPN
dpc-2201	70	2	-	-	PUNCT
dpc-2201	70	3	hansen	hansen	PROPN
dpc-2201	70	4	et	et	PROPN
dpc-2201	70	5	al	al	PROPN
dpc-2201	70	6	conducted	conduct	VERB
dpc-2201	70	7	a	a	DET
dpc-2201	70	8	systematic	systematic	ADJ
dpc-2201	70	9	review	review	NOUN
dpc-2201	70	10	on	on	ADP
dpc-2201	70	11	five	five	NUM
dpc-2201	70	12	clinical	clinical	ADJ
dpc-2201	70	13	trials	trial	NOUN
dpc-2201	70	14	(	(	PUNCT
dpc-2201	70	15	phase	phase	NOUN
dpc-2201	70	16	two	two	NUM
dpc-2201	70	17	and	and	CCONJ
dpc-2201	70	18	three	three	NUM
dpc-2201	70	19	trials	trial	NOUN
dpc-2201	70	20	)	)	PUNCT
dpc-2201	70	21	utilizing	utilize	VERB
dpc-2201	70	22	oral	oral	ADJ
dpc-2201	70	23	tofacitinib	tofacitinib	NOUN
dpc-2201	70	24	to	to	PART
dpc-2201	70	25	treat	treat	VERB
dpc-2201	70	26	moderate	moderate	ADJ
dpc-2201	70	27	to	to	ADP
dpc-2201	70	28	severe	severe	ADJ
dpc-2201	70	29	forms	form	NOUN
dpc-2201	70	30	of	of	ADP
dpc-2201	70	31	pv	pv	NOUN
dpc-2201	70	32	.	.	PUNCT
dpc-2201	71	1	the	the	DET
dpc-2201	71	2	effectiveness	effectiveness	NOUN
dpc-2201	71	3	was	be	AUX
dpc-2201	71	4	calculated	calculate	VERB
dpc-2201	71	5	based	base	VERB
dpc-2201	71	6	on	on	ADP
dpc-2201	71	7	pasi75	pasi75	NOUN
dpc-2201	71	8	(	(	PUNCT
dpc-2201	71	9	psoriasis	psoriasis	NOUN
dpc-2201	71	10	area	area	NOUN
dpc-2201	71	11	&	&	CCONJ
dpc-2201	71	12	severity	severity	PROPN
dpc-2201	71	13	index	index	NOUN
dpc-2201	71	14	75	75	NUM
dpc-2201	71	15	%	%	NOUN
dpc-2201	71	16	reduction	reduction	NOUN
dpc-2201	71	17	)	)	PUNCT
dpc-2201	71	18	.	.	PUNCT
dpc-2201	72	1	in	in	ADP
dpc-2201	72	2	the	the	DET
dpc-2201	72	3	phase	phase	NOUN
dpc-2201	72	4	two	two	NUM
dpc-2201	72	5	studies	study	NOUN
dpc-2201	72	6	,	,	PUNCT
dpc-2201	72	7	the	the	DET
dpc-2201	72	8	effectiveness	effectiveness	NOUN
dpc-2201	72	9	of	of	ADP
dpc-2201	72	10	tofacitinib	tofacitinib	NOUN
dpc-2201	72	11	was	be	AUX
dpc-2201	72	12	reported	report	VERB
dpc-2201	72	13	25	25	NUM
dpc-2201	72	14	%	%	NOUN
dpc-2201	72	15	with	with	ADP
dpc-2201	72	16	2	2	NUM
dpc-2201	72	17	mg	mg	NOUN
dpc-2201	72	18	/	/	SYM
dpc-2201	72	19	bid	bid	NOUN
dpc-2201	72	20	,	,	PUNCT
dpc-2201	72	21	40.8	40.8	NUM
dpc-2201	72	22	%	%	NOUN
dpc-2201	72	23	with	with	ADP
dpc-2201	72	24	5	5	NUM
dpc-2201	72	25	mg	mg	NOUN
dpc-2201	72	26	/	/	SYM
dpc-2201	72	27	bid	bid	NOUN
dpc-2201	72	28	,	,	PUNCT
dpc-2201	72	29	and	and	CCONJ
dpc-2201	72	30	66.7	66.7	NUM
dpc-2201	72	31	%	%	NOUN
dpc-2201	72	32	with	with	ADP
dpc-2201	72	33	15	15	NUM
dpc-2201	72	34	mg	mg	NOUN
dpc-2201	72	35	/	/	SYM
dpc-2201	72	36	bid	bid	NOUN
dpc-2201	72	37	compared	compare	VERB
dpc-2201	72	38	to	to	ADP
dpc-2201	72	39	2	2	NUM
dpc-2201	72	40	%	%	NOUN
dpc-2201	72	41	efficacy	efficacy	NOUN
dpc-2201	72	42	in	in	ADP
dpc-2201	72	43	placebo	placebo	NOUN
dpc-2201	72	44	.	.	PUNCT
dpc-2201	73	1	in	in	ADP
dpc-2201	73	2	the	the	DET
dpc-2201	73	3	phase	phase	NOUN
dpc-2201	73	4	three	three	NUM
dpc-2201	73	5	studies	study	NOUN
dpc-2201	73	6	,	,	PUNCT
dpc-2201	73	7	the	the	DET
dpc-2201	73	8	effectiveness	effectiveness	NOUN
dpc-2201	73	9	was	be	AUX
dpc-2201	73	10	reported	report	VERB
dpc-2201	73	11	39.5	39.5	NUM
dpc-2201	73	12	%	%	NOUN
dpc-2201	73	13	–	–	PUNCT
dpc-2201	73	14	54.3	54.3	NUM
dpc-2201	73	15	%	%	NOUN
dpc-2201	73	16	with	with	ADP
dpc-2201	73	17	5	5	NUM
dpc-2201	73	18	mg	mg	NUM
dpc-2201	73	19	/	/	SYM
dpc-2201	73	20	bid	bid	NOUN
dpc-2201	73	21	and	and	CCONJ
dpc-2201	73	22	59.2	59.2	NUM
dpc-2201	73	23	%	%	NOUN
dpc-2201	73	24	81.1	81.1	NUM
dpc-2201	73	25	%	%	NOUN
dpc-2201	73	26	with	with	ADP
dpc-2201	73	27	10	10	NUM
dpc-2201	73	28	mg	mg	NUM
dpc-2201	73	29	/	/	SYM
dpc-2201	73	30	bid	bid	NOUN
dpc-2201	73	31	compared	compare	VERB
dpc-2201	73	32	to	to	ADP
dpc-2201	73	33	5.6	5.6	NUM
dpc-2201	73	34	%	%	NOUN
dpc-2201	73	35	12.5	12.5	NUM
dpc-2201	73	36	%	%	NOUN
dpc-2201	73	37	for	for	ADP
dpc-2201	73	38	the	the	DET
dpc-2201	73	39	placebo	placebo	NOUN
dpc-2201	73	40	recipients	recipient	NOUN
dpc-2201	73	41	at	at	ADP
dpc-2201	73	42	weeks	week	NOUN
dpc-2201	73	43	16	16	NUM
dpc-2201	73	44	24	24	NUM
dpc-2201	73	45	.	.	PUNCT
dpc-2201	74	1	moreover	moreover	ADV
dpc-2201	74	2	,	,	PUNCT
dpc-2201	74	3	clinical	clinical	ADJ
dpc-2201	74	4	efficacy	efficacy	NOUN
dpc-2201	74	5	was	be	AUX
dpc-2201	74	6	reported	report	VERB
dpc-2201	74	7	based	base	VERB
dpc-2201	74	8	on	on	ADP
dpc-2201	74	9	dermatology	dermatology	NOUN
dpc-2201	74	10	life	life	NOUN
dpc-2201	74	11	quality	quality	NOUN
dpc-2201	74	12	index	index	NOUN
dpc-2201	74	13	(	(	PUNCT
dpc-2201	74	14	dlqi	dlqi	PROPN
dpc-2201	74	15	)	)	PUNCT
dpc-2201	74	16	and	and	CCONJ
dpc-2201	74	17	nail	nail	NOUN
dpc-2201	74	18	psoriasis	psoriasis	NOUN
dpc-2201	74	19	severity	severity	NOUN
dpc-2201	74	20	index	index	NOUN
dpc-2201	74	21	(	(	PUNCT
dpc-2201	74	22	npsi	npsi	PROPN
dpc-2201	74	23	)	)	PUNCT
dpc-2201	74	24	.	.	PUNCT
dpc-2201	75	1	aes	aes	NOUN
dpc-2201	75	2	such	such	ADJ
dpc-2201	75	3	as	as	ADP
dpc-2201	75	4	hyperlipidemia	hyperlipidemia	NOUN
dpc-2201	75	5	,	,	PUNCT
dpc-2201	75	6	cpk	cpk	PROPN
dpc-2201	75	7	elevation	elevation	PROPN
dpc-2201	75	8	,	,	PUNCT
dpc-2201	75	9	anemia	anemia	NOUN
dpc-2201	75	10	and	and	CCONJ
dpc-2201	75	11	lymphopenia	lymphopenia	NOUN
dpc-2201	75	12	were	be	AUX
dpc-2201	75	13	observed	observe	VERB
dpc-2201	75	14	in	in	ADP
dpc-2201	75	15	some	some	DET
dpc-2201	75	16	patients	patient	NOUN
dpc-2201	75	17	[	[	X
dpc-2201	75	18	17	17	NUM
dpc-2201	75	19	]	]	PUNCT
dpc-2201	75	20	.	.	PUNCT
dpc-2201	76	1	tian	tian	PROPN
dpc-2201	76	2	et	et	PROPN
dpc-2201	76	3	al	al	PROPN
dpc-2201	76	4	meta	meta	PROPN
dpc-2201	76	5	-	-	PUNCT
dpc-2201	76	6	analyzed	analyze	VERB
dpc-2201	76	7	seven	seven	NUM
dpc-2201	76	8	randomized	randomized	ADJ
dpc-2201	76	9	clinical	clinical	ADJ
dpc-2201	76	10	trials	trial	NOUN
dpc-2201	76	11	(	(	PUNCT
dpc-2201	76	12	rcts	rct	NOUN
dpc-2201	76	13	)	)	PUNCT
dpc-2201	76	14	about	about	ADP
dpc-2201	76	15	oral	oral	ADJ
dpc-2201	76	16	tofacitinib	tofacitinib	NOUN
dpc-2201	76	17	in	in	ADP
dpc-2201	76	18	chronic	chronic	ADJ
dpc-2201	76	19	plaque	plaque	NOUN
dpc-2201	76	20	psoriasis	psoriasis	NOUN
dpc-2201	76	21	.	.	PUNCT
dpc-2201	77	1	physician	physician	NOUN
dpc-2201	77	2	global	global	ADJ
dpc-2201	77	3	assessment	assessment	NOUN
dpc-2201	77	4	(	(	PUNCT
dpc-2201	77	5	pga	pga	PROPN
dpc-2201	77	6	)	)	PUNCT
dpc-2201	77	7	and	and	CCONJ
dpc-2201	77	8	pasi	pasi	NOUN
dpc-2201	77	9	75	75	NUM
dpc-2201	77	10	(	(	PUNCT
dpc-2201	77	11	4	4	NUM
dpc-2201	77	12	studies	study	NOUN
dpc-2201	77	13	reported	report	VERB
dpc-2201	77	14	pasi	pasi	NOUN
dpc-2201	77	15	90	90	NUM
dpc-2201	77	16	)	)	PUNCT
dpc-2201	77	17	showed	show	VERB
dpc-2201	77	18	denoting	denote	VERB
dpc-2201	77	19	difference	difference	NOUN
dpc-2201	77	20	between	between	ADP
dpc-2201	77	21	the	the	DET
dpc-2201	77	22	group	group	NOUN
dpc-2201	77	23	of	of	ADP
dpc-2201	77	24	tofacitinib	tofacitinib	NOUN
dpc-2201	77	25	5	5	NUM
dpc-2201	77	26	mg	mg	NUM
dpc-2201	77	27	/	/	SYM
dpc-2201	77	28	bid	bid	NOUN
dpc-2201	77	29	users	user	NOUN
dpc-2201	77	30	and	and	CCONJ
dpc-2201	77	31	control	control	NOUN
dpc-2201	77	32	group	group	NOUN
dpc-2201	77	33	(	(	PUNCT
dpc-2201	77	34	p	p	X
dpc-2201	77	35	<	<	X
dpc-2201	77	36	  	  	SPACE
dpc-2201	77	37	0.00001	0.00001	NUM
dpc-2201	77	38	)	)	PUNCT
dpc-2201	77	39	.	.	PUNCT
dpc-2201	78	1	the	the	DET
dpc-2201	78	2	effectiveness	effectiveness	NOUN
dpc-2201	78	3	of	of	ADP
dpc-2201	78	4	tofacitinib	tofacitinib	PROPN
dpc-2201	78	5	10	10	NUM
dpc-2201	78	6	mg/	mg/	ADJ
dpc-2201	78	7	bid	bid	NOUN
dpc-2201	78	8	was	be	AUX
dpc-2201	78	9	also	also	ADV
dpc-2201	78	10	significantly	significantly	ADV
dpc-2201	78	11	distinct	distinct	ADJ
dpc-2201	78	12	from	from	ADP
dpc-2201	78	13	the	the	DET
dpc-2201	78	14	control	control	NOUN
dpc-2201	78	15	group	group	NOUN
dpc-2201	78	16	(	(	PUNCT
dpc-2201	78	17	p	p	X
dpc-2201	78	18	 	 	SPACE
dpc-2201	78	19	<	<	X
dpc-2201	78	20	 	 	SPACE
dpc-2201	78	21	0.00001	0.00001	NUM
dpc-2201	78	22	)	)	PUNCT
dpc-2201	78	23	.	.	PUNCT
dpc-2201	79	1	moreover	moreover	ADV
dpc-2201	79	2	,	,	PUNCT
dpc-2201	79	3	5	5	NUM
dpc-2201	79	4	mg	mg	NOUN
dpc-2201	79	5	/	/	SYM
dpc-2201	79	6	bid	bid	NOUN
dpc-2201	79	7	of	of	ADP
dpc-2201	79	8	tofacitinib	tofacitinib	NOUN
dpc-2201	79	9	showed	show	VERB
dpc-2201	79	10	less	less	ADJ
dpc-2201	79	11	efficacy	efficacy	NOUN
dpc-2201	79	12	than	than	ADP
dpc-2201	79	13	10	10	NUM
dpc-2201	79	14	mg	mg	NUM
dpc-2201	79	15	/	/	SYM
dpc-2201	79	16	bid	bid	NOUN
dpc-2201	79	17	.	.	PUNCT
dpc-2201	80	1	even	even	ADV
dpc-2201	80	2	though	though	ADV
dpc-2201	80	3	,	,	PUNCT
dpc-2201	80	4	there	there	PRON
dpc-2201	80	5	was	be	VERB
dpc-2201	80	6	no	no	DET
dpc-2201	80	7	statistically	statistically	ADV
dpc-2201	80	8	significant	significant	ADJ
dpc-2201	80	9	difference	difference	NOUN
dpc-2201	80	10	in	in	ADP
dpc-2201	80	11	aes	aes	NOUN
dpc-2201	80	12	between	between	ADP
dpc-2201	80	13	5	5	NUM
dpc-2201	80	14	and	and	CCONJ
dpc-2201	80	15	10	10	NUM
dpc-2201	80	16	mg	mg	PROPN
dpc-2201	80	17	tofacitinib	tofacitinib	NOUN
dpc-2201	80	18	,	,	PUNCT
dpc-2201	80	19	more	more	ADJ
dpc-2201	80	20	aes	aes	PROPN
dpc-2201	80	21	were	be	AUX
dpc-2201	80	22	related	relate	VERB
dpc-2201	80	23	to	to	ADP
dpc-2201	80	24	10	10	NUM
dpc-2201	80	25	mg	mg	NUM
dpc-2201	80	26	/	/	SYM
dpc-2201	80	27	bid	bid	NOUN
dpc-2201	80	28	dosage	dosage	NOUN
dpc-2201	80	29	[	[	X
dpc-2201	80	30	18	18	NUM
dpc-2201	80	31	]	]	PUNCT
dpc-2201	80	32	.	.	PUNCT
dpc-2201	81	1	further	far	ADV
dpc-2201	81	2	,	,	PUNCT
dpc-2201	81	3	it	it	PRON
dpc-2201	81	4	is	be	AUX
dpc-2201	81	5	recommended	recommend	VERB
dpc-2201	81	6	to	to	PART
dpc-2201	81	7	conduct	conduct	VERB
dpc-2201	81	8	clinical	clinical	ADJ
dpc-2201	81	9	trials	trial	NOUN
dpc-2201	81	10	on	on	ADP
dpc-2201	81	11	topical	topical	ADJ
dpc-2201	81	12	types	type	NOUN
dpc-2201	81	13	of	of	ADP
dpc-2201	81	14	jaki	jaki	PROPN
dpc-2201	81	15	in	in	ADP
dpc-2201	81	16	treating	treat	VERB
dpc-2201	81	17	pv	pv	INTJ
dpc-2201	81	18	.	.	PUNCT
dpc-2201	82	1	psoriatic	psoriatic	ADJ
dpc-2201	82	2	arthritis	arthritis	NOUN
dpc-2201	82	3	approximately	approximately	ADV
dpc-2201	82	4	19.4	19.4	NUM
dpc-2201	82	5	%	%	NOUN
dpc-2201	82	6	of	of	ADP
dpc-2201	82	7	patients	patient	NOUN
dpc-2201	82	8	with	with	ADP
dpc-2201	82	9	psoriasis	psoriasis	NOUN
dpc-2201	82	10	present	present	ADJ
dpc-2201	82	11	joints	joint	NOUN
dpc-2201	82	12	involvement	involvement	NOUN
dpc-2201	82	13	[	[	X
dpc-2201	82	14	19	19	NUM
dpc-2201	82	15	]	]	PUNCT
dpc-2201	82	16	.	.	PUNCT
dpc-2201	83	1	psa	psa	NOUN
dpc-2201	83	2	manifestations	manifestation	NOUN
dpc-2201	83	3	include	include	VERB
dpc-2201	83	4	peripheral	peripheral	ADJ
dpc-2201	83	5	arthritis	arthritis	NOUN
dpc-2201	83	6	,	,	PUNCT
dpc-2201	83	7	enthesitis	enthesitis	NOUN
dpc-2201	83	8	,	,	PUNCT
dpc-2201	83	9	axial	axial	ADJ
dpc-2201	83	10	disease	disease	NOUN
dpc-2201	83	11	,	,	PUNCT
dpc-2201	83	12	dactylitis	dactylitis	NOUN
dpc-2201	83	13	,	,	PUNCT
dpc-2201	83	14	and	and	CCONJ
dpc-2201	83	15	skin	skin	NOUN
dpc-2201	83	16	characteristics	characteristic	NOUN
dpc-2201	83	17	[	[	X
dpc-2201	83	18	20	20	NUM
dpc-2201	83	19	]	]	PUNCT
dpc-2201	83	20	.	.	PUNCT
dpc-2201	84	1	no	no	DET
dpc-2201	84	2	serology	serology	NOUN
dpc-2201	84	3	markers	marker	NOUN
dpc-2201	84	4	are	be	AUX
dpc-2201	84	5	available	available	ADJ
dpc-2201	84	6	to	to	PART
dpc-2201	84	7	distinguish	distinguish	VERB
dpc-2201	84	8	psa	psa	NOUN
dpc-2201	84	9	from	from	ADP
dpc-2201	84	10	psoriasis	psoriasis	NOUN
dpc-2201	84	11	;	;	PUNCT
dpc-2201	84	12	however	however	ADV
dpc-2201	84	13	,	,	PUNCT
dpc-2201	84	14	hyperlipidemia	hyperlipidemia	NOUN
dpc-2201	84	15	,	,	PUNCT
dpc-2201	84	16	gout	gout	NOUN
dpc-2201	84	17	,	,	PUNCT
dpc-2201	84	18	axial	axial	ADJ
dpc-2201	84	19	spondylopathy	spondylopathy	ADJ
dpc-2201	84	20	or	or	CCONJ
dpc-2201	84	21	allergic	allergic	ADJ
dpc-2201	84	22	rhinitis	rhinitis	NOUN
dpc-2201	84	23	are	be	AUX
dpc-2201	84	24	more	more	ADV
dpc-2201	84	25	common	common	ADJ
dpc-2201	84	26	in	in	ADP
dpc-2201	84	27	psa	psa	NOUN
dpc-2201	84	28	[	[	X
dpc-2201	84	29	19	19	NUM
dpc-2201	84	30	]	]	PUNCT
dpc-2201	84	31	.	.	PUNCT
dpc-2201	85	1	companaro	companaro	NOUN
dpc-2201	85	2	et	et	PROPN
dpc-2201	85	3	al	al	PROPN
dpc-2201	85	4	systematically	systematically	ADV
dpc-2201	85	5	reviewed	review	VERB
dpc-2201	85	6	three	three	NUM
dpc-2201	85	7	rcts	rct	NOUN
dpc-2201	85	8	studying	study	VERB
dpc-2201	85	9	oral	oral	ADJ
dpc-2201	85	10	tofacitinib	tofacitinib	NOUN
dpc-2201	85	11	.	.	PUNCT
dpc-2201	86	1	in	in	ADP
dpc-2201	86	2	these	these	DET
dpc-2201	86	3	studies	study	NOUN
dpc-2201	86	4	,	,	PUNCT
dpc-2201	86	5	947	947	NUM
dpc-2201	86	6	patients	patient	NOUN
dpc-2201	86	7	treated	treat	VERB
dpc-2201	86	8	with	with	ADP
dpc-2201	86	9	tofacitinib	tofacitinib	NOUN
dpc-2201	86	10	and	and	CCONJ
dpc-2201	86	11	those	those	PRON
dpc-2201	86	12	who	who	PRON
dpc-2201	86	13	only	only	ADV
dpc-2201	86	14	received	receive	VERB
dpc-2201	86	15	5	5	NUM
dpc-2201	86	16	mg	mg	NOUN
dpc-2201	86	17	/	/	SYM
dpc-2201	86	18	bid	bid	NOUN
dpc-2201	86	19	were	be	AUX
dpc-2201	86	20	assessed	assess	VERB
dpc-2201	86	21	in	in	ADP
dpc-2201	86	22	the	the	DET
dpc-2201	86	23	review	review	NOUN
dpc-2201	86	24	.	.	PUNCT
dpc-2201	87	1	the	the	DET
dpc-2201	87	2	results	result	NOUN
dpc-2201	87	3	at	at	ADP
dpc-2201	87	4	week	week	NOUN
dpc-2201	87	5	16	16	NUM
dpc-2201	87	6	revealed	reveal	VERB
dpc-2201	87	7	a	a	DET
dpc-2201	87	8	significant	significant	ADJ
dpc-2201	87	9	higher	high	ADJ
dpc-2201	87	10	acr20	acr20	NOUN
dpc-2201	87	11	(	(	PUNCT
dpc-2201	87	12	number	number	NOUN
dpc-2201	87	13	of	of	ADP
dpc-2201	87	14	patients	patient	NOUN
dpc-2201	87	15	who	who	PRON
dpc-2201	87	16	achieved	achieve	VERB
dpc-2201	87	17	≥20	≥20	NOUN
dpc-2201	87	18	%	%	NOUN
dpc-2201	87	19	response	response	NOUN
dpc-2201	87	20	rate	rate	NOUN
dpc-2201	87	21	to	to	ADP
dpc-2201	87	22	the	the	DET
dpc-2201	87	23	treatment	treatment	NOUN
dpc-2201	87	24	based	base	VERB
dpc-2201	87	25	on	on	ADP
dpc-2201	87	26	the	the	DET
dpc-2201	87	27	american	american	PROPN
dpc-2201	87	28	college	college	PROPN
dpc-2201	87	29	of	of	ADP
dpc-2201	87	30	rheumatology	rheumatology	PROPN
dpc-2201	87	31	index	index	PROPN
dpc-2201	87	32	)	)	PUNCT
dpc-2201	87	33	response	response	NOUN
dpc-2201	87	34	than	than	ADP
dpc-2201	87	35	placebo	placebo	NOUN
dpc-2201	87	36	.	.	PUNCT
dpc-2201	88	1	moreover	moreover	ADV
dpc-2201	88	2	,	,	PUNCT
dpc-2201	88	3	tofacitinib	tofacitinib	NOUN
dpc-2201	88	4	also	also	ADV
dpc-2201	88	5	presented	present	VERB
dpc-2201	88	6	statistically	statistically	ADV
dpc-2201	88	7	higher	higher	ADV
dpc-2201	88	8	acr50	acr50	ADJ
dpc-2201	88	9	,	,	PUNCT
dpc-2201	88	10	acr70	acr70	ADV
dpc-2201	88	11	and	and	CCONJ
dpc-2201	88	12	pasi75	pasi75	VERB
dpc-2201	88	13	response	response	NOUN
dpc-2201	88	14	rates	rate	NOUN
dpc-2201	88	15	compared	compare	VERB
dpc-2201	88	16	to	to	ADP
dpc-2201	88	17	placebo	placebo	NOUN
dpc-2201	88	18	,	,	PUNCT
dpc-2201	88	19	and	and	CCONJ
dpc-2201	88	20	health	health	NOUN
dpc-2201	88	21	assessment	assessment	NOUN
dpc-2201	88	22	questionnaire	questionnaire	NOUN
dpc-2201	88	23	-	-	PUNCT
dpc-2201	88	24	disability	disability	NOUN
dpc-2201	88	25	index	index	NOUN
dpc-2201	88	26	(	(	PUNCT
dpc-2201	88	27	haq	haq	PROPN
dpc-2201	88	28	-	-	PUNCT
dpc-2201	88	29	di	di	NOUN
dpc-2201	88	30	)	)	PUNCT
dpc-2201	88	31	score	score	NOUN
dpc-2201	88	32	and	and	CCONJ
dpc-2201	88	33	post	post	ADJ
dpc-2201	88	34	-	-	ADJ
dpc-2201	88	35	treatment	treatment	ADJ
dpc-2201	88	36	fatigue	fatigue	NOUN
dpc-2201	88	37	assessment	assessment	NOUN
dpc-2201	88	38	showed	show	VERB
dpc-2201	88	39	lower	low	ADJ
dpc-2201	88	40	rate	rate	NOUN
dpc-2201	88	41	,	,	PUNCT
dpc-2201	88	42	which	which	PRON
dpc-2201	88	43	means	mean	VERB
dpc-2201	88	44	better	well	ADJ
dpc-2201	88	45	response	response	NOUN
dpc-2201	88	46	.	.	PUNCT
dpc-2201	89	1	serious	serious	ADJ
dpc-2201	89	2	aes	aes	PROPN
dpc-2201	89	3	were	be	AUX
dpc-2201	89	4	greater	great	ADJ
dpc-2201	89	5	in	in	ADP
dpc-2201	89	6	the	the	DET
dpc-2201	89	7	treatment	treatment	NOUN
dpc-2201	89	8	group	group	NOUN
dpc-2201	89	9	than	than	ADP
dpc-2201	89	10	the	the	DET
dpc-2201	89	11	control	control	NOUN
dpc-2201	89	12	group	group	NOUN
dpc-2201	89	13	;	;	PUNCT
dpc-2201	89	14	however	however	ADV
dpc-2201	89	15	,	,	PUNCT
dpc-2201	89	16	it	it	PRON
dpc-2201	89	17	was	be	AUX
dpc-2201	89	18	not	not	PART
dpc-2201	89	19	proved	prove	VERB
dpc-2201	89	20	statistically	statistically	ADV
dpc-2201	89	21	[	[	X
dpc-2201	89	22	21	21	NUM
dpc-2201	89	23	]	]	PUNCT
dpc-2201	89	24	.	.	PUNCT
dpc-2201	90	1	paik	paik	PROPN
dpc-2201	90	2	et	et	PROPN
dpc-2201	90	3	al	al	PROPN
dpc-2201	90	4	reviewed	review	VERB
dpc-2201	90	5	tofacitinib	tofacitinib	NOUN
dpc-2201	90	6	efficacy	efficacy	NOUN
dpc-2201	90	7	in	in	ADP
dpc-2201	90	8	two	two	NUM
dpc-2201	90	9	well	well	ADV
dpc-2201	90	10	-	-	PUNCT
dpc-2201	90	11	designed	design	VERB
dpc-2201	90	12	parallel	parallel	ADJ
dpc-2201	90	13	rcts	rct	NOUN
dpc-2201	90	14	(	(	PUNCT
dpc-2201	90	15	phase	phase	NOUN
dpc-2201	90	16	3	3	NUM
dpc-2201	90	17	)	)	PUNCT
dpc-2201	90	18	in	in	ADP
dpc-2201	90	19	psa	psa	NOUN
dpc-2201	90	20	patients	patient	NOUN
dpc-2201	90	21	:	:	PUNCT
dpc-2201	90	22	the	the	DET
dpc-2201	90	23	opal	opal	NOUN
dpc-2201	90	24	broaden	broaden	VERB
dpc-2201	90	25	with	with	ADP
dpc-2201	90	26	442	442	NUM
dpc-2201	90	27	patients	patient	NOUN
dpc-2201	90	28	for	for	ADP
dpc-2201	90	29	12	12	NUM
dpc-2201	90	30	months	month	NOUN
dpc-2201	90	31	and	and	CCONJ
dpc-2201	90	32	the	the	DET
dpc-2201	90	33	opal	opal	NOUN
dpc-2201	90	34	beyond	beyond	ADP
dpc-2201	90	35	with	with	ADP
dpc-2201	90	36	394	394	NUM
dpc-2201	90	37	patients	patient	NOUN
dpc-2201	90	38	for	for	ADP
dpc-2201	90	39	six	six	NUM
dpc-2201	90	40	months	month	NOUN
dpc-2201	90	41	.	.	PUNCT
dpc-2201	91	1	patients	patient	NOUN
dpc-2201	91	2	received	receive	VERB
dpc-2201	91	3	tofacitinib	tofacitinib	NOUN
dpc-2201	91	4	5	5	NUM
dpc-2201	91	5	or	or	CCONJ
dpc-2201	91	6	10	10	NUM
dpc-2201	91	7	mg	mg	NUM
dpc-2201	91	8	/	/	SYM
dpc-2201	91	9	bid	bid	NOUN
dpc-2201	91	10	or	or	CCONJ
dpc-2201	91	11	placebo	placebo	NOUN
dpc-2201	91	12	(	(	PUNCT
dpc-2201	91	13	or	or	CCONJ
dpc-2201	91	14	adalimumab	adalimumab	VERB
dpc-2201	91	15	40	40	NUM
dpc-2201	91	16	mg	mg	PROPN
dpc-2201	91	17	/	/	SYM
dpc-2201	91	18	sc	sc	PROPN
dpc-2201	91	19	combined	combine	VERB
dpc-2201	91	20	with	with	ADP
dpc-2201	91	21	a	a	DET
dpc-2201	91	22	csdmard	csdmard	NOUN
dpc-2201	91	23	instead	instead	ADV
dpc-2201	91	24	of	of	ADP
dpc-2201	91	25	placebo	placebo	NOUN
dpc-2201	91	26	in	in	ADP
dpc-2201	91	27	opal	opal	NOUN
dpc-2201	91	28	broaden	broaden	VERB
dpc-2201	91	29	)	)	PUNCT
dpc-2201	91	30	in	in	ADP
dpc-2201	91	31	both	both	DET
dpc-2201	91	32	trials	trial	NOUN
dpc-2201	91	33	.	.	PUNCT
dpc-2201	92	1	the	the	DET
dpc-2201	92	2	efficacy	efficacy	NOUN
dpc-2201	92	3	of	of	ADP
dpc-2201	92	4	tofacitinib	tofacitinib	PROPN
dpc-2201	92	5	over	over	ADP
dpc-2201	92	6	placebo	placebo	NOUN
dpc-2201	92	7	was	be	AUX
dpc-2201	92	8	evaluated	evaluate	VERB
dpc-2201	92	9	with	with	ADP
dpc-2201	92	10	acr20	acr20	NOUN
dpc-2201	92	11	,	,	PUNCT
dpc-2201	92	12	acr50	acr50	ADJ
dpc-2201	92	13	,	,	PUNCT
dpc-2201	92	14	acr70	acr70	PROPN
dpc-2201	92	15	,	,	PUNCT
dpc-2201	92	16	haq	haq	PROPN
dpc-2201	92	17	-	-	PUNCT
dpc-2201	92	18	di	di	NOUN
dpc-2201	92	19	and	and	CCONJ
dpc-2201	92	20	pasi75	pasi75	NOUN
dpc-2201	92	21	.	.	PUNCT
dpc-2201	93	1	after	after	ADP
dpc-2201	93	2	three	three	NUM
dpc-2201	93	3	months	month	NOUN
dpc-2201	93	4	,	,	PUNCT
dpc-2201	93	5	tofacitinib	tofacitinib	NOUN
dpc-2201	93	6	5	5	NUM
dpc-2201	93	7	mg	mg	NUM
dpc-2201	93	8	/	/	SYM
dpc-2201	93	9	bid	bid	NOUN
dpc-2201	93	10	recipients	recipient	NOUN
dpc-2201	93	11	achieved	achieve	VERB
dpc-2201	93	12	statistically	statistically	ADV
dpc-2201	93	13	significant	significant	ADJ
dpc-2201	93	14	acr20	acr20	NOUN
dpc-2201	93	15	or	or	CCONJ
dpc-2201	93	16	acr50	acr50	ADJ
dpc-2201	93	17	and	and	CCONJ
dpc-2201	93	18	haq	haq	PROPN
dpc-2201	93	19	-	-	PUNCT
dpc-2201	93	20	di	di	NOUN
dpc-2201	93	21	4	4	NUM
dpc-2201	93	22	review	review	NOUN
dpc-2201	93	23	|	|	ADV
dpc-2201	93	24	dermatol	dermatol	ADJ
dpc-2201	93	25	pract	pract	NOUN
dpc-2201	93	26	concept	concept	NOUN
dpc-2201	93	27	.	.	PUNCT
dpc-2201	94	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	94	2	patients	patient	NOUN
dpc-2201	94	3	received	receive	VERB
dpc-2201	94	4	oral	oral	ADJ
dpc-2201	94	5	tofacitinib	tofacitinib	NOUN
dpc-2201	94	6	5	5	NUM
dpc-2201	94	7	–	–	SYM
dpc-2201	94	8	10	10	NUM
dpc-2201	94	9	mg	mg	NUM
dpc-2201	94	10	/	/	SYM
dpc-2201	94	11	bid	bid	NOUN
dpc-2201	94	12	for	for	ADP
dpc-2201	94	13	12	12	NUM
dpc-2201	94	14	–	–	SYM
dpc-2201	94	15	40	40	NUM
dpc-2201	94	16	weeks	week	NOUN
dpc-2201	94	17	;	;	PUNCT
dpc-2201	94	18	11	11	NUM
dpc-2201	94	19	patients	patient	NOUN
dpc-2201	94	20	received	receive	VERB
dpc-2201	94	21	topical	topical	ADJ
dpc-2201	94	22	tofacitinib	tofacitinib	NOUN
dpc-2201	94	23	2	2	NUM
dpc-2201	94	24	%	%	NOUN
dpc-2201	94	25	bid	bid	NOUN
dpc-2201	94	26	+	+	CCONJ
dpc-2201	94	27	uvb	uvb	ADJ
dpc-2201	94	28	phototherapy	phototherapy	NOUN
dpc-2201	94	29	for	for	ADP
dpc-2201	94	30	12	12	NUM
dpc-2201	94	31	weeks	week	NOUN
dpc-2201	94	32	,	,	PUNCT
dpc-2201	94	33	21	21	NUM
dpc-2201	94	34	patients	patient	NOUN
dpc-2201	94	35	received	receive	VERB
dpc-2201	94	36	topical	topical	ADJ
dpc-2201	94	37	ruxolitinib	ruxolitinib	NOUN
dpc-2201	94	38	1.5	1.5	NUM
dpc-2201	94	39	%	%	NOUN
dpc-2201	94	40	bid	bid	NOUN
dpc-2201	94	41	for	for	ADP
dpc-2201	94	42	12	12	NUM
dpc-2201	94	43	–	–	SYM
dpc-2201	94	44	38	38	NUM
dpc-2201	94	45	weeks	week	NOUN
dpc-2201	94	46	(	(	PUNCT
dpc-2201	94	47	in	in	ADP
dpc-2201	94	48	one	one	NUM
dpc-2201	94	49	study	study	NOUN
dpc-2201	94	50	uvb	uvb	ADJ
dpc-2201	94	51	phototherapy	phototherapy	NOUN
dpc-2201	94	52	was	be	AUX
dpc-2201	94	53	also	also	ADV
dpc-2201	94	54	added	add	VERB
dpc-2201	94	55	)	)	PUNCT
dpc-2201	94	56	,	,	PUNCT
dpc-2201	94	57	and	and	CCONJ
dpc-2201	94	58	one	one	NUM
dpc-2201	94	59	patient	patient	NOUN
dpc-2201	94	60	received	receive	VERB
dpc-2201	94	61	oral	oral	ADJ
dpc-2201	94	62	ruxolitinib	ruxolitinib	NOUN
dpc-2201	94	63	20	20	NUM
dpc-2201	94	64	mg	mg	NUM
dpc-2201	94	65	/	/	SYM
dpc-2201	94	66	bid	bid	NOUN
dpc-2201	94	67	for	for	ADP
dpc-2201	94	68	20	20	NUM
dpc-2201	94	69	weeks	week	NOUN
dpc-2201	94	70	.	.	PUNCT
dpc-2201	95	1	efficacy	efficacy	NOUN
dpc-2201	95	2	was	be	AUX
dpc-2201	95	3	assessed	assess	VERB
dpc-2201	95	4	with	with	ADP
dpc-2201	95	5	vitiligo	vitiligo	NOUN
dpc-2201	95	6	area	area	NOUN
dpc-2201	95	7	and	and	CCONJ
dpc-2201	95	8	severity	severity	NOUN
dpc-2201	95	9	index	index	NOUN
dpc-2201	95	10	(	(	PUNCT
dpc-2201	95	11	vasi	vasi	PROPN
dpc-2201	95	12	)	)	PUNCT
dpc-2201	95	13	and	and	CCONJ
dpc-2201	95	14	facial	facial	ADJ
dpc-2201	95	15	vitiligo	vitiligo	NOUN
dpc-2201	95	16	area	area	NOUN
dpc-2201	95	17	and	and	CCONJ
dpc-2201	95	18	severity	severity	NOUN
dpc-2201	95	19	index	index	NOUN
dpc-2201	95	20	(	(	PUNCT
dpc-2201	95	21	fvasi	fvasi	PROPN
dpc-2201	95	22	)	)	PUNCT
dpc-2201	95	23	.	.	PUNCT
dpc-2201	96	1	overall	overall	ADJ
dpc-2201	96	2	effectiveness	effectiveness	NOUN
dpc-2201	96	3	in	in	ADP
dpc-2201	96	4	the	the	DET
dpc-2201	96	5	jaki	jaki	PROPN
dpc-2201	96	6	-	-	PUNCT
dpc-2201	96	7	alone	alone	ADJ
dpc-2201	96	8	recipients	recipient	NOUN
dpc-2201	96	9	was	be	AUX
dpc-2201	96	10	reported	report	VERB
dpc-2201	96	11	as	as	ADP
dpc-2201	96	12	57.8	57.8	NUM
dpc-2201	96	13	%	%	NOUN
dpc-2201	96	14	good	good	ADJ
dpc-2201	96	15	response	response	NOUN
dpc-2201	96	16	,	,	PUNCT
dpc-2201	96	17	22.2	22.2	NUM
dpc-2201	96	18	%	%	NOUN
dpc-2201	96	19	partial	partial	ADJ
dpc-2201	96	20	and	and	CCONJ
dpc-2201	96	21	20	20	NUM
dpc-2201	96	22	%	%	NOUN
dpc-2201	96	23	none	none	NOUN
dpc-2201	96	24	or	or	CCONJ
dpc-2201	96	25	minimal	minimal	ADJ
dpc-2201	96	26	response	response	NOUN
dpc-2201	96	27	.	.	PUNCT
dpc-2201	97	1	moreover	moreover	ADV
dpc-2201	97	2	,	,	PUNCT
dpc-2201	97	3	the	the	DET
dpc-2201	97	4	response	response	NOUN
dpc-2201	97	5	to	to	ADP
dpc-2201	97	6	the	the	DET
dpc-2201	97	7	treatment	treatment	NOUN
dpc-2201	97	8	with	with	ADP
dpc-2201	97	9	concurrent	concurrent	ADJ
dpc-2201	97	10	uvb	uvb	ADJ
dpc-2201	97	11	phototherapy	phototherapy	NOUN
dpc-2201	97	12	was	be	AUX
dpc-2201	97	13	statistically	statistically	ADV
dpc-2201	97	14	higher	high	ADJ
dpc-2201	97	15	than	than	ADP
dpc-2201	97	16	jaki	jaki	PROPN
dpc-2201	97	17	alone	alone	ADV
dpc-2201	97	18	(	(	PUNCT
dpc-2201	97	19	p	p	X
dpc-2201	97	20	<	<	X
dpc-2201	97	21	0.001	0.001	NUM
dpc-2201	97	22	)	)	PUNCT
dpc-2201	97	23	.	.	PUNCT
dpc-2201	98	1	the	the	DET
dpc-2201	98	2	improvement	improvement	NOUN
dpc-2201	98	3	turned	turn	VERB
dpc-2201	98	4	more	more	ADV
dpc-2201	98	5	significant	significant	ADJ
dpc-2201	98	6	(	(	PUNCT
dpc-2201	98	7	fvasi	fvasi	NOUN
dpc-2201	98	8	reduction	reduction	NOUN
dpc-2201	98	9	)	)	PUNCT
dpc-2201	98	10	in	in	ADP
dpc-2201	98	11	facial	facial	ADJ
dpc-2201	98	12	vitiligo	vitiligo	NOUN
dpc-2201	98	13	than	than	ADP
dpc-2201	98	14	other	other	ADJ
dpc-2201	98	15	body	body	NOUN
dpc-2201	98	16	sites	site	NOUN
dpc-2201	98	17	(	(	PUNCT
dpc-2201	98	18	p	p	X
dpc-2201	98	19	<	<	X
dpc-2201	98	20	0.001	0.001	NUM
dpc-2201	98	21	)	)	PUNCT
dpc-2201	98	22	when	when	SCONJ
dpc-2201	98	23	the	the	DET
dpc-2201	98	24	studies	study	NOUN
dpc-2201	98	25	were	be	AUX
dpc-2201	98	26	sub	sub	ADJ
dpc-2201	98	27	-	-	VERB
dpc-2201	98	28	grouped	group	VERB
dpc-2201	98	29	based	base	VERB
dpc-2201	98	30	on	on	ADP
dpc-2201	98	31	specific	specific	ADJ
dpc-2201	98	32	body	body	NOUN
dpc-2201	98	33	areas	area	NOUN
dpc-2201	98	34	.	.	PUNCT
dpc-2201	99	1	no	no	DET
dpc-2201	99	2	significant	significant	ADJ
dpc-2201	99	3	difference	difference	NOUN
dpc-2201	99	4	was	be	AUX
dpc-2201	99	5	observed	observe	VERB
dpc-2201	99	6	between	between	ADP
dpc-2201	99	7	different	different	ADJ
dpc-2201	99	8	routes	route	NOUN
dpc-2201	99	9	of	of	ADP
dpc-2201	99	10	jaki	jaki	PROPN
dpc-2201	99	11	administration	administration	PROPN
dpc-2201	99	12	(	(	PUNCT
dpc-2201	99	13	p	p	NOUN
dpc-2201	99	14	=	=	NOUN
dpc-2201	99	15	0.1	0.1	NUM
dpc-2201	99	16	)	)	PUNCT
dpc-2201	99	17	.	.	PUNCT
dpc-2201	100	1	aes	aes	PROPN
dpc-2201	100	2	were	be	AUX
dpc-2201	100	3	erythema	erythema	ADJ
dpc-2201	100	4	,	,	PUNCT
dpc-2201	100	5	transient	transient	ADJ
dpc-2201	100	6	acne	acne	NOUN
dpc-2201	100	7	,	,	PUNCT
dpc-2201	100	8	hyperpigmentation	hyperpigmentation	NOUN
dpc-2201	100	9	,	,	PUNCT
dpc-2201	100	10	transient	transient	ADJ
dpc-2201	100	11	hyperlipidemia	hyperlipidemia	NOUN
dpc-2201	100	12	,	,	PUNCT
dpc-2201	100	13	urtis	urtis	PROPN
dpc-2201	100	14	,	,	PUNCT
dpc-2201	100	15	weight	weight	NOUN
dpc-2201	100	16	gain	gain	NOUN
dpc-2201	100	17	and	and	CCONJ
dpc-2201	100	18	joint	joint	ADJ
dpc-2201	100	19	pain	pain	NOUN
dpc-2201	101	1	[	[	X
dpc-2201	101	2	27	27	NUM
dpc-2201	101	3	]	]	PUNCT
dpc-2201	101	4	.	.	PUNCT
dpc-2201	102	1	in	in	ADP
dpc-2201	102	2	a	a	DET
dpc-2201	102	3	case	case	NOUN
dpc-2201	102	4	report	report	NOUN
dpc-2201	102	5	,	,	PUNCT
dpc-2201	102	6	komnitski	komnitski	PROPN
dpc-2201	102	7	et	et	PROPN
dpc-2201	102	8	al	al	PROPN
dpc-2201	102	9	presented	present	VERB
dpc-2201	102	10	a	a	DET
dpc-2201	102	11	40	40	NUM
dpc-2201	102	12	-	-	PUNCT
dpc-2201	102	13	year	year	NOUN
dpc-2201	102	14	-	-	PUNCT
dpc-2201	102	15	old	old	ADJ
dpc-2201	102	16	lady	lady	NOUN
dpc-2201	102	17	with	with	ADP
dpc-2201	102	18	vitiligo	vitiligo	NOUN
dpc-2201	102	19	and	and	CCONJ
dpc-2201	102	20	rheumatoid	rheumatoid	VERB
dpc-2201	102	21	arthritis	arthritis	NOUN
dpc-2201	102	22	receiving	receive	VERB
dpc-2201	102	23	5	5	NUM
dpc-2201	102	24	mg	mg	PROPN
dpc-2201	102	25	oral	oral	ADJ
dpc-2201	102	26	tofacitinib	tofacitinib	NOUN
dpc-2201	102	27	twice	twice	ADV
dpc-2201	102	28	daily	daily	ADV
dpc-2201	102	29	.	.	PUNCT
dpc-2201	103	1	after	after	ADP
dpc-2201	103	2	2	2	NUM
dpc-2201	103	3	years	year	NOUN
dpc-2201	103	4	of	of	ADP
dpc-2201	103	5	the	the	DET
dpc-2201	103	6	treatment	treatment	NOUN
dpc-2201	103	7	without	without	ADP
dpc-2201	103	8	being	be	AUX
dpc-2201	103	9	sun	sun	NOUN
dpc-2201	103	10	-	-	PUNCT
dpc-2201	103	11	exposed	expose	VERB
dpc-2201	103	12	,	,	PUNCT
dpc-2201	103	13	complete	complete	ADJ
dpc-2201	103	14	re	re	NOUN
dpc-2201	103	15	-	-	NOUN
dpc-2201	103	16	pigmentation	pigmentation	NOUN
dpc-2201	103	17	of	of	ADP
dpc-2201	103	18	the	the	DET
dpc-2201	103	19	frontal	frontal	ADJ
dpc-2201	103	20	and	and	CCONJ
dpc-2201	103	21	peri	peri	NOUN
dpc-2201	103	22	-	-	PUNCT
dpc-2201	103	23	labial	labial	NOUN
dpc-2201	103	24	were	be	AUX
dpc-2201	103	25	observed	observe	VERB
dpc-2201	103	26	.	.	PUNCT
dpc-2201	104	1	further	far	ADV
dpc-2201	104	2	,	,	PUNCT
dpc-2201	104	3	partial	partial	ADJ
dpc-2201	104	4	improvement	improvement	NOUN
dpc-2201	104	5	in	in	ADP
dpc-2201	104	6	the	the	DET
dpc-2201	104	7	back	back	NOUN
dpc-2201	104	8	of	of	ADP
dpc-2201	104	9	the	the	DET
dpc-2201	104	10	neck	neck	NOUN
dpc-2201	104	11	and	and	CCONJ
dpc-2201	104	12	upper	upper	ADJ
dpc-2201	104	13	chest	chest	NOUN
dpc-2201	104	14	were	be	AUX
dpc-2201	104	15	also	also	ADV
dpc-2201	104	16	noted	note	VERB
dpc-2201	104	17	.	.	PUNCT
dpc-2201	105	1	no	no	DET
dpc-2201	105	2	aes	aes	PROPN
dpc-2201	105	3	were	be	AUX
dpc-2201	105	4	reported	report	VERB
dpc-2201	105	5	during	during	ADP
dpc-2201	105	6	the	the	DET
dpc-2201	105	7	treatment	treatment	NOUN
dpc-2201	105	8	in	in	ADP
dpc-2201	105	9	this	this	DET
dpc-2201	105	10	case	case	NOUN
dpc-2201	106	1	[	[	X
dpc-2201	106	2	28	28	NUM
dpc-2201	106	3	]	]	PUNCT
dpc-2201	106	4	.	.	PUNCT
dpc-2201	107	1	lichen	lichen	NOUN
dpc-2201	107	2	planus	planus	PROPN
dpc-2201	107	3	lichen	lichen	NOUN
dpc-2201	107	4	planus	planus	PROPN
dpc-2201	107	5	is	be	AUX
dpc-2201	107	6	a	a	DET
dpc-2201	107	7	chronic	chronic	ADJ
dpc-2201	107	8	inflammatory	inflammatory	ADJ
dpc-2201	107	9	disorder	disorder	NOUN
dpc-2201	107	10	that	that	PRON
dpc-2201	107	11	can	can	AUX
dpc-2201	107	12	involve	involve	VERB
dpc-2201	107	13	derma	derma	NOUN
dpc-2201	107	14	,	,	PUNCT
dpc-2201	107	15	mucous	mucous	ADJ
dpc-2201	107	16	,	,	PUNCT
dpc-2201	107	17	nail	nail	NOUN
dpc-2201	107	18	and	and	CCONJ
dpc-2201	107	19	hair	hair	NOUN
dpc-2201	107	20	follicles	follicle	NOUN
dpc-2201	107	21	.	.	PUNCT
dpc-2201	108	1	the	the	DET
dpc-2201	108	2	etiology	etiology	NOUN
dpc-2201	108	3	of	of	ADP
dpc-2201	108	4	lp	lp	PROPN
dpc-2201	108	5	seems	seem	VERB
dpc-2201	108	6	to	to	PART
dpc-2201	108	7	be	be	AUX
dpc-2201	108	8	autoimmune	autoimmune	ADJ
dpc-2201	108	9	with	with	ADP
dpc-2201	108	10	the	the	DET
dpc-2201	108	11	incidence	incidence	ADJ
dpc-2201	108	12	rate	rate	NOUN
dpc-2201	108	13	of	of	ADP
dpc-2201	108	14	2	2	NUM
dpc-2201	108	15	%	%	NOUN
dpc-2201	108	16	–	–	PUNCT
dpc-2201	108	17	3	3	NUM
dpc-2201	108	18	%	%	NOUN
dpc-2201	108	19	[	[	X
dpc-2201	108	20	30	30	NUM
dpc-2201	108	21	]	]	PUNCT
dpc-2201	108	22	.	.	PUNCT
dpc-2201	109	1	the	the	DET
dpc-2201	109	2	overactivation	overactivation	NOUN
dpc-2201	109	3	of	of	ADP
dpc-2201	109	4	cd8	cd8	PROPN
dpc-2201	109	5	+	+	PROPN
dpc-2201	109	6	t	t	PROPN
dpc-2201	109	7	-	-	PUNCT
dpc-2201	109	8	call	call	NOUN
dpc-2201	109	9	lymphocytes	lymphocyte	NOUN
dpc-2201	109	10	and	and	CCONJ
dpc-2201	109	11	dysregulation	dysregulation	NOUN
dpc-2201	109	12	of	of	ADP
dpc-2201	109	13	cd4	cd4	PROPN
dpc-2201	109	14	+	+	PROPN
dpc-2201	109	15	t	t	PROPN
dpc-2201	109	16	-	-	PUNCT
dpc-2201	109	17	cells	cell	NOUN
dpc-2201	109	18	have	have	AUX
dpc-2201	109	19	been	be	AUX
dpc-2201	109	20	observed	observe	VERB
dpc-2201	109	21	to	to	PART
dpc-2201	109	22	play	play	VERB
dpc-2201	109	23	a	a	DET
dpc-2201	109	24	major	major	ADJ
dpc-2201	109	25	role	role	NOUN
dpc-2201	109	26	in	in	ADP
dpc-2201	109	27	the	the	DET
dpc-2201	109	28	pathogenesis	pathogenesis	NOUN
dpc-2201	109	29	of	of	ADP
dpc-2201	109	30	lp	lp	NOUN
dpc-2201	110	1	[	[	X
dpc-2201	110	2	30	30	NUM
dpc-2201	110	3	]	]	PUNCT
dpc-2201	110	4	.	.	PUNCT
dpc-2201	111	1	damsky	damsky	PROPN
dpc-2201	111	2	et	et	PROPN
dpc-2201	111	3	al	al	PROPN
dpc-2201	111	4	2020	2020	NUM
dpc-2201	111	5	evaluated	evaluate	VERB
dpc-2201	111	6	the	the	DET
dpc-2201	111	7	benefit	benefit	NOUN
dpc-2201	111	8	of	of	ADP
dpc-2201	111	9	oral	oral	ADJ
dpc-2201	111	10	tofacitinib	tofacitinib	NOUN
dpc-2201	111	11	in	in	ADP
dpc-2201	111	12	a	a	DET
dpc-2201	111	13	case	case	NOUN
dpc-2201	111	14	series	series	NOUN
dpc-2201	111	15	of	of	ADP
dpc-2201	111	16	three	three	NUM
dpc-2201	111	17	patients	patient	NOUN
dpc-2201	111	18	with	with	ADP
dpc-2201	111	19	erosive	erosive	ADJ
dpc-2201	111	20	lichen	lichen	NOUN
dpc-2201	111	21	planus	planus	NOUN
dpc-2201	111	22	(	(	PUNCT
dpc-2201	111	23	elp	elp	PROPN
dpc-2201	111	24	)	)	PUNCT
dpc-2201	111	25	.	.	PUNCT
dpc-2201	112	1	treatment	treatment	NOUN
dpc-2201	112	2	with	with	ADP
dpc-2201	112	3	oral	oral	ADJ
dpc-2201	112	4	tofacitinib	tofacitinib	NOUN
dpc-2201	112	5	5	5	NUM
dpc-2201	112	6	mg	mg	NUM
dpc-2201	112	7	/	/	SYM
dpc-2201	112	8	bid	bid	NOUN
dpc-2201	112	9	was	be	AUX
dpc-2201	112	10	initiated	initiate	VERB
dpc-2201	112	11	for	for	ADP
dpc-2201	112	12	all	all	DET
dpc-2201	112	13	patients	patient	NOUN
dpc-2201	112	14	.	.	PUNCT
dpc-2201	113	1	additional	additional	ADJ
dpc-2201	113	2	therapy	therapy	NOUN
dpc-2201	113	3	with	with	ADP
dpc-2201	113	4	methotrexate	methotrexate	NOUN
dpc-2201	113	5	and	and	CCONJ
dpc-2201	113	6	prednisolone	prednisolone	PROPN
dpc-2201	113	7	was	be	AUX
dpc-2201	113	8	added	add	VERB
dpc-2201	113	9	to	to	ADP
dpc-2201	113	10	the	the	DET
dpc-2201	113	11	therapeutic	therapeutic	ADJ
dpc-2201	113	12	regimen	regiman	NOUN
dpc-2201	113	13	of	of	ADP
dpc-2201	113	14	patient	patient	NOUN
dpc-2201	113	15	#	#	SYM
dpc-2201	113	16	1	1	NUM
dpc-2201	113	17	due	due	ADP
dpc-2201	113	18	to	to	ADP
dpc-2201	113	19	the	the	DET
dpc-2201	113	20	refractory	refractory	NOUN
dpc-2201	113	21	course	course	NOUN
dpc-2201	113	22	of	of	ADP
dpc-2201	113	23	his	his	PRON
dpc-2201	113	24	condition	condition	NOUN
dpc-2201	113	25	.	.	PUNCT
dpc-2201	114	1	all	all	DET
dpc-2201	114	2	patients	patient	NOUN
dpc-2201	114	3	showed	show	VERB
dpc-2201	114	4	dramatic	dramatic	ADJ
dpc-2201	114	5	improvements	improvement	NOUN
dpc-2201	114	6	and	and	CCONJ
dpc-2201	114	7	complete	complete	ADJ
dpc-2201	114	8	or	or	CCONJ
dpc-2201	114	9	near	near	ADV
dpc-2201	114	10	-	-	PUNCT
dpc-2201	114	11	complete	complete	ADJ
dpc-2201	114	12	remission	remission	NOUN
dpc-2201	114	13	while	while	SCONJ
dpc-2201	114	14	they	they	PRON
dpc-2201	114	15	were	be	AUX
dpc-2201	114	16	on	on	ADP
dpc-2201	114	17	tofacitinib	tofacitinib	NOUN
dpc-2201	114	18	.	.	PUNCT
dpc-2201	115	1	discontinuation	discontinuation	NOUN
dpc-2201	115	2	of	of	ADP
dpc-2201	115	3	tofacitinib	tofacitinib	NOUN
dpc-2201	115	4	in	in	ADP
dpc-2201	115	5	patient	patient	NOUN
dpc-2201	115	6	#	#	SYM
dpc-2201	115	7	1	1	NUM
dpc-2201	115	8	resulted	result	VERB
dpc-2201	115	9	in	in	ADP
dpc-2201	115	10	elp	elp	NOUN
dpc-2201	115	11	relapse	relapse	VERB
dpc-2201	115	12	even	even	ADV
dpc-2201	115	13	when	when	SCONJ
dpc-2201	115	14	he	he	PRON
dpc-2201	115	15	continued	continue	VERB
dpc-2201	115	16	methotrexate	methotrexate	NOUN
dpc-2201	115	17	and	and	CCONJ
dpc-2201	115	18	prednisolone	prednisolone	PROPN
dpc-2201	115	19	.	.	PROPN
dpc-2201	115	20	re	re	PROPN
dpc-2201	115	21	-	-	NOUN
dpc-2201	115	22	initiation	initiation	NOUN
dpc-2201	115	23	of	of	ADP
dpc-2201	115	24	tofacitinib	tofacitinib	NOUN
dpc-2201	115	25	5	5	NUM
dpc-2201	115	26	mg	mg	NUM
dpc-2201	115	27	/	/	SYM
dpc-2201	115	28	bid	bid	NOUN
dpc-2201	115	29	resulted	result	VERB
dpc-2201	115	30	again	again	ADV
dpc-2201	115	31	in	in	ADP
dpc-2201	115	32	improvement	improvement	NOUN
dpc-2201	115	33	in	in	ADP
dpc-2201	115	34	patient	patient	NOUN
dpc-2201	115	35	#	#	SYM
dpc-2201	115	36	1	1	NUM
dpc-2201	115	37	.	.	PUNCT
dpc-2201	115	38	tofacitinib	tofacitinib	PROPN
dpc-2201	115	39	was	be	AUX
dpc-2201	115	40	tolerated	tolerate	VERB
dpc-2201	115	41	well	well	ADV
dpc-2201	115	42	with	with	ADP
dpc-2201	115	43	no	no	DET
dpc-2201	115	44	reported	reported	ADJ
dpc-2201	115	45	aes	aes	NOUN
dpc-2201	115	46	in	in	ADP
dpc-2201	115	47	any	any	PRON
dpc-2201	115	48	of	of	ADP
dpc-2201	115	49	the	the	DET
dpc-2201	115	50	cases	case	NOUN
dpc-2201	115	51	[	[	X
dpc-2201	115	52	31	31	NUM
dpc-2201	115	53	]	]	PUNCT
dpc-2201	115	54	.	.	PUNCT
dpc-2201	116	1	another	another	DET
dpc-2201	116	2	case	case	NOUN
dpc-2201	116	3	series	series	NOUN
dpc-2201	116	4	by	by	ADP
dpc-2201	116	5	yang	yang	PROPN
dpc-2201	116	6	et	et	PROPN
dpc-2201	116	7	al	al	PROPN
dpc-2201	116	8	reported	report	VERB
dpc-2201	116	9	the	the	DET
dpc-2201	116	10	effectiveness	effectiveness	NOUN
dpc-2201	116	11	of	of	ADP
dpc-2201	116	12	oral	oral	ADJ
dpc-2201	116	13	tofacitinib	tofacitinib	NOUN
dpc-2201	116	14	in	in	ADP
dpc-2201	116	15	ten	ten	NUM
dpc-2201	116	16	patients	patient	NOUN
dpc-2201	116	17	with	with	ADP
dpc-2201	116	18	refractory	refractory	NOUN
dpc-2201	116	19	lichen	lichen	NOUN
dpc-2201	116	20	planopilaris	planopilaris	NOUN
dpc-2201	116	21	(	(	PUNCT
dpc-2201	116	22	lpp	lpp	PROPN
dpc-2201	116	23	)	)	PUNCT
dpc-2201	116	24	.	.	PUNCT
dpc-2201	117	1	treatment	treatment	NOUN
dpc-2201	117	2	with	with	ADP
dpc-2201	117	3	tofacitinib	tofacitinib	PROPN
dpc-2201	117	4	5	5	NUM
dpc-2201	117	5	mg/	mg/	NOUN
dpc-2201	117	6	bid	bid	NOUN
dpc-2201	117	7	for	for	ADP
dpc-2201	117	8	8	8	NUM
dpc-2201	117	9	patients	patient	NOUN
dpc-2201	117	10	and	and	CCONJ
dpc-2201	117	11	5	5	NUM
dpc-2201	117	12	mg	mg	PROPN
dpc-2201	117	13	/	/	SYM
dpc-2201	117	14	tds	tds	PROPN
dpc-2201	117	15	for	for	ADP
dpc-2201	117	16	the	the	DET
dpc-2201	117	17	other	other	ADJ
dpc-2201	117	18	2	2	NUM
dpc-2201	117	19	patients	patient	NOUN
dpc-2201	117	20	,	,	PUNCT
dpc-2201	117	21	scores	score	NOUN
dpc-2201	117	22	than	than	ADP
dpc-2201	117	23	placebo	placebo	NOUN
dpc-2201	117	24	in	in	ADP
dpc-2201	117	25	both	both	DET
dpc-2201	117	26	trials	trial	NOUN
dpc-2201	117	27	,	,	PUNCT
dpc-2201	117	28	and	and	CCONJ
dpc-2201	117	29	in	in	ADP
dpc-2201	117	30	the	the	DET
dpc-2201	117	31	opal	opal	NOUN
dpc-2201	117	32	broaden	broaden	VERB
dpc-2201	117	33	study	study	NOUN
dpc-2201	117	34	,	,	PUNCT
dpc-2201	117	35	significantly	significantly	ADV
dpc-2201	117	36	more	more	ADJ
dpc-2201	117	37	patients	patient	NOUN
dpc-2201	117	38	treated	treat	VERB
dpc-2201	117	39	with	with	ADP
dpc-2201	117	40	5	5	NUM
dpc-2201	117	41	mg	mg	NUM
dpc-2201	117	42	/	/	SYM
dpc-2201	117	43	bid	bid	NOUN
dpc-2201	117	44	tofacitinib	tofacitinib	NOUN
dpc-2201	117	45	achieved	achieve	VERB
dpc-2201	117	46	pasi75	pasi75	NOUN
dpc-2201	117	47	score	score	NOUN
dpc-2201	117	48	than	than	ADP
dpc-2201	117	49	placebo	placebo	NOUN
dpc-2201	117	50	.	.	PUNCT
dpc-2201	118	1	after	after	ADP
dpc-2201	118	2	12	12	NUM
dpc-2201	118	3	months	month	NOUN
dpc-2201	118	4	,	,	PUNCT
dpc-2201	118	5	minimal	minimal	ADJ
dpc-2201	118	6	disease	disease	NOUN
dpc-2201	118	7	activity	activity	NOUN
dpc-2201	118	8	was	be	AUX
dpc-2201	118	9	attained	attain	VERB
dpc-2201	118	10	in	in	ADP
dpc-2201	118	11	37	37	NUM
dpc-2201	118	12	%	%	NOUN
dpc-2201	118	13	of	of	ADP
dpc-2201	118	14	tofacitinib	tofacitinib	NOUN
dpc-2201	118	15	5	5	NUM
dpc-2201	118	16	mg	mg	PROPN
dpc-2201	118	17	recipients	recipient	NOUN
dpc-2201	118	18	.	.	PUNCT
dpc-2201	119	1	a	a	DET
dpc-2201	119	2	minimal	minimal	ADJ
dpc-2201	119	3	progression	progression	NOUN
dpc-2201	119	4	in	in	ADP
dpc-2201	119	5	radiography	radiography	NOUN
dpc-2201	119	6	was	be	AUX
dpc-2201	119	7	reported	report	VERB
dpc-2201	119	8	in	in	ADP
dpc-2201	119	9	the	the	DET
dpc-2201	119	10	opal	opal	NOUN
dpc-2201	119	11	broaden	broaden	VERB
dpc-2201	119	12	trial	trial	NOUN
dpc-2201	119	13	,	,	PUNCT
dpc-2201	119	14	and	and	CCONJ
dpc-2201	119	15	more	more	ADJ
dpc-2201	119	16	than	than	ADP
dpc-2201	119	17	90	90	NUM
dpc-2201	119	18	%	%	NOUN
dpc-2201	119	19	of	of	ADP
dpc-2201	119	20	patients	patient	NOUN
dpc-2201	119	21	showed	show	VERB
dpc-2201	119	22	non	non	ADJ
dpc-2201	119	23	-	-	ADJ
dpc-2201	119	24	progression	progression	ADJ
dpc-2201	119	25	criteria	criterion	NOUN
dpc-2201	120	1	[	[	X
dpc-2201	120	2	22	22	NUM
dpc-2201	120	3	]	]	PUNCT
dpc-2201	120	4	.	.	PUNCT
dpc-2201	121	1	all	all	DET
dpc-2201	121	2	reviewed	review	VERB
dpc-2201	121	3	studies	study	NOUN
dpc-2201	121	4	reported	report	VERB
dpc-2201	121	5	favorable	favorable	ADJ
dpc-2201	121	6	safety	safety	NOUN
dpc-2201	121	7	and	and	CCONJ
dpc-2201	121	8	efficacy	efficacy	NOUN
dpc-2201	121	9	profiles	profile	NOUN
dpc-2201	121	10	of	of	ADP
dpc-2201	121	11	oral	oral	ADJ
dpc-2201	121	12	tofacitinib	tofacitinib	NOUN
dpc-2201	121	13	and	and	CCONJ
dpc-2201	121	14	ruxolitinib	ruxolitinib	NOUN
dpc-2201	121	15	.	.	PUNCT
dpc-2201	122	1	atopic	atopic	NOUN
dpc-2201	122	2	dermatitis	dermatitis	NOUN
dpc-2201	122	3	atopic	atopic	NOUN
dpc-2201	122	4	dermatitis	dermatitis	NOUN
dpc-2201	122	5	is	be	AUX
dpc-2201	122	6	the	the	DET
dpc-2201	122	7	most	most	ADV
dpc-2201	122	8	common	common	ADJ
dpc-2201	122	9	chronic	chronic	ADJ
dpc-2201	122	10	inflammatory	inflammatory	ADJ
dpc-2201	122	11	skin	skin	NOUN
dpc-2201	122	12	disease	disease	NOUN
dpc-2201	122	13	with	with	ADP
dpc-2201	122	14	3	3	NUM
dpc-2201	122	15	%	%	NOUN
dpc-2201	122	16	–	–	PUNCT
dpc-2201	122	17	10	10	NUM
dpc-2201	122	18	%	%	NOUN
dpc-2201	122	19	prevalence	prevalence	NOUN
dpc-2201	122	20	in	in	ADP
dpc-2201	122	21	adults	adult	NOUN
dpc-2201	122	22	and	and	CCONJ
dpc-2201	122	23	15	15	NUM
dpc-2201	122	24	%	%	NOUN
dpc-2201	122	25	–	–	PUNCT
dpc-2201	122	26	25	25	NUM
dpc-2201	122	27	%	%	NOUN
dpc-2201	122	28	in	in	ADP
dpc-2201	122	29	children	child	NOUN
dpc-2201	122	30	.	.	PUNCT
dpc-2201	123	1	moderate	moderate	ADJ
dpc-2201	123	2	-	-	PUNCT
dpc-2201	123	3	to	to	ADP
dpc-2201	123	4	-	-	PUNCT
dpc-2201	123	5	severe	severe	ADJ
dpc-2201	123	6	ad	ad	NOUN
dpc-2201	123	7	can	can	AUX
dpc-2201	123	8	alter	alter	VERB
dpc-2201	123	9	the	the	DET
dpc-2201	123	10	health	health	NOUN
dpc-2201	123	11	-	-	PUNCT
dpc-2201	123	12	related	relate	VERB
dpc-2201	123	13	quality	quality	NOUN
dpc-2201	123	14	of	of	ADP
dpc-2201	123	15	life	life	NOUN
dpc-2201	123	16	(	(	PUNCT
dpc-2201	123	17	hrqol	hrqol	NOUN
dpc-2201	123	18	)	)	PUNCT
dpc-2201	123	19	because	because	SCONJ
dpc-2201	123	20	of	of	ADP
dpc-2201	123	21	sleep	sleep	NOUN
dpc-2201	123	22	disturbance	disturbance	NOUN
dpc-2201	123	23	,	,	PUNCT
dpc-2201	123	24	purities	purity	NOUN
dpc-2201	123	25	and	and	CCONJ
dpc-2201	123	26	comorbid	comorbid	ADJ
dpc-2201	123	27	mental	mental	ADJ
dpc-2201	123	28	conditions	condition	NOUN
dpc-2201	123	29	.	.	PUNCT
dpc-2201	124	1	multiple	multiple	ADJ
dpc-2201	124	2	inflammatory	inflammatory	ADJ
dpc-2201	124	3	pathways	pathway	NOUN
dpc-2201	124	4	and	and	CCONJ
dpc-2201	124	5	cytokines	cytokine	NOUN
dpc-2201	124	6	are	be	AUX
dpc-2201	124	7	involved	involve	VERB
dpc-2201	124	8	in	in	ADP
dpc-2201	124	9	the	the	DET
dpc-2201	124	10	pathogenesis	pathogenesis	NOUN
dpc-2201	124	11	of	of	ADP
dpc-2201	124	12	ad	ad	NOUN
dpc-2201	124	13	,	,	PUNCT
dpc-2201	124	14	and	and	CCONJ
dpc-2201	124	15	they	they	PRON
dpc-2201	124	16	can	can	AUX
dpc-2201	124	17	be	be	AUX
dpc-2201	124	18	considered	consider	VERB
dpc-2201	124	19	as	as	ADP
dpc-2201	124	20	therapeutic	therapeutic	ADJ
dpc-2201	124	21	targets	target	NOUN
dpc-2201	125	1	[	[	X
dpc-2201	125	2	15,23	15,23	NUM
dpc-2201	125	3	]	]	PUNCT
dpc-2201	125	4	.	.	PUNCT
dpc-2201	126	1	tsai	tsai	PROPN
dpc-2201	126	2	et	et	PROPN
dpc-2201	126	3	al	al	PROPN
dpc-2201	126	4	conducted	conduct	VERB
dpc-2201	126	5	a	a	DET
dpc-2201	126	6	meta	meta	ADJ
dpc-2201	126	7	-	-	PUNCT
dpc-2201	126	8	analysis	analysis	NOUN
dpc-2201	126	9	on	on	ADP
dpc-2201	126	10	15	15	NUM
dpc-2201	126	11	rcts	rct	NOUN
dpc-2201	126	12	and	and	CCONJ
dpc-2201	126	13	reviewed	review	VERB
dpc-2201	126	14	the	the	DET
dpc-2201	126	15	efficacy	efficacy	NOUN
dpc-2201	126	16	and	and	CCONJ
dpc-2201	126	17	safety	safety	NOUN
dpc-2201	126	18	of	of	ADP
dpc-2201	126	19	jaki	jaki	PROPN
dpc-2201	126	20	in	in	ADP
dpc-2201	126	21	treating	treat	VERB
dpc-2201	126	22	ad	ad	NOUN
dpc-2201	126	23	.	.	PUNCT
dpc-2201	127	1	among	among	ADP
dpc-2201	127	2	4,367	4,367	NUM
dpc-2201	127	3	participants	participant	NOUN
dpc-2201	127	4	,	,	PUNCT
dpc-2201	127	5	69	69	NUM
dpc-2201	127	6	patients	patient	NOUN
dpc-2201	127	7	received	receive	VERB
dpc-2201	127	8	topical	topical	ADJ
dpc-2201	127	9	tofacitinib	tofacitinib	NOUN
dpc-2201	127	10	2	2	NUM
dpc-2201	127	11	%	%	NOUN
dpc-2201	127	12	bid	bid	NOUN
dpc-2201	127	13	for	for	ADP
dpc-2201	127	14	4	4	NUM
dpc-2201	127	15	weeks	week	NOUN
dpc-2201	127	16	,	,	PUNCT
dpc-2201	127	17	and	and	CCONJ
dpc-2201	127	18	307	307	NUM
dpc-2201	127	19	patients	patient	NOUN
dpc-2201	127	20	received	receive	VERB
dpc-2201	127	21	topical	topical	ADJ
dpc-2201	127	22	ruxolitinib	ruxolitinib	NOUN
dpc-2201	127	23	0.15	0.15	NUM
dpc-2201	127	24	%	%	NOUN
dpc-2201	127	25	,	,	PUNCT
dpc-2201	127	26	0.5	0.5	NUM
dpc-2201	127	27	%	%	NOUN
dpc-2201	127	28	,	,	PUNCT
dpc-2201	127	29	or	or	CCONJ
dpc-2201	127	30	1.5	1.5	NUM
dpc-2201	127	31	%	%	NOUN
dpc-2201	127	32	once	once	ADV
dpc-2201	127	33	daily	daily	ADV
dpc-2201	127	34	,	,	PUNCT
dpc-2201	127	35	or	or	CCONJ
dpc-2201	127	36	1.5	1.5	NUM
dpc-2201	127	37	%	%	NOUN
dpc-2201	127	38	bid	bid	NOUN
dpc-2201	127	39	for	for	ADP
dpc-2201	127	40	8	8	NUM
dpc-2201	127	41	weeks	week	NOUN
dpc-2201	127	42	.	.	PUNCT
dpc-2201	128	1	in	in	ADP
dpc-2201	128	2	the	the	DET
dpc-2201	128	3	tofacitinib	tofacitinib	PROPN
dpc-2201	128	4	study	study	NOUN
dpc-2201	128	5	,	,	PUNCT
dpc-2201	128	6	efficacy	efficacy	NOUN
dpc-2201	128	7	was	be	AUX
dpc-2201	128	8	evaluated	evaluate	VERB
dpc-2201	128	9	by	by	ADP
dpc-2201	128	10	investigator	investigator	NOUN
dpc-2201	128	11	global	global	ADJ
dpc-2201	128	12	assessment	assessment	NOUN
dpc-2201	128	13	(	(	PUNCT
dpc-2201	128	14	iga	iga	PROPN
dpc-2201	128	15	)	)	PUNCT
dpc-2201	128	16	,	,	PUNCT
dpc-2201	128	17	eczema	eczema	NOUN
dpc-2201	128	18	area	area	NOUN
dpc-2201	128	19	and	and	CCONJ
dpc-2201	128	20	severity	severity	NOUN
dpc-2201	128	21	index	index	NOUN
dpc-2201	128	22	(	(	PUNCT
dpc-2201	128	23	easi-75	easi-75	PROPN
dpc-2201	128	24	%	%	NOUN
dpc-2201	128	25	)	)	PUNCT
dpc-2201	128	26	and	and	CCONJ
dpc-2201	128	27	body	body	NOUN
dpc-2201	128	28	surface	surface	NOUN
dpc-2201	128	29	area	area	NOUN
dpc-2201	128	30	(	(	PUNCT
dpc-2201	128	31	bsa	bsa	PROPN
dpc-2201	128	32	)	)	PUNCT
dpc-2201	128	33	response	response	NOUN
dpc-2201	128	34	.	.	PUNCT
dpc-2201	129	1	there	there	PRON
dpc-2201	129	2	were	be	VERB
dpc-2201	129	3	statistically	statistically	ADV
dpc-2201	129	4	significant	significant	ADJ
dpc-2201	129	5	higher	high	ADJ
dpc-2201	129	6	rates	rate	NOUN
dpc-2201	129	7	of	of	ADP
dpc-2201	129	8	achievement	achievement	NOUN
dpc-2201	129	9	to	to	ADP
dpc-2201	129	10	iga	iga	PROPN
dpc-2201	129	11	,	,	PUNCT
dpc-2201	129	12	easi-75	easi-75	PROPN
dpc-2201	129	13	%	%	NOUN
dpc-2201	129	14	,	,	PUNCT
dpc-2201	129	15	and	and	CCONJ
dpc-2201	129	16	bsa	bsa	PROPN
dpc-2201	129	17	responses	response	NOUN
dpc-2201	129	18	in	in	ADP
dpc-2201	129	19	the	the	DET
dpc-2201	129	20	treatment	treatment	NOUN
dpc-2201	129	21	group	group	NOUN
dpc-2201	129	22	compared	compare	VERB
dpc-2201	129	23	to	to	ADP
dpc-2201	129	24	the	the	DET
dpc-2201	129	25	control	control	NOUN
dpc-2201	129	26	group	group	NOUN
dpc-2201	129	27	.	.	PUNCT
dpc-2201	130	1	in	in	ADP
dpc-2201	130	2	assessing	assess	VERB
dpc-2201	130	3	topical	topical	ADJ
dpc-2201	130	4	ruxolitinib	ruxolitinib	NOUN
dpc-2201	130	5	among	among	ADP
dpc-2201	130	6	307	307	NUM
dpc-2201	130	7	patients	patient	NOUN
dpc-2201	130	8	,	,	PUNCT
dpc-2201	130	9	efficacy	efficacy	NOUN
dpc-2201	130	10	was	be	AUX
dpc-2201	130	11	evaluated	evaluate	VERB
dpc-2201	130	12	by	by	ADP
dpc-2201	130	13	pruritus	pruritus	PROPN
dpc-2201	130	14	numerical	numerical	PROPN
dpc-2201	130	15	rating	rating	NOUN
dpc-2201	130	16	scale	scale	NOUN
dpc-2201	130	17	(	(	PUNCT
dpc-2201	130	18	pruritus	pruritus	NOUN
dpc-2201	130	19	-	-	PUNCT
dpc-2201	130	20	nrs	nrs	ADJ
dpc-2201	130	21	)	)	PUNCT
dpc-2201	130	22	response	response	NOUN
dpc-2201	130	23	.	.	PUNCT
dpc-2201	131	1	participants	participant	NOUN
dpc-2201	131	2	in	in	ADP
dpc-2201	131	3	the	the	DET
dpc-2201	131	4	treatment	treatment	NOUN
dpc-2201	131	5	group	group	NOUN
dpc-2201	131	6	disclosed	disclose	VERB
dpc-2201	131	7	statistically	statistically	ADV
dpc-2201	131	8	greater	great	ADJ
dpc-2201	131	9	rates	rate	NOUN
dpc-2201	131	10	of	of	ADP
dpc-2201	131	11	achieving	achieve	VERB
dpc-2201	131	12	pruritus	pruritus	PROPN
dpc-2201	131	13	-	-	PUNCT
dpc-2201	131	14	nrs	nrs	PROPN
dpc-2201	131	15	response	response	NOUN
dpc-2201	131	16	than	than	ADP
dpc-2201	131	17	placebo	placebo	NOUN
dpc-2201	131	18	recipients	recipient	NOUN
dpc-2201	131	19	.	.	PUNCT
dpc-2201	132	1	additionally	additionally	ADV
dpc-2201	132	2	,	,	PUNCT
dpc-2201	132	3	safety	safety	NOUN
dpc-2201	132	4	was	be	AUX
dpc-2201	132	5	reported	report	VERB
dpc-2201	132	6	with	with	ADP
dpc-2201	132	7	treatment	treatment	NOUN
dpc-2201	132	8	-	-	PUNCT
dpc-2201	132	9	emergent	emergent	ADJ
dpc-2201	132	10	adverse	adverse	ADJ
dpc-2201	132	11	events	event	NOUN
dpc-2201	132	12	(	(	PUNCT
dpc-2201	132	13	teaes	teaes	ADJ
dpc-2201	132	14	)	)	PUNCT
dpc-2201	132	15	,	,	PUNCT
dpc-2201	132	16	showing	show	VERB
dpc-2201	132	17	a	a	DET
dpc-2201	132	18	higher	high	ADJ
dpc-2201	132	19	rate	rate	NOUN
dpc-2201	132	20	of	of	ADP
dpc-2201	132	21	aes	aes	PROPN
dpc-2201	132	22	in	in	ADP
dpc-2201	132	23	the	the	DET
dpc-2201	132	24	treatment	treatment	NOUN
dpc-2201	132	25	groups	group	NOUN
dpc-2201	132	26	that	that	PRON
dpc-2201	132	27	was	be	AUX
dpc-2201	132	28	directly	directly	ADV
dpc-2201	132	29	related	relate	VERB
dpc-2201	132	30	to	to	ADP
dpc-2201	132	31	the	the	DET
dpc-2201	132	32	length	length	NOUN
dpc-2201	132	33	of	of	ADP
dpc-2201	132	34	treatment	treatment	NOUN
dpc-2201	132	35	(	(	PUNCT
dpc-2201	132	36	24	24	NUM
dpc-2201	132	37	)	)	PUNCT
dpc-2201	132	38	.	.	PUNCT
dpc-2201	133	1	further	far	ADV
dpc-2201	133	2	,	,	PUNCT
dpc-2201	133	3	it	it	PRON
dpc-2201	133	4	is	be	AUX
dpc-2201	133	5	suggested	suggest	VERB
dpc-2201	133	6	that	that	SCONJ
dpc-2201	133	7	topical	topical	ADJ
dpc-2201	133	8	jaki	jaki	NOUN
dpc-2201	133	9	are	be	AUX
dpc-2201	133	10	rational	rational	ADJ
dpc-2201	133	11	modalities	modality	NOUN
dpc-2201	133	12	in	in	ADP
dpc-2201	133	13	treating	treat	VERB
dpc-2201	133	14	refractory	refractory	NOUN
dpc-2201	133	15	ad	ad	NOUN
dpc-2201	133	16	;	;	PUNCT
dpc-2201	133	17	however	however	ADV
dpc-2201	133	18	,	,	PUNCT
dpc-2201	133	19	more	more	ADV
dpc-2201	133	20	clinical	clinical	ADJ
dpc-2201	133	21	trials	trial	NOUN
dpc-2201	133	22	are	be	AUX
dpc-2201	133	23	required	require	VERB
dpc-2201	133	24	to	to	PART
dpc-2201	133	25	evaluate	evaluate	VERB
dpc-2201	133	26	the	the	DET
dpc-2201	133	27	long	long	ADJ
dpc-2201	133	28	-	-	PUNCT
dpc-2201	133	29	term	term	NOUN
dpc-2201	133	30	safety	safety	NOUN
dpc-2201	133	31	.	.	PUNCT
dpc-2201	134	1	vitiligo	vitiligo	PROPN
dpc-2201	134	2	vitiligo	vitiligo	PROPN
dpc-2201	134	3	is	be	AUX
dpc-2201	134	4	an	an	DET
dpc-2201	134	5	autoimmune	autoimmune	ADJ
dpc-2201	134	6	skin	skin	NOUN
dpc-2201	134	7	disease	disease	NOUN
dpc-2201	134	8	with	with	ADP
dpc-2201	134	9	acquired	acquire	VERB
dpc-2201	134	10	loss	loss	NOUN
dpc-2201	134	11	of	of	ADP
dpc-2201	134	12	function	function	NOUN
dpc-2201	134	13	in	in	ADP
dpc-2201	134	14	epidermal	epidermal	ADJ
dpc-2201	134	15	melanocytes	melanocyte	NOUN
dpc-2201	134	16	,	,	PUNCT
dpc-2201	134	17	resulting	result	VERB
dpc-2201	134	18	in	in	ADP
dpc-2201	134	19	depigmented	depigmented	ADJ
dpc-2201	134	20	white	white	ADJ
dpc-2201	134	21	patches	patch	NOUN
dpc-2201	134	22	of	of	ADP
dpc-2201	134	23	skin	skin	NOUN
dpc-2201	134	24	.	.	PUNCT
dpc-2201	135	1	the	the	DET
dpc-2201	135	2	unregulated	unregulated	ADJ
dpc-2201	135	3	activity	activity	NOUN
dpc-2201	135	4	of	of	ADP
dpc-2201	135	5	t	t	PROPN
dpc-2201	135	6	-	-	PUNCT
dpc-2201	135	7	helper1	helper1	NOUN
dpc-2201	135	8	and	and	CCONJ
dpc-2201	135	9	high	high	ADJ
dpc-2201	135	10	levels	level	NOUN
dpc-2201	135	11	of	of	ADP
dpc-2201	135	12	ifn	ifn	PROPN
dpc-2201	135	13	-	-	PUNCT
dpc-2201	135	14	γ	γ	NOUN
dpc-2201	135	15	,	,	PUNCT
dpc-2201	135	16	il-9	il-9	PUNCT
dpc-2201	135	17	and	and	CCONJ
dpc-2201	135	18	il-10	il-10	PRON
dpc-2201	135	19	seem	seem	VERB
dpc-2201	135	20	to	to	PART
dpc-2201	135	21	be	be	AUX
dpc-2201	135	22	the	the	DET
dpc-2201	135	23	leading	lead	VERB
dpc-2201	135	24	cause	cause	NOUN
dpc-2201	135	25	of	of	ADP
dpc-2201	135	26	autoimmunity	autoimmunity	NOUN
dpc-2201	135	27	in	in	ADP
dpc-2201	135	28	vitiligo	vitiligo	NOUN
dpc-2201	135	29	,	,	PUNCT
dpc-2201	135	30	and	and	CCONJ
dpc-2201	135	31	treatments	treatment	NOUN
dpc-2201	135	32	aiming	aim	VERB
dpc-2201	135	33	to	to	PART
dpc-2201	135	34	lower	lower	VERB
dpc-2201	135	35	the	the	DET
dpc-2201	135	36	levels	level	NOUN
dpc-2201	135	37	of	of	ADP
dpc-2201	135	38	ils	ils	X
dpc-2201	135	39	seem	seem	VERB
dpc-2201	135	40	to	to	PART
dpc-2201	135	41	be	be	AUX
dpc-2201	135	42	rationale	rationale	NOUN
dpc-2201	135	43	[	[	X
dpc-2201	135	44	25,26	25,26	NUM
dpc-2201	135	45	]	]	X
dpc-2201	135	46	.	.	PUNCT
dpc-2201	136	1	phan	phan	PROPN
dpc-2201	136	2	et	et	PROPN
dpc-2201	136	3	al	al	PROPN
dpc-2201	136	4	meta	meta	PROPN
dpc-2201	136	5	-	-	PUNCT
dpc-2201	136	6	analyzed	analyze	VERB
dpc-2201	136	7	data	datum	NOUN
dpc-2201	136	8	from	from	ADP
dpc-2201	136	9	nine	nine	NUM
dpc-2201	136	10	case	case	NOUN
dpc-2201	136	11	reports	report	NOUN
dpc-2201	136	12	and	and	CCONJ
dpc-2201	136	13	case	case	NOUN
dpc-2201	136	14	series	series	NOUN
dpc-2201	136	15	to	to	PART
dpc-2201	136	16	assess	assess	VERB
dpc-2201	136	17	the	the	DET
dpc-2201	136	18	pooled	pool	VERB
dpc-2201	136	19	results	result	NOUN
dpc-2201	136	20	about	about	ADP
dpc-2201	136	21	the	the	DET
dpc-2201	136	22	efficacy	efficacy	NOUN
dpc-2201	136	23	and	and	CCONJ
dpc-2201	136	24	safety	safety	NOUN
dpc-2201	136	25	of	of	ADP
dpc-2201	136	26	jaki	jaki	PROPN
dpc-2201	136	27	in	in	ADP
dpc-2201	136	28	the	the	DET
dpc-2201	136	29	treatment	treatment	NOUN
dpc-2201	136	30	of	of	ADP
dpc-2201	136	31	vitiligo	vitiligo	NOUN
dpc-2201	136	32	.	.	PUNCT
dpc-2201	137	1	twenty	twenty	NUM
dpc-2201	137	2	-	-	PUNCT
dpc-2201	137	3	three	three	NUM
dpc-2201	137	4	review	review	NOUN
dpc-2201	137	5	|	|	ADV
dpc-2201	137	6	dermatol	dermatol	ADJ
dpc-2201	137	7	pract	pract	NOUN
dpc-2201	137	8	concept	concept	NOUN
dpc-2201	137	9	.	.	PUNCT
dpc-2201	138	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	138	2	5	5	NUM
dpc-2201	138	3	including	include	VERB
dpc-2201	138	4	adalimumab	adalimumab	NOUN
dpc-2201	138	5	,	,	PUNCT
dpc-2201	138	6	tacrolimus	tacrolimus	NOUN
dpc-2201	138	7	,	,	PUNCT
dpc-2201	138	8	prednisolone	prednisolone	PROPN
dpc-2201	138	9	,	,	PUNCT
dpc-2201	138	10	and	and	CCONJ
dpc-2201	138	11	rituximab	rituximab	NOUN
dpc-2201	138	12	.	.	PUNCT
dpc-2201	139	1	treatment	treatment	NOUN
dpc-2201	139	2	was	be	AUX
dpc-2201	139	3	transitioned	transition	VERB
dpc-2201	139	4	to	to	ADP
dpc-2201	139	5	oral	oral	ADJ
dpc-2201	139	6	tofacitinib	tofacitinib	NOUN
dpc-2201	139	7	5	5	NUM
dpc-2201	139	8	mg	mg	NUM
dpc-2201	139	9	/	/	SYM
dpc-2201	139	10	bid	bid	NOUN
dpc-2201	139	11	:	:	PUNCT
dpc-2201	139	12	significant	significant	ADJ
dpc-2201	139	13	improvement	improvement	NOUN
dpc-2201	139	14	was	be	AUX
dpc-2201	139	15	observed	observe	VERB
dpc-2201	139	16	after	after	ADP
dpc-2201	139	17	two	two	NUM
dpc-2201	139	18	weeks	week	NOUN
dpc-2201	139	19	,	,	PUNCT
dpc-2201	139	20	and	and	CCONJ
dpc-2201	139	21	95	95	NUM
dpc-2201	139	22	%	%	NOUN
dpc-2201	139	23	improvement	improvement	NOUN
dpc-2201	139	24	and	and	CCONJ
dpc-2201	139	25	sustained	sustained	ADJ
dpc-2201	139	26	remission	remission	NOUN
dpc-2201	139	27	were	be	AUX
dpc-2201	139	28	reported	report	VERB
dpc-2201	139	29	at	at	ADP
dpc-2201	139	30	three	three	NUM
dpc-2201	139	31	months	month	NOUN
dpc-2201	140	1	post	post	ADJ
dpc-2201	140	2	-	-	ADJ
dpc-2201	140	3	treatment	treatment	NOUN
dpc-2201	140	4	[	[	X
dpc-2201	140	5	42	42	NUM
dpc-2201	140	6	]	]	PUNCT
dpc-2201	140	7	.	.	PUNCT
dpc-2201	141	1	another	another	DET
dpc-2201	141	2	case	case	NOUN
dpc-2201	141	3	report	report	NOUN
dpc-2201	141	4	was	be	AUX
dpc-2201	141	5	conducted	conduct	VERB
dpc-2201	141	6	by	by	ADP
dpc-2201	141	7	kochar	kochar	PROPN
dpc-2201	141	8	et	et	PROPN
dpc-2201	141	9	al	al	PROPN
dpc-2201	141	10	presenting	present	VERB
dpc-2201	141	11	three	three	NUM
dpc-2201	141	12	patients	patient	NOUN
dpc-2201	141	13	with	with	ADP
dpc-2201	141	14	refractory	refractory	NOUN
dpc-2201	141	15	pg	pg	NOUN
dpc-2201	141	16	.	.	PUNCT
dpc-2201	142	1	the	the	DET
dpc-2201	142	2	first	first	ADJ
dpc-2201	142	3	two	two	NUM
dpc-2201	142	4	patients	patient	NOUN
dpc-2201	142	5	were	be	AUX
dpc-2201	142	6	treated	treat	VERB
dpc-2201	142	7	with	with	ADP
dpc-2201	142	8	5	5	NUM
dpc-2201	142	9	mg	mg	NOUN
dpc-2201	142	10	of	of	ADP
dpc-2201	142	11	tofacitinib	tofacitinib	PROPN
dpc-2201	142	12	twice	twice	ADV
dpc-2201	142	13	daily	daily	ADV
dpc-2201	142	14	,	,	PUNCT
dpc-2201	142	15	and	and	CCONJ
dpc-2201	142	16	no	no	DET
dpc-2201	142	17	signs	sign	NOUN
dpc-2201	142	18	of	of	ADP
dpc-2201	142	19	disease	disease	NOUN
dpc-2201	142	20	activity	activity	NOUN
dpc-2201	142	21	and	and	CCONJ
dpc-2201	142	22	aes	aes	PROPN
dpc-2201	142	23	were	be	AUX
dpc-2201	142	24	reported	report	VERB
dpc-2201	142	25	after	after	ADP
dpc-2201	142	26	12	12	NUM
dpc-2201	142	27	months	month	NOUN
dpc-2201	142	28	.	.	PUNCT
dpc-2201	143	1	the	the	DET
dpc-2201	143	2	third	third	ADJ
dpc-2201	143	3	patient	patient	NOUN
dpc-2201	143	4	commenced	commence	VERB
dpc-2201	143	5	on	on	ADP
dpc-2201	143	6	tofacitinib	tofacitinib	NOUN
dpc-2201	143	7	5	5	NUM
dpc-2201	143	8	mg	mg	NUM
dpc-2201	143	9	/	/	SYM
dpc-2201	143	10	bid	bid	NOUN
dpc-2201	143	11	and	and	CCONJ
dpc-2201	143	12	concomitant	concomitant	ADJ
dpc-2201	143	13	steroid	steroid	NOUN
dpc-2201	143	14	,	,	PUNCT
dpc-2201	143	15	and	and	CCONJ
dpc-2201	143	16	his	his	PRON
dpc-2201	143	17	pg	pg	NOUN
dpc-2201	143	18	lesions	lesion	NOUN
dpc-2201	143	19	were	be	AUX
dpc-2201	143	20	improved	improve	VERB
dpc-2201	143	21	but	but	CCONJ
dpc-2201	143	22	not	not	PART
dpc-2201	143	23	healed	heal	VERB
dpc-2201	143	24	entirely	entirely	ADV
dpc-2201	143	25	within	within	ADP
dpc-2201	143	26	a	a	DET
dpc-2201	143	27	month	month	NOUN
dpc-2201	143	28	.	.	PUNCT
dpc-2201	144	1	then	then	ADV
dpc-2201	144	2	steroid	steroid	PROPN
dpc-2201	144	3	was	be	AUX
dpc-2201	144	4	stopped	stop	VERB
dpc-2201	144	5	,	,	PUNCT
dpc-2201	144	6	and	and	CCONJ
dpc-2201	144	7	tofacitinib	tofacitinib	NOUN
dpc-2201	144	8	up	up	ADV
dpc-2201	144	9	-	-	PUNCT
dpc-2201	144	10	titrated	titrate	VERB
dpc-2201	144	11	to	to	ADP
dpc-2201	144	12	10	10	NUM
dpc-2201	144	13	mg	mg	NUM
dpc-2201	144	14	/	/	SYM
dpc-2201	144	15	bid	bid	NOUN
dpc-2201	144	16	and	and	CCONJ
dpc-2201	144	17	improvement	improvement	NOUN
dpc-2201	144	18	continued	continue	VERB
dpc-2201	144	19	[	[	X
dpc-2201	144	20	43	43	NUM
dpc-2201	144	21	]	]	PUNCT
dpc-2201	144	22	.	.	PUNCT
dpc-2201	145	1	reviewed	review	VERB
dpc-2201	145	2	studies	study	NOUN
dpc-2201	145	3	indicated	indicate	VERB
dpc-2201	145	4	the	the	DET
dpc-2201	145	5	effectiveness	effectiveness	NOUN
dpc-2201	145	6	of	of	ADP
dpc-2201	145	7	oral	oral	ADJ
dpc-2201	145	8	tofacitinib	tofacitinib	NOUN
dpc-2201	145	9	in	in	ADP
dpc-2201	145	10	the	the	DET
dpc-2201	145	11	treatment	treatment	NOUN
dpc-2201	145	12	of	of	ADP
dpc-2201	145	13	pg	pg	NOUN
dpc-2201	145	14	;	;	PUNCT
dpc-2201	145	15	however	however	ADV
dpc-2201	145	16	,	,	PUNCT
dpc-2201	145	17	more	more	ADJ
dpc-2201	145	18	studies	study	NOUN
dpc-2201	145	19	with	with	ADP
dpc-2201	145	20	larger	large	ADJ
dpc-2201	145	21	scales	scale	NOUN
dpc-2201	145	22	are	be	AUX
dpc-2201	145	23	needed	need	VERB
dpc-2201	145	24	to	to	PART
dpc-2201	145	25	assess	assess	VERB
dpc-2201	145	26	the	the	DET
dpc-2201	145	27	accuracy	accuracy	NOUN
dpc-2201	145	28	of	of	ADP
dpc-2201	145	29	this	this	DET
dpc-2201	145	30	allegation	allegation	NOUN
dpc-2201	145	31	.	.	PUNCT
dpc-2201	146	1	conclusions	conclusion	NOUN
dpc-2201	146	2	tofacitinib	tofacitinib	PROPN
dpc-2201	146	3	and	and	CCONJ
dpc-2201	146	4	ruxolitinib	ruxolitinib	NOUN
dpc-2201	146	5	showed	show	VERB
dpc-2201	146	6	potential	potential	ADJ
dpc-2201	146	7	efficacy	efficacy	NOUN
dpc-2201	146	8	in	in	ADP
dpc-2201	146	9	the	the	DET
dpc-2201	146	10	treatment	treatment	NOUN
dpc-2201	146	11	of	of	ADP
dpc-2201	146	12	several	several	ADJ
dpc-2201	146	13	autoimmune	autoimmune	ADJ
dpc-2201	146	14	disorders	disorder	NOUN
dpc-2201	146	15	.	.	PUNCT
dpc-2201	147	1	based	base	VERB
dpc-2201	147	2	on	on	ADP
dpc-2201	147	3	a	a	DET
dpc-2201	147	4	thorough	thorough	ADJ
dpc-2201	147	5	review	review	NOUN
dpc-2201	147	6	of	of	ADP
dpc-2201	147	7	the	the	DET
dpc-2201	147	8	literature	literature	NOUN
dpc-2201	147	9	,	,	PUNCT
dpc-2201	147	10	it	it	PRON
dpc-2201	147	11	is	be	AUX
dpc-2201	147	12	concluded	conclude	VERB
dpc-2201	147	13	that	that	SCONJ
dpc-2201	147	14	both	both	DET
dpc-2201	147	15	medications	medication	NOUN
dpc-2201	147	16	have	have	VERB
dpc-2201	147	17	acceptable	acceptable	ADJ
dpc-2201	147	18	safety	safety	NOUN
dpc-2201	147	19	profiles	profile	NOUN
dpc-2201	147	20	;	;	PUNCT
dpc-2201	147	21	however	however	ADV
dpc-2201	147	22	,	,	PUNCT
dpc-2201	147	23	physicians	physician	NOUN
dpc-2201	147	24	are	be	AUX
dpc-2201	147	25	recommended	recommend	VERB
dpc-2201	147	26	to	to	PART
dpc-2201	147	27	outweigh	outweigh	VERB
dpc-2201	147	28	the	the	DET
dpc-2201	147	29	risks	risk	NOUN
dpc-2201	147	30	and	and	CCONJ
dpc-2201	147	31	benefits	benefit	NOUN
dpc-2201	147	32	of	of	ADP
dpc-2201	147	33	the	the	DET
dpc-2201	147	34	treatment	treatment	NOUN
dpc-2201	147	35	for	for	ADP
dpc-2201	147	36	each	each	DET
dpc-2201	147	37	specific	specific	ADJ
dpc-2201	147	38	condition	condition	NOUN
dpc-2201	147	39	.	.	PUNCT
dpc-2201	148	1	further	far	ADV
dpc-2201	148	2	,	,	PUNCT
dpc-2201	148	3	there	there	PRON
dpc-2201	148	4	are	be	VERB
dpc-2201	148	5	not	not	PART
dpc-2201	148	6	enough	enough	ADJ
dpc-2201	148	7	data	datum	NOUN
dpc-2201	148	8	and	and	CCONJ
dpc-2201	148	9	studies	study	NOUN
dpc-2201	148	10	about	about	ADP
dpc-2201	148	11	the	the	DET
dpc-2201	148	12	benefit	benefit	NOUN
dpc-2201	148	13	and	and	CCONJ
dpc-2201	148	14	safety	safety	NOUN
dpc-2201	148	15	of	of	ADP
dpc-2201	148	16	tofacitinib	tofacitinib	NOUN
dpc-2201	148	17	and	and	CCONJ
dpc-2201	148	18	ruxolitinib	ruxolitinib	NOUN
dpc-2201	148	19	in	in	ADP
dpc-2201	148	20	treating	treat	VERB
dpc-2201	148	21	disorders	disorder	NOUN
dpc-2201	148	22	such	such	ADJ
dpc-2201	148	23	as	as	ADP
dpc-2201	148	24	hs	hs	PROPN
dpc-2201	148	25	,	,	PUNCT
dpc-2201	148	26	pg	pg	NOUN
dpc-2201	148	27	,	,	PUNCT
dpc-2201	148	28	and	and	CCONJ
dpc-2201	148	29	lp	lp	NOUN
dpc-2201	148	30	.	.	PUNCT
dpc-2201	149	1	we	we	PRON
dpc-2201	149	2	predict	predict	VERB
dpc-2201	149	3	that	that	SCONJ
dpc-2201	149	4	jaki	jaki	PROPN
dpc-2201	149	5	will	will	AUX
dpc-2201	149	6	be	be	AUX
dpc-2201	149	7	utilized	utilize	VERB
dpc-2201	149	8	more	more	ADV
dpc-2201	149	9	broadly	broadly	ADV
dpc-2201	149	10	in	in	ADP
dpc-2201	149	11	treating	treat	VERB
dpc-2201	149	12	autoimmune	autoimmune	ADJ
dpc-2201	149	13	disorders	disorder	NOUN
dpc-2201	149	14	,	,	PUNCT
dpc-2201	149	15	and	and	CCONJ
dpc-2201	149	16	future	future	ADJ
dpc-2201	149	17	reviews	review	NOUN
dpc-2201	149	18	can	can	AUX
dpc-2201	149	19	be	be	AUX
dpc-2201	149	20	a	a	DET
dpc-2201	149	21	paradigm	paradigm	NOUN
dpc-2201	149	22	guideline	guideline	NOUN
dpc-2201	149	23	helping	help	VERB
dpc-2201	149	24	clinicians	clinician	NOUN
dpc-2201	149	25	to	to	PART
dpc-2201	149	26	treat	treat	VERB
dpc-2201	149	27	their	their	PRON
dpc-2201	149	28	patients	patient	NOUN
dpc-2201	149	29	.	.	PUNCT
dpc-2201	150	1	acknowledgement	acknowledgement	NOUN
dpc-2201	150	2	the	the	DET
dpc-2201	150	3	authors	author	NOUN
dpc-2201	150	4	would	would	AUX
dpc-2201	150	5	also	also	ADV
dpc-2201	150	6	like	like	VERB
dpc-2201	150	7	to	to	PART
dpc-2201	150	8	express	express	VERB
dpc-2201	150	9	their	their	PRON
dpc-2201	150	10	gratitude	gratitude	NOUN
dpc-2201	150	11	to	to	ADP
dpc-2201	150	12	zeena	zeena	PROPN
dpc-2201	150	13	amini	amini	PROPN
dpc-2201	150	14	,	,	PUNCT
dpc-2201	150	15	for	for	ADP
dpc-2201	150	16	an	an	DET
dpc-2201	150	17	extraordinary	extraordinary	ADJ
dpc-2201	150	18	helpful	helpful	ADJ
dpc-2201	150	19	comments	comment	NOUN
dpc-2201	150	20	during	during	ADP
dpc-2201	150	21	the	the	DET
dpc-2201	150	22	review	review	NOUN
dpc-2201	150	23	process	process	NOUN
dpc-2201	150	24	,	,	PUNCT
dpc-2201	150	25	and	and	CCONJ
dpc-2201	150	26	to	to	ADP
dpc-2201	150	27	the	the	DET
dpc-2201	150	28	authorities	authority	NOUN
dpc-2201	150	29	of	of	ADP
dpc-2201	150	30	rasool	rasool	PROPN
dpc-2201	150	31	akram	akram	PROPN
dpc-2201	150	32	medical	medical	PROPN
dpc-2201	150	33	complex	complex	ADJ
dpc-2201	150	34	clinical	clinical	ADJ
dpc-2201	150	35	research	research	NOUN
dpc-2201	150	36	development	development	NOUN
dpc-2201	150	37	center	center	NOUN
dpc-2201	150	38	(	(	PUNCT
dpc-2201	150	39	rcrdc)or	rcrdc)or	VERB
dpc-2201	150	40	their	their	PRON
dpc-2201	150	41	technical	technical	ADJ
dpc-2201	150	42	assistance	assistance	NOUN
dpc-2201	150	43	.	.	PUNCT
dpc-2201	151	1	references	reference	NOUN
dpc-2201	151	2	1	1	NUM
dpc-2201	151	3	.	.	PUNCT
dpc-2201	151	4	choy	choy	NOUN
dpc-2201	151	5	eh	eh	INTJ
dpc-2201	151	6	.	.	PUNCT
dpc-2201	152	1	clinical	clinical	ADJ
dpc-2201	152	2	significance	significance	NOUN
dpc-2201	152	3	of	of	ADP
dpc-2201	152	4	janus	janus	PROPN
dpc-2201	152	5	kinase	kinase	PROPN
dpc-2201	152	6	inhibitor	inhibitor	PROPN
dpc-2201	152	7	selectivity	selectivity	NOUN
dpc-2201	152	8	.	.	PUNCT
dpc-2201	153	1	rheumatology	rheumatology	NOUN
dpc-2201	153	2	(	(	PUNCT
dpc-2201	153	3	oxford	oxford	PROPN
dpc-2201	153	4	)	)	PUNCT
dpc-2201	153	5	.	.	PUNCT
dpc-2201	154	1	2019;58(6):953	2019;58(6):953	NUM
dpc-2201	154	2	-	-	PUNCT
dpc-2201	154	3	962	962	NUM
dpc-2201	154	4	.	.	PUNCT
dpc-2201	155	1	doi	doi	NOUN
dpc-2201	155	2	:	:	PUNCT
dpc-2201	155	3	10.1093	10.1093	NUM
dpc-2201	155	4	/	/	SYM
dpc-2201	155	5	rheumatology	rheumatology	NOUN
dpc-2201	155	6	/	/	SYM
dpc-2201	155	7	key339	key339	PROPN
dpc-2201	155	8	.	.	PUNCT
dpc-2201	156	1	pmid	pmid	NOUN
dpc-2201	156	2	:	:	PUNCT
dpc-2201	156	3	30508136	30508136	NUM
dpc-2201	156	4	.	.	PUNCT
dpc-2201	157	1	pmcid	pmcid	NOUN
dpc-2201	157	2	:	:	PUNCT
dpc-2201	157	3	pmc6532440	pmc6532440	ADJ
dpc-2201	157	4	.	.	PUNCT
dpc-2201	158	1	2	2	X
dpc-2201	158	2	.	.	X
dpc-2201	158	3	damsky	damsky	PROPN
dpc-2201	158	4	w	w	PROPN
dpc-2201	158	5	,	,	PUNCT
dpc-2201	158	6	king	king	PROPN
dpc-2201	158	7	ba	ba	PROPN
dpc-2201	158	8	.	.	PUNCT
dpc-2201	159	1	jak	jak	PROPN
dpc-2201	159	2	inhibitors	inhibitor	NOUN
dpc-2201	159	3	in	in	ADP
dpc-2201	159	4	dermatology	dermatology	NOUN
dpc-2201	159	5	:	:	PUNCT
dpc-2201	159	6	the	the	DET
dpc-2201	159	7	promise	promise	NOUN
dpc-2201	159	8	of	of	ADP
dpc-2201	159	9	a	a	DET
dpc-2201	159	10	new	new	ADJ
dpc-2201	159	11	drug	drug	NOUN
dpc-2201	159	12	class	class	NOUN
dpc-2201	159	13	.	.	PUNCT
dpc-2201	160	1	j	j	PROPN
dpc-2201	160	2	am	be	AUX
dpc-2201	160	3	acad	acad	ADJ
dpc-2201	160	4	dermatol	dermatol	NOUN
dpc-2201	160	5	.	.	PUNCT
dpc-2201	161	1	2017;76(4):736	2017;76(4):736	NUM
dpc-2201	161	2	-	-	PUNCT
dpc-2201	161	3	744	744	NUM
dpc-2201	161	4	.	.	PUNCT
dpc-2201	161	5	doi	doi	PROPN
dpc-2201	161	6	10.1016	10.1016	NUM
dpc-2201	161	7	/	/	SYM
dpc-2201	161	8	j.jaad.2016.12.005	j.jaad.2016.12.005	PROPN
dpc-2201	161	9	.	.	PUNCT
dpc-2201	162	1	pmid	pmid	NOUN
dpc-2201	162	2	:	:	PUNCT
dpc-2201	162	3	28139263	28139263	NUM
dpc-2201	162	4	.	.	PUNCT
dpc-2201	163	1	pmcid	pmcid	NOUN
dpc-2201	163	2	:	:	PUNCT
dpc-2201	163	3	pmc6035868	pmc6035868	ADJ
dpc-2201	163	4	.	.	PUNCT
dpc-2201	164	1	3	3	X
dpc-2201	164	2	.	.	X
dpc-2201	164	3	o’shea	o’shea	PROPN
dpc-2201	164	4	jj	jj	PROPN
dpc-2201	164	5	,	,	PUNCT
dpc-2201	164	6	kontzias	kontzias	PROPN
dpc-2201	164	7	a	a	PROPN
dpc-2201	164	8	,	,	PUNCT
dpc-2201	164	9	yamaoka	yamaoka	PROPN
dpc-2201	164	10	k	k	PROPN
dpc-2201	164	11	,	,	PUNCT
dpc-2201	164	12	tanaka	tanaka	PROPN
dpc-2201	164	13	y	y	PROPN
dpc-2201	164	14	,	,	PUNCT
dpc-2201	164	15	laurence	laurence	PROPN
dpc-2201	164	16	a.	a.	PROPN
dpc-2201	164	17	janus	janus	PROPN
dpc-2201	164	18	kinase	kinase	PROPN
dpc-2201	164	19	inhibitors	inhibitor	NOUN
dpc-2201	164	20	in	in	ADP
dpc-2201	164	21	autoimmune	autoimmune	ADJ
dpc-2201	164	22	diseases	disease	NOUN
dpc-2201	164	23	.	.	PUNCT
dpc-2201	165	1	ann	ann	PROPN
dpc-2201	165	2	rheum	rheum	PROPN
dpc-2201	165	3	dis	dis	PROPN
dpc-2201	165	4	.	.	PUNCT
dpc-2201	166	1	2013;72	2013;72	NUM
dpc-2201	166	2	suppl	suppl	ADJ
dpc-2201	166	3	2(0	2(0	NUM
dpc-2201	166	4	2):ii111	2):ii111	NUM
dpc-2201	166	5	-	-	SYM
dpc-2201	166	6	ii115	ii115	PROPN
dpc-2201	166	7	.	.	PUNCT
dpc-2201	167	1	doi	doi	NOUN
dpc-2201	167	2	:	:	PUNCT
dpc-2201	167	3	10.1136/	10.1136/	NUM
dpc-2201	167	4	with	with	ADP
dpc-2201	167	5	more	more	ADV
dpc-2201	167	6	severe	severe	ADJ
dpc-2201	167	7	disease	disease	NOUN
dpc-2201	167	8	,	,	PUNCT
dpc-2201	167	9	was	be	AUX
dpc-2201	167	10	commenced	commence	VERB
dpc-2201	167	11	and	and	CCONJ
dpc-2201	167	12	continued	continue	VERB
dpc-2201	167	13	for	for	ADP
dpc-2201	167	14	2	2	NUM
dpc-2201	167	15	–	–	SYM
dpc-2201	167	16	19	19	NUM
dpc-2201	167	17	months	month	NOUN
dpc-2201	167	18	.	.	PUNCT
dpc-2201	168	1	disease	disease	NOUN
dpc-2201	168	2	activity	activity	NOUN
dpc-2201	168	3	assessed	assess	VERB
dpc-2201	168	4	by	by	ADP
dpc-2201	168	5	lpp	lpp	PROPN
dpc-2201	168	6	activity	activity	NOUN
dpc-2201	168	7	index	index	NOUN
dpc-2201	168	8	(	(	PUNCT
dpc-2201	168	9	lppai	lppai	PROPN
dpc-2201	168	10	)	)	PUNCT
dpc-2201	168	11	,	,	PUNCT
dpc-2201	168	12	and	and	CCONJ
dpc-2201	168	13	showed	show	VERB
dpc-2201	168	14	statistically	statistically	ADV
dpc-2201	168	15	significant	significant	ADJ
dpc-2201	168	16	improvement	improvement	NOUN
dpc-2201	168	17	compared	compare	VERB
dpc-2201	168	18	to	to	ADP
dpc-2201	168	19	pre	pre	ADJ
dpc-2201	168	20	-	-	NOUN
dpc-2201	168	21	treatment	treatment	NOUN
dpc-2201	168	22	(	(	PUNCT
dpc-2201	168	23	p	p	NOUN
dpc-2201	168	24	=	=	NOUN
dpc-2201	168	25	0.0014	0.0014	NUM
dpc-2201	168	26	)	)	PUNCT
dpc-2201	168	27	.	.	PUNCT
dpc-2201	169	1	one	one	NUM
dpc-2201	169	2	patient	patient	NOUN
dpc-2201	169	3	reported	report	VERB
dpc-2201	169	4	hair	hair	NOUN
dpc-2201	169	5	loss	loss	NOUN
dpc-2201	169	6	upon	upon	SCONJ
dpc-2201	169	7	treatment	treatment	NOUN
dpc-2201	169	8	discontinuation	discontinuation	NOUN
dpc-2201	169	9	(	(	PUNCT
dpc-2201	169	10	due	due	ADP
dpc-2201	169	11	to	to	ADP
dpc-2201	169	12	weight	weight	NOUN
dpc-2201	169	13	gain	gain	NOUN
dpc-2201	169	14	)	)	PUNCT
dpc-2201	169	15	,	,	PUNCT
dpc-2201	169	16	which	which	PRON
dpc-2201	169	17	stabilized	stabilize	VERB
dpc-2201	169	18	when	when	SCONJ
dpc-2201	169	19	medication	medication	NOUN
dpc-2201	169	20	was	be	AUX
dpc-2201	169	21	re	re	VERB
dpc-2201	169	22	-	-	VERB
dpc-2201	169	23	started	start	VERB
dpc-2201	169	24	with	with	ADP
dpc-2201	169	25	a	a	DET
dpc-2201	169	26	5	5	NUM
dpc-2201	169	27	mg	mg	NUM
dpc-2201	169	28	/	/	SYM
dpc-2201	169	29	bid	bid	NOUN
dpc-2201	169	30	dosage	dosage	NOUN
dpc-2201	169	31	[	[	X
dpc-2201	169	32	32	32	NUM
dpc-2201	169	33	]	]	PUNCT
dpc-2201	169	34	.	.	PUNCT
dpc-2201	170	1	a	a	DET
dpc-2201	170	2	significant	significant	ADJ
dpc-2201	170	3	efficacy	efficacy	NOUN
dpc-2201	170	4	and	and	CCONJ
dpc-2201	170	5	low	low	ADJ
dpc-2201	170	6	aes	aes	PROPN
dpc-2201	170	7	were	be	AUX
dpc-2201	170	8	reported	report	VERB
dpc-2201	170	9	in	in	ADP
dpc-2201	170	10	the	the	DET
dpc-2201	170	11	reviewed	review	VERB
dpc-2201	170	12	case	case	NOUN
dpc-2201	170	13	series	series	NOUN
dpc-2201	170	14	.	.	PUNCT
dpc-2201	171	1	large	large	ADJ
dpc-2201	171	2	-	-	PUNCT
dpc-2201	171	3	scale	scale	NOUN
dpc-2201	171	4	and	and	CCONJ
dpc-2201	171	5	long	long	ADJ
dpc-2201	171	6	-	-	PUNCT
dpc-2201	171	7	term	term	NOUN
dpc-2201	171	8	studies	study	NOUN
dpc-2201	171	9	are	be	AUX
dpc-2201	171	10	required	require	VERB
dpc-2201	171	11	to	to	PART
dpc-2201	171	12	assess	assess	VERB
dpc-2201	171	13	the	the	DET
dpc-2201	171	14	safety	safety	NOUN
dpc-2201	171	15	and	and	CCONJ
dpc-2201	171	16	efficacy	efficacy	NOUN
dpc-2201	171	17	of	of	ADP
dpc-2201	171	18	the	the	DET
dpc-2201	171	19	treatment	treatment	NOUN
dpc-2201	171	20	.	.	PUNCT
dpc-2201	172	1	hidradenitis	hidradenitis	PROPN
dpc-2201	172	2	suppurativa	suppurativa	PROPN
dpc-2201	172	3	hidradenitis	hidradenitis	PROPN
dpc-2201	172	4	suppurativa	suppurativa	PROPN
dpc-2201	172	5	is	be	AUX
dpc-2201	172	6	a	a	DET
dpc-2201	172	7	chronic	chronic	ADJ
dpc-2201	172	8	inflammatory	inflammatory	ADJ
dpc-2201	172	9	disorder	disorder	NOUN
dpc-2201	172	10	in	in	ADP
dpc-2201	172	11	1	1	NUM
dpc-2201	172	12	%	%	NOUN
dpc-2201	172	13	of	of	ADP
dpc-2201	172	14	general	general	ADJ
dpc-2201	172	15	population	population	NOUN
dpc-2201	173	1	[	[	X
dpc-2201	173	2	33,34	33,34	NOUN
dpc-2201	173	3	]	]	PUNCT
dpc-2201	173	4	.	.	PUNCT
dpc-2201	174	1	pathogenesis	pathogenesis	NOUN
dpc-2201	174	2	of	of	ADP
dpc-2201	174	3	hs	hs	PROPN
dpc-2201	174	4	starts	start	VERB
dpc-2201	174	5	with	with	ADP
dpc-2201	174	6	cutaneous	cutaneous	ADJ
dpc-2201	174	7	changes	change	NOUN
dpc-2201	174	8	around	around	ADP
dpc-2201	174	9	hair	hair	NOUN
dpc-2201	174	10	follicles	follicle	NOUN
dpc-2201	174	11	and	and	CCONJ
dpc-2201	174	12	dysregulation	dysregulation	NOUN
dpc-2201	174	13	of	of	ADP
dpc-2201	174	14	innate	innate	ADJ
dpc-2201	174	15	and	and	CCONJ
dpc-2201	174	16	adaptive	adaptive	ADJ
dpc-2201	174	17	immunity	immunity	NOUN
dpc-2201	174	18	:	:	PUNCT
dpc-2201	174	19	elevated	elevated	ADJ
dpc-2201	174	20	levels	level	NOUN
dpc-2201	174	21	of	of	ADP
dpc-2201	174	22	ils	ils	NOUN
dpc-2201	174	23	following	follow	VERB
dpc-2201	174	24	the	the	DET
dpc-2201	174	25	overactivity	overactivity	NOUN
dpc-2201	174	26	of	of	ADP
dpc-2201	174	27	t	t	PROPN
dpc-2201	174	28	-	-	PUNCT
dpc-2201	174	29	helpers	helper	NOUN
dpc-2201	174	30	,	,	PUNCT
dpc-2201	174	31	ultimately	ultimately	ADV
dpc-2201	174	32	affect	affect	VERB
dpc-2201	174	33	neutrophils	neutrophil	NOUN
dpc-2201	174	34	,	,	PUNCT
dpc-2201	174	35	macrophages	macrophage	NOUN
dpc-2201	174	36	and	and	CCONJ
dpc-2201	174	37	plasma	plasma	NOUN
dpc-2201	174	38	cells	cell	NOUN
dpc-2201	174	39	.	.	PUNCT
dpc-2201	175	1	these	these	DET
dpc-2201	175	2	changes	change	NOUN
dpc-2201	175	3	result	result	VERB
dpc-2201	175	4	in	in	ADP
dpc-2201	175	5	a	a	DET
dpc-2201	175	6	vicious	vicious	ADJ
dpc-2201	175	7	cycle	cycle	NOUN
dpc-2201	175	8	of	of	ADP
dpc-2201	175	9	inflammation	inflammation	NOUN
dpc-2201	175	10	,	,	PUNCT
dpc-2201	175	11	pain	pain	NOUN
dpc-2201	175	12	,	,	PUNCT
dpc-2201	175	13	purulence	purulence	NOUN
dpc-2201	175	14	,	,	PUNCT
dpc-2201	175	15	tissue	tissue	NOUN
dpc-2201	175	16	destruction	destruction	NOUN
dpc-2201	175	17	,	,	PUNCT
dpc-2201	175	18	and	and	CCONJ
dpc-2201	175	19	disfiguring	disfigure	VERB
dpc-2201	175	20	scars	scar	NOUN
dpc-2201	175	21	[	[	X
dpc-2201	175	22	33	33	NUM
dpc-2201	175	23	-	-	SYM
dpc-2201	175	24	36	36	NUM
dpc-2201	175	25	]	]	PUNCT
dpc-2201	175	26	.	.	PUNCT
dpc-2201	176	1	jaki	jaki	PROPN
dpc-2201	176	2	suppress	suppress	VERB
dpc-2201	176	3	the	the	DET
dpc-2201	176	4	impacts	impact	NOUN
dpc-2201	176	5	of	of	ADP
dpc-2201	176	6	ils	ils	NOUN
dpc-2201	176	7	,	,	PUNCT
dpc-2201	176	8	and	and	CCONJ
dpc-2201	176	9	thus	thus	ADV
dpc-2201	176	10	they	they	PRON
dpc-2201	176	11	can	can	AUX
dpc-2201	176	12	be	be	AUX
dpc-2201	176	13	a	a	DET
dpc-2201	176	14	potential	potential	ADJ
dpc-2201	176	15	treatment	treatment	NOUN
dpc-2201	176	16	for	for	ADP
dpc-2201	176	17	hs	hs	PROPN
dpc-2201	176	18	;	;	PUNCT
dpc-2201	176	19	however	however	ADV
dpc-2201	176	20	,	,	PUNCT
dpc-2201	176	21	limited	limited	ADJ
dpc-2201	176	22	studies	study	NOUN
dpc-2201	176	23	aim	aim	VERB
dpc-2201	176	24	to	to	PART
dpc-2201	176	25	prove	prove	VERB
dpc-2201	176	26	the	the	DET
dpc-2201	176	27	benefit	benefit	NOUN
dpc-2201	176	28	of	of	ADP
dpc-2201	176	29	jaki	jaki	PROPN
dpc-2201	176	30	in	in	ADP
dpc-2201	176	31	treating	treat	VERB
dpc-2201	176	32	hs	hs	PROPN
dpc-2201	176	33	.	.	PROPN
dpc-2201	176	34	savage	savage	NOUN
dpc-2201	176	35	et	et	PROPN
dpc-2201	176	36	al	al	PROPN
dpc-2201	176	37	reported	report	VERB
dpc-2201	176	38	two	two	NUM
dpc-2201	176	39	cases	case	NOUN
dpc-2201	176	40	of	of	ADP
dpc-2201	176	41	hs	hs	PRON
dpc-2201	176	42	treating	treat	VERB
dpc-2201	176	43	with	with	ADP
dpc-2201	176	44	oral	oral	ADJ
dpc-2201	176	45	tofacitinib	tofacitinib	NOUN
dpc-2201	176	46	5	5	NUM
dpc-2201	176	47	mg	mg	NUM
dpc-2201	176	48	/	/	SYM
dpc-2201	176	49	bid	bid	NOUN
dpc-2201	176	50	:	:	PUNCT
dpc-2201	176	51	a	a	DET
dpc-2201	176	52	patient	patient	NOUN
dpc-2201	176	53	treated	treat	VERB
dpc-2201	176	54	for	for	ADP
dpc-2201	176	55	one	one	NUM
dpc-2201	176	56	year	year	NOUN
dpc-2201	176	57	and	and	CCONJ
dpc-2201	176	58	the	the	DET
dpc-2201	176	59	other	other	ADJ
dpc-2201	176	60	patient	patient	NOUN
dpc-2201	176	61	for	for	ADP
dpc-2201	176	62	three	three	NUM
dpc-2201	176	63	years	year	NOUN
dpc-2201	176	64	.	.	PUNCT
dpc-2201	177	1	both	both	DET
dpc-2201	177	2	patients	patient	NOUN
dpc-2201	177	3	showed	show	VERB
dpc-2201	177	4	favorable	favorable	ADJ
dpc-2201	177	5	results	result	NOUN
dpc-2201	177	6	:	:	PUNCT
dpc-2201	177	7	patient	patient	ADJ
dpc-2201	177	8	#	#	SYM
dpc-2201	177	9	1	1	NUM
dpc-2201	177	10	was	be	AUX
dpc-2201	177	11	pain	pain	NOUN
dpc-2201	177	12	and	and	CCONJ
dpc-2201	177	13	drainage	drainage	NOUN
dpc-2201	177	14	free	free	ADJ
dpc-2201	177	15	after	after	ADP
dpc-2201	177	16	11	11	NUM
dpc-2201	177	17	months	month	NOUN
dpc-2201	177	18	.	.	PUNCT
dpc-2201	178	1	upon	upon	SCONJ
dpc-2201	178	2	discontinuation	discontinuation	NOUN
dpc-2201	178	3	at	at	ADP
dpc-2201	178	4	12	12	NUM
dpc-2201	178	5	months	month	NOUN
dpc-2201	178	6	,	,	PUNCT
dpc-2201	178	7	the	the	DET
dpc-2201	178	8	modest	modest	ADJ
dpc-2201	178	9	disease	disease	NOUN
dpc-2201	178	10	activity	activity	NOUN
dpc-2201	178	11	was	be	AUX
dpc-2201	178	12	observed	observe	VERB
dpc-2201	178	13	,	,	PUNCT
dpc-2201	178	14	and	and	CCONJ
dpc-2201	178	15	tofacitinib	tofacitinib	PROPN
dpc-2201	178	16	re	re	NOUN
dpc-2201	178	17	-	-	NOUN
dpc-2201	178	18	treatment	treatment	NOUN
dpc-2201	178	19	directed	direct	VERB
dpc-2201	178	20	the	the	DET
dpc-2201	178	21	disease	disease	NOUN
dpc-2201	178	22	to	to	ADP
dpc-2201	178	23	full	full	ADJ
dpc-2201	178	24	remission	remission	NOUN
dpc-2201	178	25	.	.	PUNCT
dpc-2201	179	1	patient	patient	ADJ
dpc-2201	179	2	#	#	SYM
dpc-2201	179	3	2	2	NUM
dpc-2201	179	4	experienced	experience	VERB
dpc-2201	179	5	gradual	gradual	ADJ
dpc-2201	179	6	remission	remission	NOUN
dpc-2201	179	7	over	over	ADP
dpc-2201	179	8	3	3	NUM
dpc-2201	179	9	years	year	NOUN
dpc-2201	179	10	of	of	ADP
dpc-2201	179	11	treatment	treatment	NOUN
dpc-2201	179	12	.	.	PUNCT
dpc-2201	180	1	at	at	ADP
dpc-2201	180	2	this	this	DET
dpc-2201	180	3	time	time	NOUN
dpc-2201	180	4	,	,	PUNCT
dpc-2201	180	5	localized	localized	ADJ
dpc-2201	180	6	herpes	herpe	NOUN
dpc-2201	180	7	zoster	zoster	ADJ
dpc-2201	180	8	infection	infection	NOUN
dpc-2201	180	9	was	be	AUX
dpc-2201	180	10	reported	report	VERB
dpc-2201	180	11	which	which	PRON
dpc-2201	180	12	was	be	AUX
dpc-2201	180	13	controlled	control	VERB
dpc-2201	180	14	with	with	ADP
dpc-2201	180	15	intravenous	intravenous	ADJ
dpc-2201	180	16	valacyclovir	valacyclovir	NOUN
dpc-2201	180	17	.	.	PUNCT
dpc-2201	181	1	no	no	DET
dpc-2201	181	2	other	other	ADJ
dpc-2201	181	3	aes	aes	PROPN
dpc-2201	181	4	were	be	AUX
dpc-2201	181	5	reported	report	VERB
dpc-2201	181	6	in	in	ADP
dpc-2201	181	7	either	either	PRON
dpc-2201	181	8	of	of	ADP
dpc-2201	181	9	the	the	DET
dpc-2201	181	10	two	two	NUM
dpc-2201	181	11	patients	patient	NOUN
dpc-2201	181	12	[	[	X
dpc-2201	181	13	35	35	NUM
dpc-2201	181	14	]	]	PUNCT
dpc-2201	181	15	.	.	PUNCT
dpc-2201	182	1	pyoderma	pyoderma	NOUN
dpc-2201	182	2	gangrenosum	gangrenosum	NOUN
dpc-2201	182	3	pyoderma	pyoderma	NOUN
dpc-2201	182	4	gangrenosum	gangrenosum	NOUN
dpc-2201	182	5	is	be	AUX
dpc-2201	182	6	a	a	DET
dpc-2201	182	7	rare	rare	ADJ
dpc-2201	182	8	,	,	PUNCT
dpc-2201	182	9	ulcerative	ulcerative	ADJ
dpc-2201	182	10	and	and	CCONJ
dpc-2201	182	11	painful	painful	ADJ
dpc-2201	182	12	dermatological	dermatological	ADJ
dpc-2201	182	13	condition	condition	NOUN
dpc-2201	182	14	with	with	ADP
dpc-2201	182	15	a	a	DET
dpc-2201	182	16	multifactorial	multifactorial	ADJ
dpc-2201	182	17	pathogenesis	pathogenesis	NOUN
dpc-2201	182	18	.	.	PUNCT
dpc-2201	183	1	diagnosis	diagnosis	NOUN
dpc-2201	183	2	of	of	ADP
dpc-2201	183	3	pg	pg	PROPN
dpc-2201	183	4	is	be	AUX
dpc-2201	183	5	clinical	clinical	ADJ
dpc-2201	183	6	after	after	ADP
dpc-2201	183	7	excluding	exclude	VERB
dpc-2201	183	8	other	other	ADJ
dpc-2201	183	9	causes	cause	NOUN
dpc-2201	183	10	ie	ie	PRON
dpc-2201	183	11	infection	infection	NOUN
dpc-2201	183	12	,	,	PUNCT
dpc-2201	183	13	neoplasia	neoplasia	NOUN
dpc-2201	183	14	,	,	PUNCT
dpc-2201	183	15	thrombophilia	thrombophilia	NOUN
dpc-2201	183	16	,	,	PUNCT
dpc-2201	183	17	and	and	CCONJ
dpc-2201	183	18	other	other	ADJ
dpc-2201	183	19	inflammatory	inflammatory	ADJ
dpc-2201	183	20	conditions	condition	NOUN
dpc-2201	183	21	.	.	PUNCT
dpc-2201	184	1	pg	pg	VERB
dpc-2201	184	2	often	often	ADV
dpc-2201	184	3	is	be	AUX
dpc-2201	184	4	related	relate	VERB
dpc-2201	184	5	to	to	ADP
dpc-2201	184	6	other	other	ADJ
dpc-2201	184	7	systemic	systemic	ADJ
dpc-2201	184	8	inflammatory	inflammatory	ADJ
dpc-2201	184	9	conditions	condition	NOUN
dpc-2201	184	10	[	[	X
dpc-2201	184	11	37	37	NUM
dpc-2201	184	12	-	-	SYM
dpc-2201	184	13	40	40	NUM
dpc-2201	184	14	]	]	PUNCT
dpc-2201	184	15	.	.	PUNCT
dpc-2201	185	1	pathophysiology	pathophysiology	NOUN
dpc-2201	185	2	of	of	ADP
dpc-2201	185	3	pg	pg	PROPN
dpc-2201	185	4	is	be	AUX
dpc-2201	185	5	not	not	PART
dpc-2201	185	6	entirely	entirely	ADV
dpc-2201	185	7	known	know	VERB
dpc-2201	185	8	;	;	PUNCT
dpc-2201	185	9	however	however	ADV
dpc-2201	185	10	,	,	PUNCT
dpc-2201	185	11	it	it	PRON
dpc-2201	185	12	represents	represent	VERB
dpc-2201	185	13	dysregulation	dysregulation	NOUN
dpc-2201	185	14	of	of	ADP
dpc-2201	185	15	the	the	DET
dpc-2201	185	16	innate	innate	ADJ
dpc-2201	185	17	and	and	CCONJ
dpc-2201	185	18	adaptive	adaptive	ADJ
dpc-2201	185	19	immune	immune	ADJ
dpc-2201	185	20	systems	system	NOUN
dpc-2201	185	21	:	:	PUNCT
dpc-2201	185	22	neutrophil	neutrophil	ADJ
dpc-2201	185	23	dysfunction	dysfunction	NOUN
dpc-2201	185	24	,	,	PUNCT
dpc-2201	185	25	jak2	jak2	NOUN
dpc-2201	185	26	mutation	mutation	NOUN
dpc-2201	185	27	,	,	PUNCT
dpc-2201	185	28	overexpression	overexpression	NOUN
dpc-2201	185	29	of	of	ADP
dpc-2201	185	30	integrin	integrin	NOUN
dpc-2201	185	31	and	and	CCONJ
dpc-2201	185	32	dysregulation	dysregulation	NOUN
dpc-2201	185	33	of	of	ADP
dpc-2201	185	34	integrin	integrin	NOUN
dpc-2201	185	35	signaling	signal	VERB
dpc-2201	185	36	,	,	PUNCT
dpc-2201	185	37	and	and	CCONJ
dpc-2201	185	38	overproduction	overproduction	NOUN
dpc-2201	185	39	of	of	ADP
dpc-2201	185	40	ils	ils	NOUN
dpc-2201	185	41	seems	seem	VERB
dpc-2201	185	42	to	to	PART
dpc-2201	185	43	be	be	AUX
dpc-2201	185	44	involved	involve	VERB
dpc-2201	185	45	in	in	ADP
dpc-2201	185	46	the	the	DET
dpc-2201	185	47	course	course	NOUN
dpc-2201	185	48	of	of	ADP
dpc-2201	185	49	pg	pg	NOUN
dpc-2201	186	1	[	[	X
dpc-2201	186	2	41	41	NUM
dpc-2201	186	3	]	]	PUNCT
dpc-2201	186	4	.	.	PUNCT
dpc-2201	187	1	there	there	PRON
dpc-2201	187	2	are	be	VERB
dpc-2201	187	3	few	few	ADJ
dpc-2201	187	4	studies	study	NOUN
dpc-2201	187	5	about	about	ADP
dpc-2201	187	6	the	the	DET
dpc-2201	187	7	efficacy	efficacy	NOUN
dpc-2201	187	8	of	of	ADP
dpc-2201	187	9	jaki	jaki	PROPN
dpc-2201	187	10	in	in	ADP
dpc-2201	187	11	treating	treat	VERB
dpc-2201	187	12	pg	pg	NOUN
dpc-2201	187	13	;	;	PUNCT
dpc-2201	187	14	however	however	ADV
dpc-2201	187	15	,	,	PUNCT
dpc-2201	187	16	few	few	ADJ
dpc-2201	187	17	case	case	NOUN
dpc-2201	187	18	reports	report	NOUN
dpc-2201	187	19	show	show	VERB
dpc-2201	187	20	potential	potential	ADJ
dpc-2201	187	21	benefits	benefit	NOUN
dpc-2201	187	22	that	that	PRON
dpc-2201	187	23	need	need	VERB
dpc-2201	187	24	further	further	ADJ
dpc-2201	187	25	large	large	ADJ
dpc-2201	187	26	-	-	PUNCT
dpc-2201	187	27	scale	scale	NOUN
dpc-2201	187	28	rcts	rct	NOUN
dpc-2201	187	29	.	.	PUNCT
dpc-2201	188	1	in	in	ADP
dpc-2201	188	2	a	a	DET
dpc-2201	188	3	case	case	NOUN
dpc-2201	188	4	report	report	NOUN
dpc-2201	188	5	,	,	PUNCT
dpc-2201	188	6	choi	choi	PROPN
dpc-2201	188	7	et	et	PROPN
dpc-2201	188	8	al	al	PROPN
dpc-2201	188	9	presented	present	VERB
dpc-2201	188	10	a	a	DET
dpc-2201	188	11	patient	patient	NOUN
dpc-2201	188	12	with	with	ADP
dpc-2201	188	13	a	a	DET
dpc-2201	188	14	history	history	NOUN
dpc-2201	188	15	of	of	ADP
dpc-2201	188	16	cocaine	cocaine	NOUN
dpc-2201	188	17	abuse	abuse	NOUN
dpc-2201	188	18	and	and	CCONJ
dpc-2201	188	19	10	10	NUM
dpc-2201	188	20	-	-	PUNCT
dpc-2201	188	21	month	month	NOUN
dpc-2201	188	22	pg	pg	NOUN
dpc-2201	188	23	lesions	lesion	NOUN
dpc-2201	188	24	refractory	refractory	NOUN
dpc-2201	188	25	to	to	ADP
dpc-2201	188	26	other	other	ADJ
dpc-2201	188	27	forms	form	NOUN
dpc-2201	188	28	of	of	ADP
dpc-2201	188	29	treatment	treatment	NOUN
dpc-2201	188	30	,	,	PUNCT
dpc-2201	188	31	6	6	NUM
dpc-2201	188	32	review	review	NOUN
dpc-2201	188	33	|	|	ADV
dpc-2201	188	34	dermatol	dermatol	ADJ
dpc-2201	188	35	pract	pract	NOUN
dpc-2201	188	36	concept	concept	NOUN
dpc-2201	188	37	.	.	PUNCT
dpc-2201	189	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	189	2	10.1177/0300060519847414	10.1177/0300060519847414	NUM
dpc-2201	189	3	.	.	PUNCT
dpc-2201	190	1	pmid	pmid	NOUN
dpc-2201	190	2	:	:	PUNCT
dpc-2201	190	3	31096817	31096817	NUM
dpc-2201	190	4	.	.	PUNCT
dpc-2201	191	1	pmcid	pmcid	NOUN
dpc-2201	191	2	:	:	PUNCT
dpc-2201	191	3	pmc6567701	pmc6567701	ADJ
dpc-2201	191	4	.	.	PUNCT
dpc-2201	192	1	19	19	NUM
dpc-2201	192	2	.	.	PUNCT
dpc-2201	192	3	su	su	PROPN
dpc-2201	192	4	yj	yj	PROPN
dpc-2201	192	5	.	.	PROPN
dpc-2201	193	1	early	early	ADJ
dpc-2201	193	2	diagnosis	diagnosis	NOUN
dpc-2201	193	3	of	of	ADP
dpc-2201	193	4	psoriatic	psoriatic	ADJ
dpc-2201	193	5	arthritis	arthritis	NOUN
dpc-2201	193	6	among	among	ADP
dpc-2201	193	7	psoriasis	psoriasis	NOUN
dpc-2201	193	8	patients	patient	NOUN
dpc-2201	193	9	:	:	PUNCT
dpc-2201	193	10	clinical	clinical	ADJ
dpc-2201	193	11	experience	experience	NOUN
dpc-2201	193	12	sharing	sharing	NOUN
dpc-2201	193	13	.	.	PUNCT
dpc-2201	194	1	clin	clin	PROPN
dpc-2201	194	2	rheumatol	rheumatol	NOUN
dpc-2201	194	3	.	.	PUNCT
dpc-2201	195	1	2020;39(12):3677	2020;39(12):3677	X
dpc-2201	195	2	-	-	SYM
dpc-2201	195	3	3684	3684	NUM
dpc-2201	195	4	.	.	PUNCT
dpc-2201	196	1	doi	doi	NOUN
dpc-2201	196	2	:	:	PUNCT
dpc-2201	196	3	10.1007	10.1007	NUM
dpc-2201	196	4	/	/	SYM
dpc-2201	196	5	s10067	s10067	NOUN
dpc-2201	196	6	-	-	PUNCT
dpc-2201	196	7	020	020	NUM
dpc-2201	196	8	-	-	PUNCT
dpc-2201	196	9	05132	05132	NUM
dpc-2201	196	10	-	-	SYM
dpc-2201	196	11	1	1	NUM
dpc-2201	196	12	.	.	PUNCT
dpc-2201	197	1	pmid	pmid	NOUN
dpc-2201	197	2	:	:	PUNCT
dpc-2201	197	3	32468320	32468320	NUM
dpc-2201	197	4	.	.	PUNCT
dpc-2201	198	1	pmcid	pmcid	NOUN
dpc-2201	198	2	:	:	PUNCT
dpc-2201	198	3	pmc7648743	pmc7648743	NOUN
dpc-2201	198	4	.	.	PUNCT
dpc-2201	199	1	20	20	NUM
dpc-2201	199	2	.	.	X
dpc-2201	199	3	gladman	gladman	NOUN
dpc-2201	199	4	d	d	PROPN
dpc-2201	199	5	,	,	PUNCT
dpc-2201	199	6	rigby	rigby	PROPN
dpc-2201	199	7	w	w	PROPN
dpc-2201	199	8	,	,	PUNCT
dpc-2201	199	9	azevedo	azevedo	PROPN
dpc-2201	199	10	vf	vf	PROPN
dpc-2201	199	11	,	,	PUNCT
dpc-2201	199	12	et	et	PROPN
dpc-2201	199	13	al	al	PROPN
dpc-2201	199	14	.	.	PROPN
dpc-2201	199	15	tofacitinib	tofacitinib	PROPN
dpc-2201	199	16	for	for	ADP
dpc-2201	199	17	psoriatic	psoriatic	ADJ
dpc-2201	199	18	arthritis	arthritis	NOUN
dpc-2201	199	19	in	in	ADP
dpc-2201	199	20	patients	patient	NOUN
dpc-2201	199	21	with	with	ADP
dpc-2201	199	22	an	an	DET
dpc-2201	199	23	inadequate	inadequate	ADJ
dpc-2201	199	24	response	response	NOUN
dpc-2201	199	25	to	to	ADP
dpc-2201	199	26	tnf	tnf	PROPN
dpc-2201	199	27	inhibitors	inhibitor	NOUN
dpc-2201	199	28	.	.	PUNCT
dpc-2201	200	1	n	n	PRON
dpc-2201	200	2	engl	engl	PROPN
dpc-2201	200	3	j	j	PROPN
dpc-2201	200	4	med	med	PROPN
dpc-2201	200	5	.	.	PUNCT
dpc-2201	201	1	2017;377(16):1525	2017;377(16):1525	NUM
dpc-2201	201	2	-	-	PUNCT
dpc-2201	201	3	1536	1536	NUM
dpc-2201	201	4	.	.	PUNCT
dpc-2201	202	1	doi	doi	NOUN
dpc-2201	202	2	:	:	PUNCT
dpc-2201	202	3	10.1056/	10.1056/	NUM
dpc-2201	202	4	nejmoa1615977	nejmoa1615977	PROPN
dpc-2201	202	5	.	.	PUNCT
dpc-2201	203	1	pmid	pmid	NOUN
dpc-2201	203	2	:	:	PUNCT
dpc-2201	203	3	29045207	29045207	NUM
dpc-2201	203	4	.	.	PUNCT
dpc-2201	204	1	21	21	NUM
dpc-2201	204	2	.	.	PUNCT
dpc-2201	205	1	campanaro	campanaro	PROPN
dpc-2201	205	2	f	f	PROPN
dpc-2201	205	3	,	,	PUNCT
dpc-2201	205	4	batticciotto	batticciotto	VERB
dpc-2201	205	5	a	a	PRON
dpc-2201	205	6	,	,	PUNCT
dpc-2201	205	7	zaffaroni	zaffaroni	PROPN
dpc-2201	205	8	a	a	X
dpc-2201	205	9	,	,	PUNCT
dpc-2201	205	10	cappelli	cappelli	PROPN
dpc-2201	205	11	a	a	PROPN
dpc-2201	205	12	,	,	PUNCT
dpc-2201	205	13	donadini	donadini	PROPN
dpc-2201	205	14	mp	mp	PROPN
dpc-2201	205	15	,	,	PUNCT
dpc-2201	205	16	squizzato	squizzato	PROPN
dpc-2201	205	17	a.	a.	PROPN
dpc-2201	205	18	jak	jak	PROPN
dpc-2201	205	19	inhibitors	inhibitor	NOUN
dpc-2201	205	20	and	and	CCONJ
dpc-2201	205	21	psoriatic	psoriatic	ADJ
dpc-2201	205	22	arthritis	arthritis	NOUN
dpc-2201	205	23	:	:	PUNCT
dpc-2201	205	24	a	a	DET
dpc-2201	205	25	systematic	systematic	ADJ
dpc-2201	205	26	review	review	NOUN
dpc-2201	205	27	and	and	CCONJ
dpc-2201	205	28	meta	meta	ADJ
dpc-2201	205	29	-	-	PUNCT
dpc-2201	205	30	analysis	analysis	NOUN
dpc-2201	205	31	.	.	PUNCT
dpc-2201	206	1	autoimmun	autoimmun	PROPN
dpc-2201	206	2	rev	rev	PROPN
dpc-2201	206	3	.	.	PUNCT
dpc-2201	207	1	2021;20(10):102902	2021;20(10):102902	NUM
dpc-2201	207	2	.	.	X
dpc-2201	207	3	doi	doi	NOUN
dpc-2201	207	4	:	:	PUNCT
dpc-2201	207	5	10.1016	10.1016	NUM
dpc-2201	207	6	/	/	SYM
dpc-2201	207	7	j.autrev.2021.102902	j.autrev.2021.102902	NOUN
dpc-2201	207	8	.	.	PUNCT
dpc-2201	208	1	pmid	pmid	NOUN
dpc-2201	208	2	:	:	PUNCT
dpc-2201	208	3	34274542	34274542	NUM
dpc-2201	208	4	.	.	PUNCT
dpc-2201	209	1	22	22	NUM
dpc-2201	209	2	.	.	PUNCT
dpc-2201	210	1	paik	paik	PROPN
dpc-2201	210	2	j	j	PROPN
dpc-2201	210	3	,	,	PUNCT
dpc-2201	210	4	deeks	deek	VERB
dpc-2201	210	5	ed	ed	PROPN
dpc-2201	210	6	.	.	PUNCT
dpc-2201	210	7	tofacitinib	tofacitinib	PROPN
dpc-2201	210	8	:	:	PUNCT
dpc-2201	210	9	a	a	DET
dpc-2201	210	10	review	review	NOUN
dpc-2201	210	11	in	in	ADP
dpc-2201	210	12	psoriatic	psoriatic	ADJ
dpc-2201	210	13	arthritis	arthritis	NOUN
dpc-2201	210	14	.	.	PUNCT
dpc-2201	211	1	drugs	drug	NOUN
dpc-2201	211	2	.	.	PUNCT
dpc-2201	212	1	2019;79(6):655	2019;79(6):655	PROPN
dpc-2201	212	2	-	-	PUNCT
dpc-2201	212	3	663	663	NUM
dpc-2201	212	4	.	.	PUNCT
dpc-2201	213	1	doi	doi	NOUN
dpc-2201	213	2	:	:	PUNCT
dpc-2201	213	3	10.1007	10.1007	NUM
dpc-2201	213	4	/	/	SYM
dpc-2201	213	5	s40265	s40265	NOUN
dpc-2201	213	6	-	-	PUNCT
dpc-2201	213	7	019	019	NUM
dpc-2201	213	8	-	-	PUNCT
dpc-2201	213	9	010913	010913	NUM
dpc-2201	213	10	.	.	PUNCT
dpc-2201	214	1	pmid	pmid	NOUN
dpc-2201	214	2	:	:	PUNCT
dpc-2201	214	3	30895473	30895473	NUM
dpc-2201	214	4	.	.	PUNCT
dpc-2201	215	1	23	23	NUM
dpc-2201	215	2	.	.	PUNCT
dpc-2201	216	1	rodrigues	rodrigues	PROPN
dpc-2201	216	2	ma	ma	PROPN
dpc-2201	216	3	,	,	PUNCT
dpc-2201	216	4	torres	torre	VERB
dpc-2201	216	5	t.	t.	PROPN
dpc-2201	216	6	jak	jak	PROPN
dpc-2201	216	7	/	/	SYM
dpc-2201	216	8	stat	stat	PROPN
dpc-2201	216	9	inhibitors	inhibitor	NOUN
dpc-2201	216	10	for	for	ADP
dpc-2201	216	11	the	the	DET
dpc-2201	216	12	treatment	treatment	NOUN
dpc-2201	216	13	of	of	ADP
dpc-2201	216	14	atopic	atopic	NOUN
dpc-2201	216	15	dermatitis	dermatitis	NOUN
dpc-2201	216	16	.	.	PUNCT
dpc-2201	217	1	j	j	PROPN
dpc-2201	217	2	dermatolog	dermatolog	PROPN
dpc-2201	217	3	treat	treat	NOUN
dpc-2201	217	4	.	.	PUNCT
dpc-2201	218	1	2020;31(1):33	2020;31(1):33	NUM
dpc-2201	218	2	-	-	SYM
dpc-2201	218	3	40	40	NUM
dpc-2201	218	4	.	.	PUNCT
dpc-2201	219	1	doi	doi	NOUN
dpc-2201	219	2	:	:	PUNCT
dpc-2201	219	3	10.1080/09546634.2019.1577549	10.1080/09546634.2019.1577549	NUM
dpc-2201	219	4	.	.	PUNCT
dpc-2201	220	1	pmid	pmid	NOUN
dpc-2201	220	2	:	:	PUNCT
dpc-2201	220	3	30703333	30703333	NUM
dpc-2201	220	4	.	.	PUNCT
dpc-2201	221	1	24	24	NUM
dpc-2201	221	2	.	.	PUNCT
dpc-2201	222	1	tsai	tsai	PROPN
dpc-2201	222	2	hr	hr	PROPN
dpc-2201	222	3	,	,	PUNCT
dpc-2201	222	4	lu	lu	PROPN
dpc-2201	222	5	jw	jw	PROPN
dpc-2201	222	6	,	,	PUNCT
dpc-2201	222	7	chen	chen	PROPN
dpc-2201	222	8	ly	ly	PROPN
dpc-2201	222	9	,	,	PUNCT
dpc-2201	222	10	chen	chen	PROPN
dpc-2201	222	11	tl	tl	PROPN
dpc-2201	222	12	.	.	PUNCT
dpc-2201	223	1	application	application	NOUN
dpc-2201	223	2	of	of	ADP
dpc-2201	223	3	janus	janus	PROPN
dpc-2201	223	4	kinase	kinase	PROPN
dpc-2201	223	5	inhibitors	inhibitor	NOUN
dpc-2201	223	6	in	in	ADP
dpc-2201	223	7	atopic	atopic	NOUN
dpc-2201	223	8	dermatitis	dermatitis	NOUN
dpc-2201	223	9	:	:	PUNCT
dpc-2201	223	10	an	an	DET
dpc-2201	223	11	updated	update	VERB
dpc-2201	223	12	systematic	systematic	ADJ
dpc-2201	223	13	review	review	NOUN
dpc-2201	223	14	and	and	CCONJ
dpc-2201	223	15	meta	meta	NOUN
dpc-2201	223	16	-	-	PUNCT
dpc-2201	223	17	analysis	analysis	NOUN
dpc-2201	223	18	of	of	ADP
dpc-2201	223	19	clinical	clinical	ADJ
dpc-2201	223	20	trials	trial	NOUN
dpc-2201	223	21	.	.	PUNCT
dpc-2201	224	1	j	j	PROPN
dpc-2201	224	2	pers	per	NOUN
dpc-2201	224	3	med	me	VERB
dpc-2201	224	4	.	.	PUNCT
dpc-2201	225	1	2021;11(4):279	2021;11(4):279	NOUN
dpc-2201	225	2	.	.	PUNCT
dpc-2201	226	1	doi	doi	NOUN
dpc-2201	226	2	:	:	PUNCT
dpc-2201	226	3	10.3390	10.3390	NUM
dpc-2201	226	4	/	/	SYM
dpc-2201	226	5	jpm11040279	jpm11040279	NOUN
dpc-2201	226	6	.	.	PUNCT
dpc-2201	227	1	pmid	pmid	NOUN
dpc-2201	227	2	:	:	PUNCT
dpc-2201	227	3	33917069	33917069	NUM
dpc-2201	227	4	.	.	PUNCT
dpc-2201	228	1	pmcid	pmcid	NOUN
dpc-2201	228	2	:	:	PUNCT
dpc-2201	228	3	pmc8067719	pmc8067719	NOUN
dpc-2201	228	4	.	.	PUNCT
dpc-2201	229	1	25	25	NUM
dpc-2201	229	2	.	.	PUNCT
dpc-2201	229	3	rothstein	rothstein	PROPN
dpc-2201	229	4	b	b	PROPN
dpc-2201	229	5	,	,	PUNCT
dpc-2201	229	6	joshipura	joshipura	X
dpc-2201	229	7	d	d	NOUN
dpc-2201	229	8	,	,	PUNCT
dpc-2201	229	9	saraiya	saraiya	NOUN
dpc-2201	229	10	a	a	NOUN
dpc-2201	229	11	,	,	PUNCT
dpc-2201	229	12	et	et	PROPN
dpc-2201	229	13	al	al	PROPN
dpc-2201	229	14	.	.	PUNCT
dpc-2201	229	15	treatment	treatment	NOUN
dpc-2201	229	16	of	of	ADP
dpc-2201	229	17	vitiligo	vitiligo	NOUN
dpc-2201	229	18	with	with	ADP
dpc-2201	229	19	the	the	DET
dpc-2201	229	20	topical	topical	ADJ
dpc-2201	229	21	janus	janus	PROPN
dpc-2201	229	22	kinase	kinase	PROPN
dpc-2201	229	23	inhibitor	inhibitor	PROPN
dpc-2201	229	24	ruxolitinib	ruxolitinib	PROPN
dpc-2201	229	25	.	.	PUNCT
dpc-2201	230	1	j	j	PROPN
dpc-2201	230	2	am	be	AUX
dpc-2201	230	3	acad	acad	ADJ
dpc-2201	230	4	dermatol	dermatol	NOUN
dpc-2201	230	5	.	.	PUNCT
dpc-2201	231	1	2017;76(6):1054	2017;76(6):1054	NUM
dpc-2201	231	2	-	-	SYM
dpc-2201	231	3	1060.e1	1060.e1	PROPN
dpc-2201	231	4	.	.	PUNCT
dpc-2201	231	5	doi	doi	NOUN
dpc-2201	231	6	:	:	PUNCT
dpc-2201	231	7	10.1016	10.1016	NUM
dpc-2201	231	8	/	/	SYM
dpc-2201	231	9	j.	j.	PROPN
dpc-2201	231	10	jaad.2017.02.049	jaad.2017.02.049	PROPN
dpc-2201	231	11	.	.	PUNCT
dpc-2201	232	1	pmid	pmid	NOUN
dpc-2201	232	2	:	:	PUNCT
dpc-2201	232	3	28390737	28390737	NUM
dpc-2201	232	4	.	.	PUNCT
dpc-2201	233	1	26	26	NUM
dpc-2201	233	2	.	.	PUNCT
dpc-2201	234	1	wang	wang	PROPN
dpc-2201	234	2	y	y	PROPN
dpc-2201	234	3	,	,	PUNCT
dpc-2201	234	4	li	li	PROPN
dpc-2201	234	5	s	s	PROPN
dpc-2201	234	6	,	,	PUNCT
dpc-2201	234	7	li	li	PROPN
dpc-2201	234	8	c.	c.	PROPN
dpc-2201	234	9	clinical	clinical	PROPN
dpc-2201	234	10	features	feature	NOUN
dpc-2201	234	11	,	,	PUNCT
dpc-2201	234	12	immunopathogenesis	immunopathogenesis	NOUN
dpc-2201	234	13	,	,	PUNCT
dpc-2201	234	14	and	and	CCONJ
dpc-2201	234	15	therapeutic	therapeutic	ADJ
dpc-2201	234	16	strategies	strategy	NOUN
dpc-2201	234	17	in	in	ADP
dpc-2201	234	18	vitiligo	vitiligo	PROPN
dpc-2201	234	19	.	.	PUNCT
dpc-2201	235	1	clin	clin	PROPN
dpc-2201	235	2	rev	rev	PROPN
dpc-2201	235	3	allergy	allergy	PROPN
dpc-2201	235	4	immunol	immunol	NOUN
dpc-2201	235	5	.	.	PUNCT
dpc-2201	236	1	2021;61(3):299	2021;61(3):299	NUM
dpc-2201	236	2	-	-	PUNCT
dpc-2201	236	3	323	323	NUM
dpc-2201	236	4	.	.	PUNCT
dpc-2201	237	1	doi	doi	NOUN
dpc-2201	237	2	:	:	PUNCT
dpc-2201	237	3	10.1007	10.1007	NUM
dpc-2201	237	4	/	/	SYM
dpc-2201	237	5	s12016	s12016	PROPN
dpc-2201	237	6	-	-	PUNCT
dpc-2201	237	7	021	021	NUM
dpc-2201	237	8	-	-	PUNCT
dpc-2201	237	9	08868	08868	NUM
dpc-2201	237	10	-	-	PUNCT
dpc-2201	237	11	z.	z.	PROPN
dpc-2201	237	12	pmid	pmid	PROPN
dpc-2201	237	13	:	:	PUNCT
dpc-2201	237	14	34283349	34283349	NUM
dpc-2201	237	15	.	.	PUNCT
dpc-2201	238	1	27	27	NUM
dpc-2201	238	2	.	.	PUNCT
dpc-2201	238	3	phan	phan	PROPN
dpc-2201	238	4	k	k	PROPN
dpc-2201	238	5	,	,	PUNCT
dpc-2201	238	6	phan	phan	PROPN
dpc-2201	238	7	s	s	PROPN
dpc-2201	238	8	,	,	PUNCT
dpc-2201	238	9	shumack	shumack	VERB
dpc-2201	238	10	s	s	PROPN
dpc-2201	238	11	,	,	PUNCT
dpc-2201	238	12	gupta	gupta	PROPN
dpc-2201	238	13	m.	m.	NOUN
dpc-2201	238	14	repigmentation	repigmentation	NOUN
dpc-2201	238	15	in	in	ADP
dpc-2201	238	16	vitiligo	vitiligo	NOUN
dpc-2201	238	17	using	use	VERB
dpc-2201	238	18	janus	janus	PROPN
dpc-2201	238	19	kinase	kinase	PROPN
dpc-2201	238	20	(	(	PUNCT
dpc-2201	238	21	jak	jak	PROPN
dpc-2201	238	22	)	)	PUNCT
dpc-2201	238	23	inhibitors	inhibitor	NOUN
dpc-2201	238	24	with	with	ADP
dpc-2201	238	25	phototherapy	phototherapy	NOUN
dpc-2201	238	26	:	:	PUNCT
dpc-2201	238	27	systematic	systematic	ADJ
dpc-2201	238	28	review	review	NOUN
dpc-2201	238	29	and	and	CCONJ
dpc-2201	238	30	meta	meta	ADJ
dpc-2201	238	31	-	-	PUNCT
dpc-2201	238	32	analysis	analysis	NOUN
dpc-2201	238	33	.	.	PUNCT
dpc-2201	239	1	j	j	PROPN
dpc-2201	239	2	dermatolog	dermatolog	PROPN
dpc-2201	239	3	treat	treat	NOUN
dpc-2201	239	4	.	.	PUNCT
dpc-2201	240	1	2022;33(1):173	2022;33(1):173	NUM
dpc-2201	240	2	-	-	PUNCT
dpc-2201	240	3	177	177	NUM
dpc-2201	240	4	.	.	PUNCT
dpc-2201	241	1	doi	doi	NOUN
dpc-2201	241	2	:	:	PUNCT
dpc-2201	241	3	10.1080/09546634.2020.1735615	10.1080/09546634.2020.1735615	NUM
dpc-2201	241	4	.	.	PUNCT
dpc-2201	242	1	pmid	pmid	NOUN
dpc-2201	242	2	:	:	PUNCT
dpc-2201	242	3	32096671	32096671	NUM
dpc-2201	242	4	.	.	PUNCT
dpc-2201	243	1	28	28	NUM
dpc-2201	243	2	.	.	PUNCT
dpc-2201	243	3	komnitski	komnitski	PROPN
dpc-2201	243	4	m	m	PROPN
dpc-2201	243	5	,	,	PUNCT
dpc-2201	243	6	komnitski	komnitski	PROPN
dpc-2201	243	7	a	a	PROPN
dpc-2201	243	8	,	,	PUNCT
dpc-2201	243	9	komnitski	komnitski	PROPN
dpc-2201	243	10	junior	junior	PROPN
dpc-2201	243	11	a	a	PRON
dpc-2201	243	12	,	,	PUNCT
dpc-2201	243	13	silva	silva	PROPN
dpc-2201	243	14	de	de	PROPN
dpc-2201	243	15	castro	castro	PROPN
dpc-2201	243	16	cc	cc	PROPN
dpc-2201	243	17	.	.	PROPN
dpc-2201	243	18	partial	partial	ADJ
dpc-2201	243	19	repigmentation	repigmentation	NOUN
dpc-2201	243	20	of	of	ADP
dpc-2201	243	21	vitiligo	vitiligo	NOUN
dpc-2201	243	22	with	with	ADP
dpc-2201	243	23	tofacitinib	tofacitinib	NOUN
dpc-2201	243	24	,	,	PUNCT
dpc-2201	243	25	without	without	ADP
dpc-2201	243	26	exposure	exposure	NOUN
dpc-2201	243	27	to	to	ADP
dpc-2201	243	28	ultraviolet	ultraviolet	ADJ
dpc-2201	243	29	radiation	radiation	NOUN
dpc-2201	243	30	.	.	PUNCT
dpc-2201	244	1	an	an	DET
dpc-2201	244	2	bras	bras	NOUN
dpc-2201	244	3	dermatol	dermatol	NOUN
dpc-2201	244	4	.	.	PUNCT
dpc-2201	245	1	2020;95(4):473	2020;95(4):473	NUM
dpc-2201	245	2	-	-	SYM
dpc-2201	245	3	476	476	NUM
dpc-2201	245	4	.	.	PUNCT
dpc-2201	246	1	doi	doi	NOUN
dpc-2201	246	2	:	:	PUNCT
dpc-2201	246	3	10.1016	10.1016	NUM
dpc-2201	246	4	/	/	SYM
dpc-2201	246	5	j.abd.2019.08.032	j.abd.2019.08.032	NOUN
dpc-2201	246	6	.	.	PUNCT
dpc-2201	247	1	pmid	pmid	NOUN
dpc-2201	247	2	:	:	PUNCT
dpc-2201	247	3	32418716	32418716	NUM
dpc-2201	247	4	.	.	PUNCT
dpc-2201	248	1	pmcid	pmcid	NOUN
dpc-2201	248	2	:	:	PUNCT
dpc-2201	248	3	pmc7335860	pmc7335860	PROPN
dpc-2201	248	4	.	.	PUNCT
dpc-2201	249	1	29	29	NUM
dpc-2201	249	2	.	.	X
dpc-2201	250	1	shao	shao	PROPN
dpc-2201	250	2	s	s	PROPN
dpc-2201	250	3	,	,	PUNCT
dpc-2201	250	4	tsoi	tsoi	PROPN
dpc-2201	250	5	lc	lc	PROPN
dpc-2201	250	6	,	,	PUNCT
dpc-2201	250	7	sarkar	sarkar	PROPN
dpc-2201	250	8	mk	mk	PROPN
dpc-2201	250	9	,	,	PUNCT
dpc-2201	250	10	xing	xing	PROPN
dpc-2201	250	11	x	x	PROPN
dpc-2201	250	12	,	,	PUNCT
dpc-2201	250	13	xue	xue	PROPN
dpc-2201	250	14	k	k	PROPN
dpc-2201	250	15	,	,	PUNCT
dpc-2201	250	16	uppala	uppala	NOUN
dpc-2201	250	17	r	r	NOUN
dpc-2201	250	18	,	,	PUNCT
dpc-2201	250	19	et	et	PROPN
dpc-2201	250	20	al	al	PROPN
dpc-2201	250	21	.	.	PUNCT
dpc-2201	251	1	ifn	ifn	PROPN
dpc-2201	251	2	-	-	PUNCT
dpc-2201	251	3	gamma	gamma	NOUN
dpc-2201	251	4	enhances	enhance	VERB
dpc-2201	251	5	cell	cell	NOUN
dpc-2201	251	6	-	-	PUNCT
dpc-2201	251	7	mediated	mediate	VERB
dpc-2201	251	8	cytotoxicity	cytotoxicity	NOUN
dpc-2201	251	9	against	against	ADP
dpc-2201	251	10	keratinocytes	keratinocyte	NOUN
dpc-2201	251	11	via	via	ADP
dpc-2201	251	12	jak2	jak2	PROPN
dpc-2201	251	13	/	/	SYM
dpc-2201	251	14	stat1	stat1	PROPN
dpc-2201	251	15	in	in	ADP
dpc-2201	251	16	lichen	lichen	NOUN
dpc-2201	251	17	planus	planus	NOUN
dpc-2201	251	18	.	.	PUNCT
dpc-2201	252	1	sci	sci	PROPN
dpc-2201	252	2	transl	transl	PROPN
dpc-2201	252	3	med	med	PROPN
dpc-2201	252	4	.	.	PUNCT
dpc-2201	253	1	2019;11(511):eaav7561	2019;11(511):eaav7561	NUM
dpc-2201	253	2	.	.	PUNCT
dpc-2201	254	1	doi	doi	NOUN
dpc-2201	254	2	:	:	PUNCT
dpc-2201	254	3	10.1126	10.1126	NUM
dpc-2201	254	4	/	/	SYM
dpc-2201	254	5	scitranslmed.aav7561	scitranslmed.aav7561	NOUN
dpc-2201	254	6	.	.	PUNCT
dpc-2201	255	1	pmid	pmid	NOUN
dpc-2201	255	2	:	:	PUNCT
dpc-2201	255	3	31554739	31554739	NUM
dpc-2201	255	4	.	.	PUNCT
dpc-2201	256	1	pmcid	pmcid	NOUN
dpc-2201	256	2	:	:	PUNCT
dpc-2201	256	3	pmc7285657	pmc7285657	PROPN
dpc-2201	256	4	.	.	PUNCT
dpc-2201	257	1	30	30	NUM
dpc-2201	257	2	.	.	X
dpc-2201	257	3	damsky	damsky	PROPN
dpc-2201	257	4	w	w	PROPN
dpc-2201	257	5	,	,	PUNCT
dpc-2201	257	6	wang	wang	PROPN
dpc-2201	257	7	a	a	X
dpc-2201	257	8	,	,	PUNCT
dpc-2201	257	9	olamiju	olamiju	PROPN
dpc-2201	257	10	b	b	PROPN
dpc-2201	257	11	,	,	PUNCT
dpc-2201	257	12	peterson	peterson	PROPN
dpc-2201	257	13	d	d	PROPN
dpc-2201	257	14	,	,	PUNCT
dpc-2201	257	15	galan	galan	PROPN
dpc-2201	257	16	a	a	PROPN
dpc-2201	257	17	,	,	PUNCT
dpc-2201	257	18	king	king	PROPN
dpc-2201	257	19	b.	b.	PROPN
dpc-2201	257	20	treatment	treatment	NOUN
dpc-2201	257	21	of	of	ADP
dpc-2201	257	22	severe	severe	ADJ
dpc-2201	257	23	lichen	lichen	NOUN
dpc-2201	257	24	planus	planus	NOUN
dpc-2201	257	25	with	with	ADP
dpc-2201	257	26	the	the	DET
dpc-2201	257	27	jak	jak	PROPN
dpc-2201	257	28	inhibitor	inhibitor	PROPN
dpc-2201	257	29	tofacitinib	tofacitinib	PROPN
dpc-2201	257	30	.	.	PUNCT
dpc-2201	258	1	j	j	PROPN
dpc-2201	258	2	allergy	allergy	PROPN
dpc-2201	258	3	clin	clin	PROPN
dpc-2201	258	4	immunol	immunol	NOUN
dpc-2201	258	5	.	.	PUNCT
dpc-2201	259	1	2020;145(6):1708	2020;145(6):1708	NUM
dpc-2201	259	2	-	-	SYM
dpc-2201	259	3	1710.e2	1710.e2	PROPN
dpc-2201	259	4	.	.	PUNCT
dpc-2201	260	1	doi	doi	NOUN
dpc-2201	260	2	:	:	PUNCT
dpc-2201	260	3	10.1016	10.1016	NUM
dpc-2201	260	4	/	/	SYM
dpc-2201	260	5	j.jaci.2020.01.031	j.jaci.2020.01.031	PROPN
dpc-2201	260	6	.	.	PUNCT
dpc-2201	261	1	pmid	pmid	NOUN
dpc-2201	261	2	:	:	PUNCT
dpc-2201	261	3	32018031	32018031	NUM
dpc-2201	261	4	.	.	PUNCT
dpc-2201	262	1	31	31	NUM
dpc-2201	262	2	.	.	PUNCT
dpc-2201	263	1	yang	yang	PROPN
dpc-2201	263	2	cc	cc	PROPN
dpc-2201	263	3	,	,	PUNCT
dpc-2201	263	4	khanna	khanna	PROPN
dpc-2201	263	5	t	t	PROPN
dpc-2201	263	6	,	,	PUNCT
dpc-2201	263	7	sallee	sallee	PROPN
dpc-2201	263	8	b	b	PROPN
dpc-2201	263	9	,	,	PUNCT
dpc-2201	263	10	christiano	christiano	PROPN
dpc-2201	263	11	am	be	AUX
dpc-2201	263	12	,	,	PUNCT
dpc-2201	263	13	bordone	bordone	PROPN
dpc-2201	263	14	la	la	PROPN
dpc-2201	263	15	.	.	PROPN
dpc-2201	263	16	tofacitinib	tofacitinib	PROPN
dpc-2201	263	17	for	for	ADP
dpc-2201	263	18	the	the	DET
dpc-2201	263	19	treatment	treatment	NOUN
dpc-2201	263	20	of	of	ADP
dpc-2201	263	21	lichen	lichen	NOUN
dpc-2201	263	22	planopilaris	planopilaris	NOUN
dpc-2201	263	23	:	:	PUNCT
dpc-2201	263	24	a	a	DET
dpc-2201	263	25	case	case	NOUN
dpc-2201	263	26	series	series	NOUN
dpc-2201	263	27	.	.	PUNCT
dpc-2201	264	1	dermatol	dermatol	NOUN
dpc-2201	264	2	ther	ther	ADV
dpc-2201	264	3	.	.	PUNCT
dpc-2201	265	1	2018;31(6):e12656	2018;31(6):e12656	X
dpc-2201	265	2	.	.	PUNCT
dpc-2201	266	1	doi	doi	NOUN
dpc-2201	266	2	:	:	PUNCT
dpc-2201	266	3	10.1111	10.1111	NUM
dpc-2201	266	4	/	/	SYM
dpc-2201	266	5	dth.12656	dth.12656	NOUN
dpc-2201	266	6	.	.	PUNCT
dpc-2201	267	1	pmid	pmid	NOUN
dpc-2201	267	2	:	:	PUNCT
dpc-2201	267	3	30264512	30264512	NUM
dpc-2201	267	4	.	.	PUNCT
dpc-2201	268	1	pmcid	pmcid	ADJ
dpc-2201	268	2	:	:	PUNCT
dpc-2201	268	3	pmc6585740	pmc6585740	NOUN
dpc-2201	268	4	.	.	PUNCT
dpc-2201	269	1	32	32	NUM
dpc-2201	269	2	.	.	PUNCT
dpc-2201	270	1	scala	scala	PROPN
dpc-2201	270	2	e	e	PROPN
dpc-2201	270	3	,	,	PUNCT
dpc-2201	270	4	cacciapuoti	cacciapuoti	PROPN
dpc-2201	270	5	s	s	PROPN
dpc-2201	270	6	,	,	PUNCT
dpc-2201	270	7	garzorz	garzorz	NOUN
dpc-2201	270	8	-	-	PUNCT
dpc-2201	270	9	stark	stark	PROPN
dpc-2201	270	10	n	n	CCONJ
dpc-2201	270	11	,	,	PUNCT
dpc-2201	270	12	et	et	PROPN
dpc-2201	270	13	al	al	PROPN
dpc-2201	270	14	.	.	PROPN
dpc-2201	270	15	hidradenitis	hidradenitis	PROPN
dpc-2201	270	16	suppurativa	suppurativa	PROPN
dpc-2201	270	17	:	:	PUNCT
dpc-2201	270	18	where	where	SCONJ
dpc-2201	270	19	we	we	PRON
dpc-2201	270	20	are	be	AUX
dpc-2201	270	21	and	and	CCONJ
dpc-2201	270	22	where	where	SCONJ
dpc-2201	270	23	we	we	PRON
dpc-2201	270	24	are	be	AUX
dpc-2201	270	25	going	go	VERB
dpc-2201	270	26	.	.	PUNCT
dpc-2201	271	1	cells	cell	NOUN
dpc-2201	271	2	.	.	PUNCT
dpc-2201	272	1	2021;10(8):2094	2021;10(8):2094	NUM
dpc-2201	272	2	.	.	PUNCT
dpc-2201	273	1	doi	doi	NOUN
dpc-2201	273	2	:	:	PUNCT
dpc-2201	273	3	10.3390	10.3390	NUM
dpc-2201	273	4	/	/	SYM
dpc-2201	273	5	cells10082094	cells10082094	PROPN
dpc-2201	273	6	.	.	PUNCT
dpc-2201	274	1	pmid	pmid	NOUN
dpc-2201	274	2	:	:	PUNCT
dpc-2201	274	3	34440863	34440863	NUM
dpc-2201	274	4	.	.	PUNCT
dpc-2201	275	1	pmcid	pmcid	NOUN
dpc-2201	275	2	:	:	PUNCT
dpc-2201	276	1	pmc8392140	pmc8392140	ADJ
dpc-2201	276	2	.	.	PUNCT
dpc-2201	277	1	annrheumdis-2012	annrheumdis-2012	NOUN
dpc-2201	277	2	-	-	PUNCT
dpc-2201	277	3	202576	202576	NUM
dpc-2201	277	4	.	.	PUNCT
dpc-2201	278	1	pmid	pmid	NOUN
dpc-2201	278	2	:	:	PUNCT
dpc-2201	278	3	23532440	23532440	NUM
dpc-2201	278	4	.	.	PUNCT
dpc-2201	279	1	pmcid	pmcid	ADJ
dpc-2201	279	2	:	:	PUNCT
dpc-2201	279	3	pmc3616338	pmc3616338	NOUN
dpc-2201	279	4	.	.	PUNCT
dpc-2201	280	1	4	4	X
dpc-2201	280	2	.	.	X
dpc-2201	280	3	cinats	cinat	NOUN
dpc-2201	280	4	a	a	DET
dpc-2201	280	5	,	,	PUNCT
dpc-2201	280	6	heck	heck	NOUN
dpc-2201	280	7	e	e	NOUN
dpc-2201	280	8	,	,	PUNCT
dpc-2201	280	9	robertson	robertson	PROPN
dpc-2201	280	10	l.	l.	PROPN
dpc-2201	280	11	janus	janus	PROPN
dpc-2201	280	12	kinase	kinase	PROPN
dpc-2201	280	13	inhibitors	inhibitor	NOUN
dpc-2201	280	14	:	:	PUNCT
dpc-2201	280	15	a	a	DET
dpc-2201	280	16	review	review	NOUN
dpc-2201	280	17	of	of	ADP
dpc-2201	280	18	their	their	PRON
dpc-2201	280	19	emerging	emerge	VERB
dpc-2201	280	20	applications	application	NOUN
dpc-2201	280	21	in	in	ADP
dpc-2201	280	22	dermatology	dermatology	NOUN
dpc-2201	280	23	.	.	PUNCT
dpc-2201	281	1	skin	skin	NOUN
dpc-2201	281	2	therapy	therapy	NOUN
dpc-2201	281	3	lett	lett	PROPN
dpc-2201	281	4	.	.	PUNCT
dpc-2201	282	1	2018;23(3):5	2018;23(3):5	NUM
dpc-2201	282	2	-	-	SYM
dpc-2201	282	3	9	9	NUM
dpc-2201	282	4	.	.	PUNCT
dpc-2201	283	1	pmid	pmid	NOUN
dpc-2201	283	2	:	:	PUNCT
dpc-2201	283	3	29772037	29772037	NUM
dpc-2201	283	4	.	.	PUNCT
dpc-2201	284	1	5	5	X
dpc-2201	284	2	.	.	X
dpc-2201	284	3	elli	elli	PROPN
dpc-2201	284	4	em	em	PRON
dpc-2201	284	5	,	,	PUNCT
dpc-2201	284	6	baratè	baratè	PROPN
dpc-2201	284	7	c	c	NOUN
dpc-2201	284	8	,	,	PUNCT
dpc-2201	284	9	mendicino	mendicino	NOUN
dpc-2201	284	10	f	f	PROPN
dpc-2201	284	11	,	,	PUNCT
dpc-2201	284	12	palandri	palandri	ADJ
dpc-2201	284	13	f	f	PROPN
dpc-2201	284	14	,	,	PUNCT
dpc-2201	284	15	palumbo	palumbo	PROPN
dpc-2201	284	16	ga	ga	PROPN
dpc-2201	284	17	.	.	PROPN
dpc-2201	284	18	mechanisms	mechanism	NOUN
dpc-2201	284	19	underlying	underlie	VERB
dpc-2201	284	20	the	the	DET
dpc-2201	284	21	anti	anti	ADJ
dpc-2201	284	22	-	-	ADJ
dpc-2201	284	23	inflammatory	inflammatory	ADJ
dpc-2201	284	24	and	and	CCONJ
dpc-2201	284	25	immunosuppressive	immunosuppressive	ADJ
dpc-2201	284	26	activity	activity	NOUN
dpc-2201	284	27	of	of	ADP
dpc-2201	284	28	ruxolitinib	ruxolitinib	NOUN
dpc-2201	284	29	.	.	PUNCT
dpc-2201	285	1	front	front	ADJ
dpc-2201	285	2	oncol	oncol	ADJ
dpc-2201	285	3	.	.	PUNCT
dpc-2201	286	1	2019;9:1186	2019;9:1186	PROPN
dpc-2201	286	2	.	.	PUNCT
dpc-2201	287	1	doi	doi	PROPN
dpc-2201	287	2	:	:	PUNCT
dpc-2201	287	3	10.3389/	10.3389/	NUM
dpc-2201	287	4	fonc.2019.01186	fonc.2019.01186	PROPN
dpc-2201	287	5	.	.	PUNCT
dpc-2201	288	1	pmid	pmid	NOUN
dpc-2201	288	2	:	:	PUNCT
dpc-2201	288	3	31788449	31788449	NUM
dpc-2201	288	4	.	.	PUNCT
dpc-2201	289	1	pmcid	pmcid	NOUN
dpc-2201	289	2	:	:	PUNCT
dpc-2201	289	3	pmc6854013	pmc6854013	NOUN
dpc-2201	289	4	.	.	PUNCT
dpc-2201	290	1	6	6	NUM
dpc-2201	290	2	.	.	PUNCT
dpc-2201	290	3	hodge	hodge	PROPN
dpc-2201	290	4	ja	ja	PROPN
dpc-2201	290	5	,	,	PUNCT
dpc-2201	290	6	kawabata	kawabata	PROPN
dpc-2201	290	7	tt	tt	PROPN
dpc-2201	290	8	,	,	PUNCT
dpc-2201	290	9	krishnaswami	krishnaswami	PROPN
dpc-2201	290	10	s	s	PROPN
dpc-2201	290	11	,	,	PUNCT
dpc-2201	290	12	et	et	PROPN
dpc-2201	290	13	al	al	PROPN
dpc-2201	290	14	.	.	PUNCT
dpc-2201	291	1	the	the	DET
dpc-2201	291	2	mechanism	mechanism	NOUN
dpc-2201	291	3	of	of	ADP
dpc-2201	291	4	action	action	NOUN
dpc-2201	291	5	of	of	ADP
dpc-2201	291	6	tofacitinib	tofacitinib	NOUN
dpc-2201	291	7	-	-	PUNCT
dpc-2201	291	8	an	an	DET
dpc-2201	291	9	oral	oral	ADJ
dpc-2201	291	10	janus	janus	PROPN
dpc-2201	291	11	kinase	kinase	PROPN
dpc-2201	291	12	inhibitor	inhibitor	NOUN
dpc-2201	291	13	for	for	ADP
dpc-2201	291	14	the	the	DET
dpc-2201	291	15	treatment	treatment	NOUN
dpc-2201	291	16	of	of	ADP
dpc-2201	291	17	rheumatoid	rheumatoid	NOUN
dpc-2201	291	18	arthritis	arthritis	NOUN
dpc-2201	291	19	.	.	PUNCT
dpc-2201	292	1	clin	clin	PROPN
dpc-2201	292	2	exp	exp	NOUN
dpc-2201	292	3	rheumatol	rheumatol	NOUN
dpc-2201	292	4	.	.	PUNCT
dpc-2201	293	1	2016;34(2):318	2016;34(2):318	PROPN
dpc-2201	293	2	-	-	PUNCT
dpc-2201	293	3	328	328	NUM
dpc-2201	293	4	.	.	PUNCT
dpc-2201	294	1	pmid	pmid	NOUN
dpc-2201	294	2	:	:	PUNCT
dpc-2201	294	3	26966791	26966791	NUM
dpc-2201	294	4	.	.	PUNCT
dpc-2201	295	1	7	7	X
dpc-2201	295	2	.	.	X
dpc-2201	295	3	agrawal	agrawal	PROPN
dpc-2201	295	4	m	m	PROPN
dpc-2201	295	5	,	,	PUNCT
dpc-2201	295	6	kim	kim	PROPN
dpc-2201	295	7	es	es	PROPN
dpc-2201	295	8	,	,	PUNCT
dpc-2201	295	9	colombel	colombel	VERB
dpc-2201	295	10	j	j	PROPN
dpc-2201	295	11	-	-	PROPN
dpc-2201	295	12	f.	f.	PROPN
dpc-2201	295	13	jak	jak	PROPN
dpc-2201	295	14	inhibitors	inhibitor	NOUN
dpc-2201	295	15	safety	safety	VERB
dpc-2201	295	16	in	in	ADP
dpc-2201	295	17	ulcerative	ulcerative	ADJ
dpc-2201	295	18	colitis	colitis	NOUN
dpc-2201	295	19	:	:	PUNCT
dpc-2201	295	20	practical	practical	ADJ
dpc-2201	295	21	implications	implication	NOUN
dpc-2201	295	22	.	.	PUNCT
dpc-2201	296	1	j	j	PROPN
dpc-2201	296	2	crohns	crohns	PROPN
dpc-2201	296	3	colitis	colitis	PROPN
dpc-2201	296	4	.	.	PUNCT
dpc-2201	297	1	2020;14(supplement_2):s755	2020;14(supplement_2):s755	NUM
dpc-2201	297	2	-	-	PUNCT
dpc-2201	297	3	s760	s760	PROPN
dpc-2201	297	4	.	.	PUNCT
dpc-2201	297	5	doi	doi	NOUN
dpc-2201	297	6	:	:	PUNCT
dpc-2201	297	7	10.1093	10.1093	NUM
dpc-2201	297	8	/	/	SYM
dpc-2201	297	9	ecco	ecco	ADJ
dpc-2201	297	10	-	-	PUNCT
dpc-2201	297	11	jcc/	jcc/	NOUN
dpc-2201	297	12	jjaa017	jjaa017	PROPN
dpc-2201	297	13	.	.	PUNCT
dpc-2201	298	1	pmid	pmid	NOUN
dpc-2201	298	2	:	:	PUNCT
dpc-2201	298	3	32006031	32006031	NUM
dpc-2201	298	4	.	.	PUNCT
dpc-2201	299	1	pmcid	pmcid	ADJ
dpc-2201	299	2	:	:	PUNCT
dpc-2201	299	3	pmc7395307	pmc7395307	NOUN
dpc-2201	299	4	.	.	PUNCT
dpc-2201	300	1	8	8	X
dpc-2201	300	2	.	.	PUNCT
dpc-2201	300	3	bewersdorf	bewersdorf	PROPN
dpc-2201	300	4	jp	jp	PROPN
dpc-2201	300	5	,	,	PUNCT
dpc-2201	300	6	jaszczur	jaszczur	PROPN
dpc-2201	300	7	sm	sm	PROPN
dpc-2201	300	8	,	,	PUNCT
dpc-2201	300	9	afifi	afifi	PROPN
dpc-2201	300	10	s	s	PROPN
dpc-2201	300	11	,	,	PUNCT
dpc-2201	300	12	zhao	zhao	PROPN
dpc-2201	300	13	jc	jc	PROPN
dpc-2201	300	14	,	,	PUNCT
dpc-2201	300	15	zeidan	zeidan	PROPN
dpc-2201	300	16	am	be	AUX
dpc-2201	300	17	.	.	PUNCT
dpc-2201	301	1	beyond	beyond	ADP
dpc-2201	301	2	ruxolitinib	ruxolitinib	NOUN
dpc-2201	301	3	:	:	PUNCT
dpc-2201	301	4	fedratinib	fedratinib	NOUN
dpc-2201	301	5	and	and	CCONJ
dpc-2201	301	6	other	other	ADJ
dpc-2201	301	7	emergent	emergent	ADJ
dpc-2201	301	8	treatment	treatment	NOUN
dpc-2201	301	9	options	option	NOUN
dpc-2201	301	10	for	for	ADP
dpc-2201	301	11	myelofibrosis	myelofibrosis	NOUN
dpc-2201	301	12	.	.	PUNCT
dpc-2201	302	1	cancer	cancer	NOUN
dpc-2201	302	2	manag	manag	PROPN
dpc-2201	302	3	res	re	NOUN
dpc-2201	302	4	.	.	PUNCT
dpc-2201	303	1	2019;11:10777	2019;11:10777	NUM
dpc-2201	303	2	-	-	SYM
dpc-2201	303	3	10790	10790	NUM
dpc-2201	303	4	.	.	PUNCT
dpc-2201	304	1	doi	doi	NOUN
dpc-2201	304	2	:	:	PUNCT
dpc-2201	304	3	10.2147	10.2147	NUM
dpc-2201	304	4	/	/	SYM
dpc-2201	304	5	cmar.s212559	cmar.s212559	X
dpc-2201	304	6	.	.	PUNCT
dpc-2201	305	1	pmid	pmid	NOUN
dpc-2201	305	2	:	:	PUNCT
dpc-2201	305	3	31920387	31920387	NUM
dpc-2201	305	4	.	.	PUNCT
dpc-2201	306	1	pmcid	pmcid	NOUN
dpc-2201	306	2	:	:	PUNCT
dpc-2201	306	3	pmc6935287	pmc6935287	ADV
dpc-2201	306	4	.	.	PUNCT
dpc-2201	307	1	9	9	X
dpc-2201	307	2	.	.	X
dpc-2201	307	3	pratt	pratt	PROPN
dpc-2201	307	4	ch	ch	PROPN
dpc-2201	307	5	,	,	PUNCT
dpc-2201	307	6	king	king	NOUN
dpc-2201	307	7	le	le	PROPN
dpc-2201	307	8	,	,	PUNCT
dpc-2201	307	9	messenger	messenger	PROPN
dpc-2201	307	10	ag	ag	PROPN
dpc-2201	307	11	,	,	PUNCT
dpc-2201	307	12	christiano	christiano	PROPN
dpc-2201	307	13	am	am	PROPN
dpc-2201	307	14	,	,	PUNCT
dpc-2201	307	15	sundberg	sundberg	PROPN
dpc-2201	307	16	jp	jp	PROPN
dpc-2201	307	17	.	.	PUNCT
dpc-2201	308	1	alopecia	alopecia	NOUN
dpc-2201	308	2	areata	areata	PROPN
dpc-2201	308	3	.	.	PUNCT
dpc-2201	309	1	nat	nat	PROPN
dpc-2201	309	2	rev	rev	VERB
dpc-2201	309	3	dis	dis	PROPN
dpc-2201	309	4	primers	primer	NOUN
dpc-2201	309	5	.	.	PUNCT
dpc-2201	310	1	2017;3:17011	2017;3:17011	PROPN
dpc-2201	310	2	.	.	PUNCT
dpc-2201	311	1	doi	doi	NOUN
dpc-2201	311	2	:	:	PUNCT
dpc-2201	311	3	10.1038	10.1038	NUM
dpc-2201	311	4	/	/	SYM
dpc-2201	311	5	nrdp.2017.11	nrdp.2017.11	NOUN
dpc-2201	311	6	.	.	PUNCT
dpc-2201	312	1	pmid	pmid	NOUN
dpc-2201	312	2	:	:	PUNCT
dpc-2201	312	3	28300084	28300084	NUM
dpc-2201	312	4	.	.	PUNCT
dpc-2201	313	1	pmcid	pmcid	NOUN
dpc-2201	313	2	:	:	PUNCT
dpc-2201	313	3	pmc5573125	pmc5573125	ADV
dpc-2201	313	4	.	.	PUNCT
dpc-2201	314	1	10	10	X
dpc-2201	314	2	.	.	X
dpc-2201	314	3	dillon	dillon	PROPN
dpc-2201	314	4	kl	kl	PROPN
dpc-2201	314	5	.	.	PUNCT
dpc-2201	315	1	a	a	DET
dpc-2201	315	2	comprehensive	comprehensive	ADJ
dpc-2201	315	3	literature	literature	NOUN
dpc-2201	315	4	review	review	NOUN
dpc-2201	315	5	of	of	ADP
dpc-2201	315	6	jak	jak	PROPN
dpc-2201	315	7	inhibitors	inhibitor	NOUN
dpc-2201	315	8	in	in	ADP
dpc-2201	315	9	treatment	treatment	NOUN
dpc-2201	315	10	of	of	ADP
dpc-2201	315	11	alopecia	alopecia	NOUN
dpc-2201	315	12	areata	areata	ADJ
dpc-2201	315	13	.	.	PUNCT
dpc-2201	316	1	clin	clin	PROPN
dpc-2201	316	2	cosmet	cosmet	PROPN
dpc-2201	316	3	investig	investig	NOUN
dpc-2201	316	4	dermatol	dermatol	NOUN
dpc-2201	316	5	.	.	PUNCT
dpc-2201	317	1	2021;14:691	2021;14:691	NOUN
dpc-2201	317	2	-	-	PUNCT
dpc-2201	317	3	714	714	NUM
dpc-2201	317	4	.	.	PUNCT
dpc-2201	318	1	doi	doi	NOUN
dpc-2201	318	2	:	:	PUNCT
dpc-2201	318	3	10.2147	10.2147	NUM
dpc-2201	318	4	/	/	SYM
dpc-2201	318	5	ccid.s309215	ccid.s309215	NOUN
dpc-2201	318	6	.	.	PUNCT
dpc-2201	319	1	pmid	pmid	NOUN
dpc-2201	319	2	:	:	PUNCT
dpc-2201	319	3	34211288	34211288	NUM
dpc-2201	319	4	.	.	PUNCT
dpc-2201	320	1	pmcid	pmcid	NOUN
dpc-2201	320	2	:	:	PUNCT
dpc-2201	320	3	pmc8242127	pmc8242127	NOUN
dpc-2201	320	4	.	.	PUNCT
dpc-2201	321	1	11	11	NUM
dpc-2201	321	2	.	.	PUNCT
dpc-2201	322	1	hordinsky	hordinsky	PROPN
dpc-2201	322	2	mk	mk	PROPN
dpc-2201	322	3	.	.	PUNCT
dpc-2201	323	1	overview	overview	NOUN
dpc-2201	323	2	of	of	ADP
dpc-2201	323	3	alopecia	alopecia	NOUN
dpc-2201	323	4	areata	areata	ADJ
dpc-2201	323	5	.	.	PUNCT
dpc-2201	324	1	j	j	PROPN
dpc-2201	324	2	investig	investig	NOUN
dpc-2201	324	3	dermatol	dermatol	NOUN
dpc-2201	324	4	symp	symp	NOUN
dpc-2201	324	5	proc	proc	NOUN
dpc-2201	324	6	.	.	PUNCT
dpc-2201	325	1	2013;16(1):s13	2013;16(1):s13	ADJ
dpc-2201	325	2	-	-	NOUN
dpc-2201	325	3	s15	s15	NOUN
dpc-2201	325	4	.	.	PUNCT
dpc-2201	326	1	doi	doi	PROPN
dpc-2201	326	2	:	:	PUNCT
dpc-2201	326	3	10.1038/	10.1038/	NUM
dpc-2201	326	4	jidsymp.2013.4	jidsymp.2013.4	NOUN
dpc-2201	326	5	.	.	PUNCT
dpc-2201	327	1	pmid	pmid	NOUN
dpc-2201	327	2	:	:	PUNCT
dpc-2201	327	3	24326541	24326541	NUM
dpc-2201	327	4	.	.	PUNCT
dpc-2201	328	1	12	12	NUM
dpc-2201	328	2	.	.	X
dpc-2201	328	3	yu	yu	PROPN
dpc-2201	329	1	d	d	PROPN
dpc-2201	329	2	-	-	PUNCT
dpc-2201	329	3	a	a	PROPN
dpc-2201	329	4	,	,	PUNCT
dpc-2201	329	5	kim	kim	PROPN
dpc-2201	329	6	ye	ye	PROPN
dpc-2201	329	7	,	,	PUNCT
dpc-2201	329	8	kwon	kwon	VERB
dpc-2201	329	9	o	o	NOUN
dpc-2201	329	10	,	,	PUNCT
dpc-2201	329	11	park	park	PROPN
dpc-2201	329	12	h.	h.	PROPN
dpc-2201	329	13	treatment	treatment	PROPN
dpc-2201	329	14	outcome	outcome	NOUN
dpc-2201	329	15	of	of	ADP
dpc-2201	329	16	oral	oral	ADJ
dpc-2201	329	17	tofacitinib	tofacitinib	NOUN
dpc-2201	329	18	and	and	CCONJ
dpc-2201	329	19	ruxolitinib	ruxolitinib	NOUN
dpc-2201	329	20	in	in	ADP
dpc-2201	329	21	patients	patient	NOUN
dpc-2201	329	22	with	with	ADP
dpc-2201	329	23	alopecia	alopecia	NOUN
dpc-2201	329	24	areata	areata	NOUN
dpc-2201	329	25	:	:	PUNCT
dpc-2201	329	26	a	a	DET
dpc-2201	329	27	systematic	systematic	ADJ
dpc-2201	329	28	review	review	NOUN
dpc-2201	329	29	and	and	CCONJ
dpc-2201	329	30	meta	meta	ADJ
dpc-2201	329	31	-	-	PUNCT
dpc-2201	329	32	analysis	analysis	NOUN
dpc-2201	329	33	.	.	PUNCT
dpc-2201	330	1	indian	indian	PROPN
dpc-2201	330	2	j	j	PROPN
dpc-2201	330	3	dermatol	dermatol	PROPN
dpc-2201	330	4	venereol	venereol	ADJ
dpc-2201	330	5	leprol	leprol	NOUN
dpc-2201	330	6	.	.	PUNCT
dpc-2201	331	1	2021;87(5):621	2021;87(5):621	NUM
dpc-2201	331	2	-	-	SYM
dpc-2201	331	3	627	627	NUM
dpc-2201	331	4	.	.	PUNCT
dpc-2201	332	1	doi	doi	NOUN
dpc-2201	332	2	:	:	PUNCT
dpc-2201	332	3	10.25259	10.25259	NUM
dpc-2201	332	4	/	/	SYM
dpc-2201	332	5	ijdvl_975_19	ijdvl_975_19	X
dpc-2201	332	6	.	.	PUNCT
dpc-2201	333	1	pmid	pmid	NOUN
dpc-2201	333	2	:	:	PUNCT
dpc-2201	333	3	34379968	34379968	NUM
dpc-2201	333	4	.	.	PUNCT
dpc-2201	334	1	13	13	NUM
dpc-2201	334	2	.	.	PUNCT
dpc-2201	334	3	hamilton	hamilton	PROPN
dpc-2201	334	4	ce	ce	PROPN
dpc-2201	334	5	,	,	PUNCT
dpc-2201	334	6	craiglow	craiglow	PROPN
dpc-2201	334	7	bg	bg	PROPN
dpc-2201	334	8	.	.	PUNCT
dpc-2201	334	9	jak	jak	PROPN
dpc-2201	334	10	inhibitors	inhibitor	NOUN
dpc-2201	334	11	for	for	ADP
dpc-2201	334	12	the	the	DET
dpc-2201	334	13	treatment	treatment	NOUN
dpc-2201	334	14	of	of	ADP
dpc-2201	334	15	pediatric	pediatric	ADJ
dpc-2201	334	16	alopecia	alopecia	NOUN
dpc-2201	334	17	areata	areata	NOUN
dpc-2201	334	18	.	.	PUNCT
dpc-2201	335	1	j	j	PROPN
dpc-2201	335	2	investig	investig	NOUN
dpc-2201	335	3	dermatol	dermatol	NOUN
dpc-2201	335	4	symp	symp	NOUN
dpc-2201	335	5	proc	proc	NOUN
dpc-2201	335	6	.	.	PUNCT
dpc-2201	336	1	2020;20(1):s31	2020;20(1):s31	NUM
dpc-2201	336	2	-	-	PUNCT
dpc-2201	336	3	s36	s36	NOUN
dpc-2201	336	4	.	.	PUNCT
dpc-2201	337	1	doi	doi	PROPN
dpc-2201	337	2	:	:	PUNCT
dpc-2201	337	3	10.1016	10.1016	NUM
dpc-2201	337	4	/	/	SYM
dpc-2201	337	5	j.jisp.2020.04.005	j.jisp.2020.04.005	PROPN
dpc-2201	337	6	.	.	PUNCT
dpc-2201	338	1	pmid	pmid	NOUN
dpc-2201	338	2	:	:	PUNCT
dpc-2201	338	3	33099381	33099381	NUM
dpc-2201	338	4	.	.	PUNCT
dpc-2201	339	1	14	14	NUM
dpc-2201	339	2	.	.	PUNCT
dpc-2201	340	1	guo	guo	PROPN
dpc-2201	340	2	l	l	PROPN
dpc-2201	340	3	,	,	PUNCT
dpc-2201	340	4	feng	feng	PROPN
dpc-2201	340	5	s	s	PROPN
dpc-2201	340	6	,	,	PUNCT
dpc-2201	340	7	sun	sun	PROPN
dpc-2201	340	8	b	b	PROPN
dpc-2201	340	9	,	,	PUNCT
dpc-2201	340	10	jiang	jiang	PROPN
dpc-2201	340	11	x	x	PROPN
dpc-2201	340	12	,	,	PUNCT
dpc-2201	340	13	liu	liu	PROPN
dpc-2201	340	14	y.	y.	PROPN
dpc-2201	340	15	benefit	benefit	PROPN
dpc-2201	340	16	and	and	CCONJ
dpc-2201	340	17	risk	risk	NOUN
dpc-2201	340	18	profile	profile	NOUN
dpc-2201	340	19	of	of	ADP
dpc-2201	340	20	tofacitinib	tofacitinib	NOUN
dpc-2201	340	21	for	for	ADP
dpc-2201	340	22	the	the	DET
dpc-2201	340	23	treatment	treatment	NOUN
dpc-2201	340	24	of	of	ADP
dpc-2201	340	25	alopecia	alopecia	NOUN
dpc-2201	340	26	areata	areata	NOUN
dpc-2201	340	27	:	:	PUNCT
dpc-2201	340	28	a	a	DET
dpc-2201	340	29	systemic	systemic	ADJ
dpc-2201	340	30	review	review	NOUN
dpc-2201	340	31	and	and	CCONJ
dpc-2201	340	32	meta	meta	NOUN
dpc-2201	340	33	-	-	PUNCT
dpc-2201	340	34	analysis	analysis	NOUN
dpc-2201	340	35	.	.	PUNCT
dpc-2201	341	1	j	j	PROPN
dpc-2201	341	2	eur	eur	PROPN
dpc-2201	341	3	acad	acad	PROPN
dpc-2201	341	4	dermatol	dermatol	NOUN
dpc-2201	341	5	venereol	venereol	NOUN
dpc-2201	341	6	.	.	PUNCT
dpc-2201	342	1	2020;34(1):192	2020;34(1):192	NOUN
dpc-2201	342	2	-	-	PUNCT
dpc-2201	342	3	201	201	NUM
dpc-2201	342	4	.	.	PUNCT
dpc-2201	343	1	doi	doi	NOUN
dpc-2201	343	2	:	:	PUNCT
dpc-2201	343	3	10.1111	10.1111	NUM
dpc-2201	343	4	/	/	SYM
dpc-2201	343	5	jdv.15937	jdv.15937	PROPN
dpc-2201	343	6	.	.	PUNCT
dpc-2201	344	1	pmid	pmid	NOUN
dpc-2201	344	2	:	:	PUNCT
dpc-2201	344	3	31494993	31494993	NUM
dpc-2201	344	4	.	.	PUNCT
dpc-2201	345	1	15	15	NUM
dpc-2201	345	2	.	.	PUNCT
dpc-2201	346	1	he	he	PRON
dpc-2201	346	2	h	h	NOUN
dpc-2201	346	3	,	,	PUNCT
dpc-2201	346	4	guttman	guttman	ADJ
dpc-2201	346	5	-	-	PUNCT
dpc-2201	346	6	yassky	yassky	NOUN
dpc-2201	346	7	e.	e.	PROPN
dpc-2201	346	8	jak	jak	PROPN
dpc-2201	346	9	inhibitors	inhibitor	NOUN
dpc-2201	346	10	for	for	ADP
dpc-2201	346	11	atopic	atopic	NOUN
dpc-2201	346	12	dermatitis	dermatitis	NOUN
dpc-2201	346	13	:	:	PUNCT
dpc-2201	346	14	an	an	DET
dpc-2201	346	15	update	update	NOUN
dpc-2201	346	16	.	.	PUNCT
dpc-2201	347	1	am	be	AUX
dpc-2201	347	2	j	j	PROPN
dpc-2201	347	3	clin	clin	PROPN
dpc-2201	347	4	dermatol	dermatol	NOUN
dpc-2201	347	5	.	.	PUNCT
dpc-2201	348	1	2019;20(2):181	2019;20(2):181	NUM
dpc-2201	348	2	-	-	PUNCT
dpc-2201	348	3	192	192	NUM
dpc-2201	348	4	.	.	PUNCT
dpc-2201	349	1	doi	doi	NOUN
dpc-2201	349	2	:	:	PUNCT
dpc-2201	349	3	10.1007	10.1007	NUM
dpc-2201	349	4	/	/	SYM
dpc-2201	349	5	s40257	s40257	NOUN
dpc-2201	349	6	-	-	PUNCT
dpc-2201	349	7	018	018	NUM
dpc-2201	349	8	-	-	PUNCT
dpc-2201	349	9	0413	0413	NUM
dpc-2201	349	10	-	-	PUNCT
dpc-2201	349	11	2	2	NUM
dpc-2201	349	12	.	.	PUNCT
dpc-2201	350	1	pmid	pmid	NOUN
dpc-2201	350	2	:	:	PUNCT
dpc-2201	350	3	30536048	30536048	NUM
dpc-2201	350	4	.	.	PUNCT
dpc-2201	351	1	16	16	NUM
dpc-2201	351	2	.	.	PUNCT
dpc-2201	352	1	rendon	rendon	PROPN
dpc-2201	352	2	a	a	PRON
dpc-2201	352	3	,	,	PUNCT
dpc-2201	352	4	schäkel	schäkel	PROPN
dpc-2201	352	5	k.	k.	PROPN
dpc-2201	352	6	psoriasis	psoriasis	NOUN
dpc-2201	352	7	pathogenesis	pathogenesis	NOUN
dpc-2201	352	8	and	and	CCONJ
dpc-2201	352	9	treatment	treatment	NOUN
dpc-2201	352	10	.	.	PUNCT
dpc-2201	353	1	int	int	PROPN
dpc-2201	353	2	j	j	PROPN
dpc-2201	353	3	mol	mol	ADP
dpc-2201	353	4	sci	sci	PROPN
dpc-2201	353	5	.	.	PUNCT
dpc-2201	354	1	2019;20(6):1475	2019;20(6):1475	NUM
dpc-2201	354	2	.	.	PUNCT
dpc-2201	355	1	doi	doi	NOUN
dpc-2201	355	2	:	:	PUNCT
dpc-2201	355	3	10.3390	10.3390	NUM
dpc-2201	355	4	/	/	SYM
dpc-2201	355	5	ijms20061475	ijms20061475	PROPN
dpc-2201	355	6	.	.	PUNCT
dpc-2201	356	1	pmid	pmid	NOUN
dpc-2201	356	2	:	:	PUNCT
dpc-2201	356	3	30909615	30909615	NUM
dpc-2201	356	4	.	.	PUNCT
dpc-2201	357	1	pmcid	pmcid	NOUN
dpc-2201	357	2	:	:	PUNCT
dpc-2201	357	3	pmc6471628	pmc6471628	PROPN
dpc-2201	357	4	.	.	PUNCT
dpc-2201	358	1	17	17	NUM
dpc-2201	358	2	.	.	X
dpc-2201	359	1	kvist	kvist	PROPN
dpc-2201	359	2	-	-	PUNCT
dpc-2201	359	3	hansen	hansen	PROPN
dpc-2201	359	4	a	a	PROPN
dpc-2201	359	5	,	,	PUNCT
dpc-2201	359	6	hansen	hansen	PROPN
dpc-2201	359	7	pr	pr	PROPN
dpc-2201	359	8	,	,	PUNCT
dpc-2201	359	9	skov	skov	PROPN
dpc-2201	359	10	l.	l.	PROPN
dpc-2201	359	11	systemic	systemic	ADJ
dpc-2201	359	12	treatment	treatment	NOUN
dpc-2201	359	13	of	of	ADP
dpc-2201	359	14	psoriasis	psoriasis	NOUN
dpc-2201	359	15	with	with	ADP
dpc-2201	359	16	jak	jak	PROPN
dpc-2201	359	17	inhibitors	inhibitor	NOUN
dpc-2201	359	18	:	:	PUNCT
dpc-2201	359	19	a	a	DET
dpc-2201	359	20	review	review	NOUN
dpc-2201	359	21	.	.	PUNCT
dpc-2201	360	1	dermatol	dermatol	NOUN
dpc-2201	360	2	ther	ther	ADV
dpc-2201	360	3	(	(	PUNCT
dpc-2201	360	4	heidelb	heidelb	NOUN
dpc-2201	360	5	)	)	PUNCT
dpc-2201	360	6	.	.	PUNCT
dpc-2201	361	1	2020;10(1):29	2020;10(1):29	NUM
dpc-2201	361	2	-	-	SYM
dpc-2201	361	3	42	42	NUM
dpc-2201	361	4	.	.	PUNCT
dpc-2201	362	1	doi	doi	NOUN
dpc-2201	362	2	:	:	PUNCT
dpc-2201	362	3	10.1007	10.1007	NUM
dpc-2201	362	4	/	/	SYM
dpc-2201	362	5	s13555	s13555	PROPN
dpc-2201	362	6	-	-	PUNCT
dpc-2201	362	7	019	019	NUM
dpc-2201	362	8	-	-	PUNCT
dpc-2201	362	9	00347	00347	NUM
dpc-2201	362	10	-	-	PUNCT
dpc-2201	362	11	w.	w.	NOUN
dpc-2201	362	12	pmid	pmid	PROPN
dpc-2201	362	13	:	:	PUNCT
dpc-2201	362	14	31893355	31893355	NUM
dpc-2201	362	15	.	.	PUNCT
dpc-2201	363	1	pmcid	pmcid	ADJ
dpc-2201	363	2	:	:	PUNCT
dpc-2201	363	3	pmc6994544	pmc6994544	NOUN
dpc-2201	363	4	.	.	PUNCT
dpc-2201	364	1	18	18	NUM
dpc-2201	364	2	.	.	X
dpc-2201	365	1	tian	tian	PROPN
dpc-2201	365	2	f	f	PROPN
dpc-2201	365	3	,	,	PUNCT
dpc-2201	365	4	chen	chen	PROPN
dpc-2201	366	1	z	z	PROPN
dpc-2201	366	2	,	,	PUNCT
dpc-2201	366	3	xu	xu	PROPN
dpc-2201	366	4	t.	t.	PROPN
dpc-2201	366	5	efficacy	efficacy	NOUN
dpc-2201	366	6	and	and	CCONJ
dpc-2201	366	7	safety	safety	NOUN
dpc-2201	366	8	of	of	ADP
dpc-2201	366	9	tofacitinib	tofacitinib	NOUN
dpc-2201	366	10	for	for	ADP
dpc-2201	366	11	the	the	DET
dpc-2201	366	12	treatment	treatment	NOUN
dpc-2201	366	13	of	of	ADP
dpc-2201	366	14	chronic	chronic	ADJ
dpc-2201	366	15	plaque	plaque	NOUN
dpc-2201	366	16	psoriasis	psoriasis	NOUN
dpc-2201	366	17	:	:	PUNCT
dpc-2201	366	18	a	a	DET
dpc-2201	366	19	systematic	systematic	ADJ
dpc-2201	366	20	review	review	NOUN
dpc-2201	366	21	and	and	CCONJ
dpc-2201	366	22	meta	meta	ADJ
dpc-2201	366	23	-	-	PUNCT
dpc-2201	366	24	analysis	analysis	NOUN
dpc-2201	366	25	.	.	PUNCT
dpc-2201	367	1	j	j	PROPN
dpc-2201	367	2	int	int	PROPN
dpc-2201	367	3	med	med	PROPN
dpc-2201	367	4	res	re	NOUN
dpc-2201	367	5	.	.	PUNCT
dpc-2201	368	1	2019;47(6):2342	2019;47(6):2342	NUM
dpc-2201	368	2	-	-	SYM
dpc-2201	368	3	2350	2350	NUM
dpc-2201	368	4	.	.	PUNCT
dpc-2201	369	1	doi	doi	NOUN
dpc-2201	369	2	:	:	PUNCT
dpc-2201	369	3	review	review	VERB
dpc-2201	369	4	|	|	ADV
dpc-2201	369	5	dermatol	dermatol	ADJ
dpc-2201	369	6	pract	pract	NOUN
dpc-2201	369	7	concept	concept	NOUN
dpc-2201	369	8	.	.	PUNCT
dpc-2201	370	1	2022;12(4):e2022178	2022;12(4):e2022178	NUM
dpc-2201	370	2	7	7	NUM
dpc-2201	370	3	33	33	NUM
dpc-2201	370	4	.	.	PUNCT
dpc-2201	371	1	sabat	sabat	PROPN
dpc-2201	371	2	r	r	PROPN
dpc-2201	371	3	,	,	PUNCT
dpc-2201	371	4	jemec	jemec	PROPN
dpc-2201	371	5	gbe	gbe	PROPN
dpc-2201	371	6	,	,	PUNCT
dpc-2201	371	7	matusiak	matusiak	PROPN
dpc-2201	371	8	ł	ł	PROPN
dpc-2201	371	9	,	,	PUNCT
dpc-2201	371	10	kimball	kimball	PROPN
dpc-2201	371	11	ab	ab	PROPN
dpc-2201	371	12	,	,	PUNCT
dpc-2201	371	13	prens	pren	VERB
dpc-2201	371	14	e	e	NOUN
dpc-2201	371	15	,	,	PUNCT
dpc-2201	371	16	wolk	wolk	NOUN
dpc-2201	371	17	k.	k.	PROPN
dpc-2201	371	18	hidradenitis	hidradenitis	PROPN
dpc-2201	371	19	suppurativa	suppurativa	PROPN
dpc-2201	371	20	.	.	PUNCT
dpc-2201	372	1	nat	nat	PROPN
dpc-2201	372	2	rev	rev	VERB
dpc-2201	372	3	dis	dis	PROPN
dpc-2201	372	4	primers	primer	NOUN
dpc-2201	372	5	.	.	PUNCT
dpc-2201	373	1	2020;6(1):18	2020;6(1):18	X
dpc-2201	373	2	.	.	PUNCT
dpc-2201	373	3	doi	doi	NOUN
dpc-2201	373	4	:	:	PUNCT
dpc-2201	373	5	10.1038	10.1038	NUM
dpc-2201	373	6	/	/	SYM
dpc-2201	373	7	s41572	s41572	NOUN
dpc-2201	373	8	-	-	PUNCT
dpc-2201	373	9	020	020	NUM
dpc-2201	373	10	-	-	PUNCT
dpc-2201	373	11	0149	0149	NUM
dpc-2201	373	12	-	-	SYM
dpc-2201	373	13	1	1	NUM
dpc-2201	373	14	.	.	PUNCT
dpc-2201	374	1	pmid	pmid	NOUN
dpc-2201	374	2	:	:	PUNCT
dpc-2201	374	3	32165620	32165620	NUM
dpc-2201	374	4	.	.	PUNCT
dpc-2201	375	1	34	34	NUM
dpc-2201	375	2	.	.	PUNCT
dpc-2201	376	1	savage	savage	PROPN
dpc-2201	376	2	kt	kt	PROPN
dpc-2201	376	3	,	,	PUNCT
dpc-2201	376	4	santillan	santillan	PROPN
dpc-2201	376	5	mr	mr	PROPN
dpc-2201	376	6	,	,	PUNCT
dpc-2201	376	7	flood	flood	PROPN
dpc-2201	376	8	ks	ks	PROPN
dpc-2201	376	9	,	,	PUNCT
dpc-2201	376	10	charrow	charrow	VERB
dpc-2201	376	11	a	a	PRON
dpc-2201	376	12	,	,	PUNCT
dpc-2201	376	13	porter	porter	NOUN
dpc-2201	376	14	ml	ml	NOUN
dpc-2201	376	15	,	,	PUNCT
dpc-2201	376	16	kimball	kimball	PROPN
dpc-2201	376	17	ab	ab	PROPN
dpc-2201	376	18	.	.	PROPN
dpc-2201	376	19	tofacitinib	tofacitinib	PROPN
dpc-2201	376	20	shows	show	VERB
dpc-2201	376	21	benefit	benefit	VERB
dpc-2201	376	22	in	in	ADP
dpc-2201	376	23	conjunction	conjunction	NOUN
dpc-2201	376	24	with	with	ADP
dpc-2201	376	25	other	other	ADJ
dpc-2201	376	26	therapies	therapy	NOUN
dpc-2201	376	27	in	in	ADP
dpc-2201	376	28	recalcitrant	recalcitrant	ADJ
dpc-2201	376	29	hidradenitis	hidradenitis	NOUN
dpc-2201	376	30	suppurativa	suppurativa	NOUN
dpc-2201	376	31	patients	patient	NOUN
dpc-2201	376	32	.	.	PUNCT
dpc-2201	377	1	jaad	jaad	NOUN
dpc-2201	377	2	case	case	NOUN
dpc-2201	377	3	rep	rep	PROPN
dpc-2201	377	4	.	.	PROPN
dpc-2201	377	5	2020;6(2):99	2020;6(2):99	NUM
dpc-2201	377	6	-	-	SYM
dpc-2201	377	7	102	102	NUM
dpc-2201	377	8	.	.	PUNCT
dpc-2201	378	1	doi	doi	NOUN
dpc-2201	378	2	:	:	PUNCT
dpc-2201	378	3	10.1016	10.1016	NUM
dpc-2201	378	4	/	/	SYM
dpc-2201	378	5	j.jdcr.2019.10.010	j.jdcr.2019.10.010	PROPN
dpc-2201	378	6	.	.	PUNCT
dpc-2201	379	1	pmid	pmid	NOUN
dpc-2201	379	2	:	:	PUNCT
dpc-2201	379	3	31993474	31993474	NUM
dpc-2201	379	4	.	.	PUNCT
dpc-2201	380	1	pmcid	pmcid	NOUN
dpc-2201	380	2	:	:	PUNCT
dpc-2201	380	3	pmc6974699	pmc6974699	ADJ
dpc-2201	380	4	.	.	PUNCT
dpc-2201	381	1	35	35	NUM
dpc-2201	381	2	.	.	X
dpc-2201	382	1	zouboulis	zouboulis	PROPN
dpc-2201	382	2	cc	cc	PROPN
dpc-2201	382	3	,	,	PUNCT
dpc-2201	382	4	frew	frew	PROPN
dpc-2201	382	5	jw	jw	PROPN
dpc-2201	382	6	,	,	PUNCT
dpc-2201	382	7	giamarellos	giamarellos	PROPN
dpc-2201	382	8	-	-	PUNCT
dpc-2201	382	9	bourboulis	bourboulis	PROPN
dpc-2201	382	10	ej	ej	PROPN
dpc-2201	382	11	,	,	PUNCT
dpc-2201	382	12	jemec	jemec	PROPN
dpc-2201	382	13	gbe	gbe	PROPN
dpc-2201	382	14	,	,	PUNCT
dpc-2201	382	15	del	del	PROPN
dpc-2201	382	16	marmol	marmol	PROPN
dpc-2201	382	17	v	v	PROPN
dpc-2201	382	18	,	,	PUNCT
dpc-2201	382	19	marzano	marzano	PROPN
dpc-2201	382	20	av	av	PROPN
dpc-2201	382	21	,	,	PUNCT
dpc-2201	382	22	et	et	PROPN
dpc-2201	382	23	al	al	PROPN
dpc-2201	382	24	.	.	PROPN
dpc-2201	382	25	target	target	NOUN
dpc-2201	382	26	molecules	molecule	NOUN
dpc-2201	382	27	for	for	ADP
dpc-2201	382	28	future	future	ADJ
dpc-2201	382	29	hidradenitis	hidradenitis	PROPN
dpc-2201	382	30	suppurativa	suppurativa	PROPN
dpc-2201	382	31	treatment	treatment	NOUN
dpc-2201	382	32	.	.	PUNCT
dpc-2201	383	1	exp	exp	NOUN
dpc-2201	383	2	dermatol	dermatol	NOUN
dpc-2201	383	3	.	.	PUNCT
dpc-2201	384	1	2021;30	2021;30	NUM
dpc-2201	384	2	suppl	suppl	ADJ
dpc-2201	384	3	1:8	1:8	NUM
dpc-2201	384	4	-	-	SYM
dpc-2201	384	5	17	17	NUM
dpc-2201	384	6	.	.	PUNCT
dpc-2201	385	1	doi	doi	NOUN
dpc-2201	385	2	:	:	PUNCT
dpc-2201	385	3	10.1111	10.1111	NUM
dpc-2201	385	4	/	/	SYM
dpc-2201	385	5	exd.14338	exd.14338	NUM
dpc-2201	385	6	.	.	PUNCT
dpc-2201	386	1	pmid	pmid	NOUN
dpc-2201	386	2	:	:	PUNCT
dpc-2201	386	3	34085329	34085329	NUM
dpc-2201	386	4	.	.	PUNCT
dpc-2201	387	1	36	36	NUM
dpc-2201	387	2	.	.	PUNCT
dpc-2201	388	1	miller	miller	PROPN
dpc-2201	388	2	j	j	PROPN
dpc-2201	388	3	,	,	PUNCT
dpc-2201	388	4	yentzer	yentzer	PROPN
dpc-2201	388	5	ba	ba	PROPN
dpc-2201	388	6	,	,	PUNCT
dpc-2201	388	7	clark	clark	PROPN
dpc-2201	388	8	a	a	PROPN
dpc-2201	388	9	,	,	PUNCT
dpc-2201	388	10	jorizzo	jorizzo	PROPN
dpc-2201	388	11	jl	jl	PROPN
dpc-2201	388	12	,	,	PUNCT
dpc-2201	388	13	feldman	feldman	PROPN
dpc-2201	388	14	sr	sr	PROPN
dpc-2201	388	15	.	.	PUNCT
dpc-2201	389	1	pyoderma	pyoderma	PROPN
dpc-2201	389	2	gangrenosum	gangrenosum	NOUN
dpc-2201	389	3	:	:	PUNCT
dpc-2201	389	4	a	a	DET
dpc-2201	389	5	review	review	NOUN
dpc-2201	389	6	and	and	CCONJ
dpc-2201	389	7	update	update	NOUN
dpc-2201	389	8	on	on	ADP
dpc-2201	389	9	new	new	ADJ
dpc-2201	389	10	therapies	therapy	NOUN
dpc-2201	389	11	.	.	PUNCT
dpc-2201	390	1	j	j	PROPN
dpc-2201	390	2	am	be	AUX
dpc-2201	390	3	acad	acad	ADJ
dpc-2201	390	4	dermatol	dermatol	NOUN
dpc-2201	390	5	.	.	PUNCT
dpc-2201	391	1	2010;62(4):646	2010;62(4):646	NOUN
dpc-2201	391	2	-	-	PUNCT
dpc-2201	391	3	654	654	NUM
dpc-2201	391	4	.	.	PUNCT
dpc-2201	392	1	doi	doi	NOUN
dpc-2201	392	2	:	:	PUNCT
dpc-2201	392	3	10.1016	10.1016	NUM
dpc-2201	392	4	/	/	SYM
dpc-2201	392	5	j.jaad.2009.05.030	j.jaad.2009.05.030	PROPN
dpc-2201	392	6	.	.	PUNCT
dpc-2201	393	1	pmid	pmid	NOUN
dpc-2201	393	2	:	:	PUNCT
dpc-2201	393	3	20227580	20227580	NUM
dpc-2201	393	4	.	.	PUNCT
dpc-2201	394	1	37	37	NUM
dpc-2201	394	2	.	.	X
dpc-2201	395	1	crowson	crowson	PROPN
dpc-2201	395	2	an	an	PROPN
dpc-2201	395	3	,	,	PUNCT
dpc-2201	395	4	mihm	mihm	PROPN
dpc-2201	395	5	mc	mc	PROPN
dpc-2201	395	6	,	,	PUNCT
dpc-2201	395	7	jr	jr	PROPN
dpc-2201	395	8	.	.	PROPN
dpc-2201	395	9	,	,	PUNCT
dpc-2201	395	10	magro	magro	PROPN
dpc-2201	395	11	c.	c.	PROPN
dpc-2201	395	12	pyoderma	pyoderma	PROPN
dpc-2201	395	13	gangrenosum	gangrenosum	NOUN
dpc-2201	395	14	:	:	PUNCT
dpc-2201	395	15	a	a	DET
dpc-2201	395	16	review	review	NOUN
dpc-2201	395	17	.	.	PUNCT
dpc-2201	396	1	j	j	PROPN
dpc-2201	396	2	cutan	cutan	PROPN
dpc-2201	396	3	pathol	pathol	NOUN
dpc-2201	396	4	.	.	PUNCT
dpc-2201	397	1	2003;30(2):97	2003;30(2):97	NUM
dpc-2201	397	2	-	-	SYM
dpc-2201	397	3	107	107	NUM
dpc-2201	397	4	.	.	PUNCT
dpc-2201	398	1	doi	doi	NOUN
dpc-2201	398	2	:	:	PUNCT
dpc-2201	398	3	10.1034	10.1034	NUM
dpc-2201	398	4	/	/	SYM
dpc-2201	398	5	j.16000560.2003.00024.x	j.16000560.2003.00024.x	NOUN
dpc-2201	398	6	.	.	PUNCT
dpc-2201	399	1	pmid	pmid	NOUN
dpc-2201	399	2	:	:	PUNCT
dpc-2201	399	3	12641787	12641787	NUM
dpc-2201	399	4	.	.	PUNCT
dpc-2201	400	1	38	38	NUM
dpc-2201	400	2	.	.	PUNCT
dpc-2201	400	3	ruocco	ruocco	PROPN
dpc-2201	401	1	e	e	NOUN
dpc-2201	401	2	,	,	PUNCT
dpc-2201	401	3	sangiuliano	sangiuliano	PROPN
dpc-2201	401	4	s	s	PROPN
dpc-2201	401	5	,	,	PUNCT
dpc-2201	401	6	gravina	gravina	PROPN
dpc-2201	401	7	ag	ag	PROPN
dpc-2201	401	8	,	,	PUNCT
dpc-2201	401	9	miranda	miranda	PROPN
dpc-2201	401	10	a	a	PRON
dpc-2201	401	11	,	,	PUNCT
dpc-2201	401	12	nicoletti	nicoletti	NOUN
dpc-2201	401	13	g.	g.	NOUN
dpc-2201	401	14	pyoderma	pyoderma	PROPN
dpc-2201	401	15	gangrenosum	gangrenosum	NOUN
dpc-2201	401	16	:	:	PUNCT
dpc-2201	401	17	an	an	DET
dpc-2201	401	18	updated	update	VERB
dpc-2201	401	19	review	review	NOUN
dpc-2201	401	20	.	.	PUNCT
dpc-2201	402	1	j	j	PROPN
dpc-2201	402	2	eur	eur	PROPN
dpc-2201	402	3	acad	acad	PROPN
dpc-2201	402	4	dermatol	dermatol	NOUN
dpc-2201	402	5	venereol	venereol	NOUN
dpc-2201	402	6	.	.	PUNCT
dpc-2201	403	1	2009;23(9):1008	2009;23(9):1008	NOUN
dpc-2201	403	2	-	-	SYM
dpc-2201	403	3	1017	1017	NUM
dpc-2201	403	4	.	.	PUNCT
dpc-2201	404	1	doi	doi	NOUN
dpc-2201	404	2	:	:	PUNCT
dpc-2201	404	3	10.1111	10.1111	NUM
dpc-2201	404	4	/	/	SYM
dpc-2201	404	5	j.14683083.2009.03199.x	j.14683083.2009.03199.x	PROPN
dpc-2201	404	6	.	.	PUNCT
dpc-2201	405	1	pmid	pmid	NOUN
dpc-2201	405	2	:	:	PUNCT
dpc-2201	405	3	19470075	19470075	NUM
dpc-2201	405	4	.	.	PUNCT
dpc-2201	406	1	39	39	NUM
dpc-2201	406	2	.	.	PUNCT
dpc-2201	407	1	braswell	braswell	PROPN
dpc-2201	407	2	sf	sf	PROPN
dpc-2201	407	3	,	,	PUNCT
dpc-2201	407	4	kostopoulos	kostopoulos	PROPN
dpc-2201	407	5	tc	tc	NUM
dpc-2201	407	6	,	,	PUNCT
dpc-2201	407	7	ortega	ortega	PROPN
dpc-2201	407	8	-	-	PUNCT
dpc-2201	407	9	loayza	loayza	PROPN
dpc-2201	407	10	ag	ag	PROPN
dpc-2201	407	11	.	.	PROPN
dpc-2201	407	12	pathophysiology	pathophysiology	NOUN
dpc-2201	407	13	of	of	ADP
dpc-2201	407	14	pyoderma	pyoderma	NOUN
dpc-2201	407	15	gangrenosum	gangrenosum	NOUN
dpc-2201	407	16	(	(	PUNCT
dpc-2201	407	17	pg	pg	NOUN
dpc-2201	407	18	):	):	PUNCT
dpc-2201	407	19	an	an	DET
dpc-2201	407	20	updated	update	VERB
dpc-2201	407	21	review	review	NOUN
dpc-2201	407	22	.	.	PUNCT
dpc-2201	408	1	j	j	PROPN
dpc-2201	408	2	am	be	AUX
dpc-2201	408	3	acad	acad	ADJ
dpc-2201	408	4	dermatol	dermatol	NOUN
dpc-2201	408	5	.	.	PUNCT
dpc-2201	409	1	2015;73(4):691	2015;73(4):691	NUM
dpc-2201	409	2	-	-	SYM
dpc-2201	409	3	698	698	NUM
dpc-2201	409	4	.	.	PUNCT
dpc-2201	410	1	doi	doi	NOUN
dpc-2201	410	2	:	:	PUNCT
dpc-2201	410	3	10.1016	10.1016	NUM
dpc-2201	410	4	/	/	SYM
dpc-2201	410	5	j.jaad.2015.06.021	j.jaad.2015.06.021	PROPN
dpc-2201	410	6	.	.	PUNCT
dpc-2201	411	1	pmid	pmid	NOUN
dpc-2201	411	2	:	:	PUNCT
dpc-2201	411	3	26253362	26253362	NUM
dpc-2201	411	4	.	.	PUNCT
dpc-2201	412	1	40	40	NUM
dpc-2201	412	2	.	.	PUNCT
dpc-2201	412	3	alavi	alavi	PROPN
dpc-2201	412	4	a	a	PRON
dpc-2201	412	5	,	,	PUNCT
dpc-2201	412	6	french	french	ADJ
dpc-2201	412	7	le	le	PROPN
dpc-2201	412	8	,	,	PUNCT
dpc-2201	412	9	davis	davis	PROPN
dpc-2201	412	10	md	md	PROPN
dpc-2201	412	11	,	,	PUNCT
dpc-2201	412	12	brassard	brassard	PROPN
dpc-2201	412	13	a	a	PRON
dpc-2201	412	14	,	,	PUNCT
dpc-2201	412	15	kirsner	kirsner	ADJ
dpc-2201	412	16	rs	r	NOUN
dpc-2201	412	17	.	.	PUNCT
dpc-2201	413	1	pyoderma	pyoderma	NOUN
dpc-2201	413	2	gangrenosum	gangrenosum	NOUN
dpc-2201	413	3	:	:	PUNCT
dpc-2201	413	4	an	an	DET
dpc-2201	413	5	update	update	NOUN
dpc-2201	413	6	on	on	ADP
dpc-2201	413	7	pathophysiology	pathophysiology	NOUN
dpc-2201	413	8	,	,	PUNCT
dpc-2201	413	9	diagnosis	diagnosis	NOUN
dpc-2201	413	10	and	and	CCONJ
dpc-2201	413	11	treatment	treatment	NOUN
dpc-2201	413	12	.	.	PUNCT
dpc-2201	414	1	am	be	AUX
dpc-2201	414	2	j	j	PROPN
dpc-2201	414	3	clin	clin	PROPN
dpc-2201	414	4	dermatol	dermatol	NOUN
dpc-2201	414	5	.	.	PUNCT
dpc-2201	415	1	2017;18(3):355	2017;18(3):355	NUM
dpc-2201	415	2	-	-	SYM
dpc-2201	415	3	372	372	NUM
dpc-2201	415	4	.	.	PUNCT
dpc-2201	415	5	doi	doi	NOUN
dpc-2201	415	6	:	:	PUNCT
dpc-2201	415	7	10.1007	10.1007	NUM
dpc-2201	415	8	/	/	SYM
dpc-2201	415	9	s40257	s40257	NOUN
dpc-2201	415	10	-	-	PUNCT
dpc-2201	415	11	017	017	NUM
dpc-2201	415	12	-	-	PUNCT
dpc-2201	415	13	0251	0251	NUM
dpc-2201	415	14	-	-	PUNCT
dpc-2201	415	15	7	7	NUM
dpc-2201	415	16	.	.	PUNCT
dpc-2201	416	1	pmid	pmid	NOUN
dpc-2201	416	2	:	:	PUNCT
dpc-2201	416	3	28224502	28224502	NUM
dpc-2201	416	4	.	.	PUNCT
dpc-2201	417	1	41	41	NUM
dpc-2201	417	2	.	.	PUNCT
dpc-2201	418	1	choi	choi	PROPN
dpc-2201	418	2	aw	aw	INTJ
dpc-2201	418	3	,	,	PUNCT
dpc-2201	418	4	abuav	abuav	NOUN
dpc-2201	418	5	r	r	NOUN
dpc-2201	418	6	,	,	PUNCT
dpc-2201	418	7	rabizadeh	rabizadeh	NOUN
dpc-2201	418	8	sm	sm	PROPN
dpc-2201	418	9	,	,	PUNCT
dpc-2201	418	10	ansari	ansari	ADJ
dpc-2201	418	11	r	r	PROPN
dpc-2201	418	12	,	,	PUNCT
dpc-2201	418	13	marsch	marsch	PROPN
dpc-2201	418	14	af	af	PROPN
dpc-2201	418	15	.	.	PROPN
dpc-2201	418	16	recalcitrant	recalcitrant	ADJ
dpc-2201	418	17	and	and	CCONJ
dpc-2201	418	18	severe	severe	ADJ
dpc-2201	418	19	pyoderma	pyoderma	NOUN
dpc-2201	418	20	gangrenosum	gangrenosum	NOUN
dpc-2201	418	21	attributable	attributable	ADJ
dpc-2201	418	22	to	to	ADP
dpc-2201	418	23	levamisole	levamisole	NOUN
dpc-2201	418	24	-	-	PUNCT
dpc-2201	418	25	adulterated	adulterate	VERB
dpc-2201	418	26	cocaine	cocaine	NOUN
dpc-2201	418	27	and	and	CCONJ
dpc-2201	418	28	treated	treat	VERB
dpc-2201	418	29	successfully	successfully	ADV
dpc-2201	418	30	with	with	ADP
dpc-2201	418	31	oral	oral	ADJ
dpc-2201	418	32	tofacitinib	tofacitinib	NOUN
dpc-2201	418	33	.	.	PUNCT
dpc-2201	419	1	jaad	jaad	NOUN
dpc-2201	419	2	case	case	NOUN
dpc-2201	419	3	rep	rep	PROPN
dpc-2201	419	4	.	.	PROPN
dpc-2201	419	5	2020;6(9):939	2020;6(9):939	PROPN
dpc-2201	419	6	-	-	SYM
dpc-2201	419	7	941	941	NUM
dpc-2201	419	8	.	.	PUNCT
dpc-2201	420	1	doi	doi	NOUN
dpc-2201	420	2	:	:	PUNCT
dpc-2201	420	3	10.1016	10.1016	NUM
dpc-2201	420	4	/	/	SYM
dpc-2201	420	5	j.	j.	PROPN
dpc-2201	420	6	jdcr.2020.07.035	jdcr.2020.07.035	PROPN
dpc-2201	420	7	.	.	PUNCT
dpc-2201	421	1	pmid	pmid	NOUN
dpc-2201	421	2	:	:	PUNCT
dpc-2201	421	3	32923571	32923571	NUM
dpc-2201	421	4	.	.	PUNCT
dpc-2201	422	1	pmcid	pmcid	NOUN
dpc-2201	422	2	:	:	PUNCT
dpc-2201	422	3	pmc7475066	pmc7475066	NOUN
dpc-2201	422	4	.	.	PUNCT
dpc-2201	423	1	42	42	NUM
dpc-2201	423	2	.	.	PUNCT
dpc-2201	424	1	kochar	kochar	PROPN
dpc-2201	424	2	b	b	X
dpc-2201	424	3	,	,	PUNCT
dpc-2201	424	4	herfarth	herfarth	NOUN
dpc-2201	424	5	n	n	CCONJ
dpc-2201	424	6	,	,	PUNCT
dpc-2201	424	7	mamie	mamie	PROPN
dpc-2201	424	8	c	c	PROPN
dpc-2201	424	9	,	,	PUNCT
dpc-2201	424	10	navarini	navarini	ADJ
dpc-2201	424	11	aa	aa	NOUN
dpc-2201	424	12	,	,	PUNCT
dpc-2201	424	13	scharl	scharl	PROPN
dpc-2201	424	14	m	m	PROPN
dpc-2201	424	15	,	,	PUNCT
dpc-2201	424	16	herfarth	herfarth	PROPN
dpc-2201	424	17	hh	hh	PROPN
dpc-2201	424	18	.	.	PROPN
dpc-2201	424	19	tofacitinib	tofacitinib	PROPN
dpc-2201	424	20	for	for	ADP
dpc-2201	424	21	the	the	DET
dpc-2201	424	22	treatment	treatment	NOUN
dpc-2201	424	23	of	of	ADP
dpc-2201	424	24	pyoderma	pyoderma	NOUN
dpc-2201	424	25	gangrenosum	gangrenosum	NOUN
dpc-2201	424	26	.	.	PUNCT
dpc-2201	425	1	clin	clin	PROPN
dpc-2201	425	2	gastroenterol	gastroenterol	PROPN
dpc-2201	425	3	hepatol	hepatol	ADV
dpc-2201	425	4	.	.	PUNCT
dpc-2201	426	1	2019;17(5):991	2019;17(5):991	NUM
dpc-2201	426	2	-	-	SYM
dpc-2201	426	3	993	993	NUM
dpc-2201	426	4	.	.	PUNCT
dpc-2201	427	1	doi	doi	NOUN
dpc-2201	427	2	:	:	PUNCT
dpc-2201	427	3	10.1016	10.1016	NUM
dpc-2201	427	4	/	/	SYM
dpc-2201	427	5	j.cgh.2018.10.047	j.cgh.2018.10.047	PROPN
dpc-2201	427	6	.	.	PUNCT
dpc-2201	428	1	pmid	pmid	NOUN
dpc-2201	428	2	:	:	PUNCT
dpc-2201	428	3	30404036	30404036	NUM
dpc-2201	428	4	.	.	PUNCT